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CHAPTER 1 
Brief Overview 
Hyperthyroidism, also referred to as thyrotoxicosis, is a spontaneous 
disease affecting both humans and domestic cats. The disease, characterized by 
an abnormal elevation of circulating concentrations of one or more thyroid 
hormones (Broussard et al. 1995; Peterson et al. 2001), has become one of the 
most commonly diagnosed endocrine disorders in middle and senior age cats 
(Broussard et al. 1995; Kohler et al. 2016; Mooney 2012; Peterson 2012; Thoday 
and Mooney 1992). It is estimated over 10% of cats in the US over age 10 will be 
diagnosed with the disease (Peterson 2012).   
Feline hyperthyroidism is clinically and pathologically similar to toxic 
nodular goiter or Plummer’s disease (Peterson 2014; Wakeling et al. 2007), one 
of the most common types of hyperthyroidism in humans (Vanderpump 2011).  It 
has been suggested that domestic cats could be a spontaneous animal model of 
toxic nodular goiter due to the high incidence of feline hyperthyroidism and the 
long subclinical state caused by the development of small automatous thyroid 
nodes that gradually increase (Peterson 2014; Wakeling et al. 2007).  
Diagnosing subclinical disease is challenging in cats as the commercially 
available thyroid stimulating hormone (TSH) assay currently used is canine 
specific (Rayalam et al. 2006) rather than feline specific.  Because the homology 
of feline TSH is 96% identical to that of canine TSH (Rayalam et al. 2006), the 
first-generation commercial assay can be used to measure feline TSH; however, 
the low sensitivity limits the ability to distinguish TSH concentrations of euthyroid 
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and subclinical hyperthyroid cats.  Furthermore, the circulating total thyroxine 
(T4) and triiodothyronine (T3) serum concentrations during the subclinical state 
are within the reference intervals for euthyroid cats (Wakeling et al. 2007).  
Once the disease progresses to overt hyperthyroidism, feline TSH 
concentrations remain at or below the detection limits of currently utilized canine 
TSH assays (Peterson 2014; Wakeling et al. 2007) while the circulating serum T4 
and, in some cats, T3 concentrations are elevated (Broussard et al. 1995; 
Peterson et al. 2001). In human toxic multinodular goiter patients, the clinical 
thyroid progression from subclinical to overt hyperthyroidism is nearly identical 
including other clinical signs such as hyperphagia and weight loss (Kravets 2016; 
Mooney 2012).  Fortunately, a third-generation TSH assay is available that 
allows differentiation between euthyroid and subclinically affected patients 
(Peterson 2014). 
The histopathology of thyroid glands from both human toxic multinodular 
goiter patients and feline hyperthyroid patients reveal automatous single or 
multiple hyperplastic or adenomatous nodules ranging from < 1 mm to 3 cm 
(Hoenig et al. 1982; Peterson 2014).  The majority of these nodules are benign, 
with approximately 2% advancing into follicular, papillary, or mixed thyroid 
carcinoma in feline patients (Hibbert et al. 2009; Turrel et al. 1988), and up to 9% 
developing into thyroid cancer in human patients (Cerci et al. 2007).  These 
benign nodules are in a hypersecretory state as evidenced by periodic acid Schiff 
(PAS) stains showing reduced storage of thyroglobulin, the precursor of thyroid 
hormones (Peter et al. 1987; Peter et al. 1991; Peterson 2014). 
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Identification of risk factors and the etiopathogenesis have been sought 
after mainly through the use of epidemiological studies.  Iodine deficiency is the 
best studied human risk factor for toxic nodular goiter (Krohn et al. 2005d), yet 
thyroid nodules still occur in iodine replete areas (Vanderpump 2011).  Other 
factors have been proposed or identified through cross-sectional epidemiological 
studies (Edinboro et al. 2004; Kass et al. 1999; Martin et al. 2000; van Hoek et al. 
2015; Vanderpas 2006), however they have been minimally investigated in 
prospective studies.  In felines, both nutritional and thyroid-disrupting compounds 
in the environment have been suggested as risk factors (Peterson 2012; van 
Hoek et al. 2015).  
The proposed risk factors for feline hyperthyroidism rely upon the 
assumption that the pathogenesis is due to chronic thyroid overstimulation that 
results in hypertrophy followed by hyperplasia of thyroid follicular cells (Peterson 
2012; van Hoek et al. 2015).  This mechanism has never been investigated in 
felines, but is a reasonable hypothesis since most cases of hyperthyroidism are 
bilateral and the follicular tissue has altered expression of G proteins in both 
thyroid glands (Hammer et al. 2000; Ward et al. 2005). 
 The proposed nutritional risk factors are largely untested in prospective 
feline studies.  Rather dietary constituents such as isoflavones, selenium, and 
iodine are routinely hypothesized to contribute to the pathogenesis of feline 
hyperthyroidism because they are known to affect thyroid hormones in felines or 
other species (Doerge and Sheehan 2002; Tarttelin et al. 1992; van Hoek et al. 
2015; White et al. 2004; Yu et al. 2002).  Additionally, it is attributed that the 
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highly variable concentrations within commercial cat food could be the inciting 
factor (Edinboro et al. 2013). These particular nutrients, and the amino acid 
taurine, which I propose may also contribute to the pathogenesis, are found at 
high concentrations within canned commercial feline diets.  It is important to 
recognize that the consumption of canned cat food, regardless of the ingredients, 
has been the only consistently identified nutritional risk factor in all 
epidemiological studies conducted to date in the US (Edinboro et al. 2004; Kass 
et al. 1999; Martin et al. 2000; Scarlett et al. 1988).  While these studies do not 
cite specific ingredients as risk factors, two of the epidemiological studies did find 
that pop-top cans (Edinboro et al. 2004) and fish- and liver and giblets-flavored 
canned food further increase the risk of developing the disease (Martin et al. 
2000). 
The purpose of this work was two-fold.  The first was to investigate 
whether the proposed dietary risk factor, selenium, and two nutrients found in 
high levels within canned diets, water (moisture) and taurine, cause an 
overstimulation of the thyroid gland and alter the function of the hypothalamic-
pituitary-thyroid axis.  The second purpose was to determine if cats are a better 
animal model than rats when investigating dietary causes of hyperthyroidism.   
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Abstract 
Consumption of canned cat food is considered a risk factor for the 
development of feline hyperthyroidism. Because selenium and water are 
substantially higher in canned diets compared to dry diets, objectives of this 
study were to determine if increased dietary selenium or water alter the function 
of the hypothalamic-pituitary-thyroid axis and lead to an increase in activity level. 
Employing a 28-day Latin Square design with a 14-day washout, 6 lean, 
neutered male domestic shorthair cats were fed 1) commercially available adult 
dry feline diet containing 0.8 ppm selenium (control), 2) control diet with added 
sodium selenite to achieve a dietary selenium concentration of 1.125 ppm 
(selenium treatment), and 3) the control diet with additional water to achieve a 
moisture content of 75% wt/wt (water treatment). Water consumption was 
determined using deuterium oxide washout. Actical activity monitors were placed 
on each cat’s collar to allow quantification of the activity of each cat. Circulating 
serum T3 and T4, were measured on day 0, 14, and 28. On day 28, a thyrotropin 
releasing hormone (TRH) stimulation test was conducted to determine treatment 
effects on serum concentrations of thyroid hormones. There was a significant 
increase in daily water consumption with dietary water treatment (192 mL ± 7.9 
SEM) compared to the control (120 mL ± 20.4) and selenium (116 mL ± 14.6) 
treatments. Both water and selenium treatments were associated with greater 
(p<0.05) activity over that of the control treatment by 20.5% and 11% 
respectively. Serum TT3 AUC concentrations (0 to 4 hr) of TRH stimulation tests 
were greater (p < 0.05) by 16% with water compared to control treatments. The 
results of this study indicate that dietary water content may alter the function of 
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the thyroid axis and that this effect is associated with an increase in physical 
activity. 
Introduction 
Hyperthyroidism is a condition observed in domestic cats defined by the 
abnormal elevation of circulating concentrations of one or more thyroid 
hormones. The elevation of circulating thyroxine (T4), the thyroid hormone most 
commonly elevated, occurs from hyperfunctioning single or multiple hyperplastic 
nodules in the feline thyroid gland that autonomously proliferate (Gerber et al. 
1994; Peterson et al. 1987). Since the first case report of spontaneously 
occurring hyperthyroidism in cats in 1979 (Peterson et al. 1979), the prevalence 
of feline hyperthyroidism has skyrocketed (Edinboro et al. 2004; Scarlett et al. 
1988). Hyperthyroidism is now considered the most common feline endocrine 
disorder in the USA (Mooney 2012; Peterson 2012) with an estimated 10% of 
cats over 10 years old are diagnosed with the disease (Peterson 2012).  Beyond 
the USA, feline hyperthyroidism is present world-wide with varying prevalence 
rates, ranging from 0.1% to 20.14% (Gójska-Zygner et al. 2014; Kohler et al. 
2016), depending on the inclusion criteria for the study.   
Many epidemiological studies have been undertaken in attempts to 
determine the etiopathogenesis and risk factors associated with feline 
hyperthyroidism. These studies have not identified a cause or a single risk factor. 
The veterinary community currently believes that the etiopathogenesis is likely 
multifactorial, with the risk factors being classified under two main categories: 1) 
nutritional and 2) thyroid-disrupting compounds in the environment (Peterson 
2012; van Hoek et al. 2015).  
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Epidemiological studies conducted in the US have consistently identified 
consumption of canned commercial cat food to be a significant risk factor for 
development of feline hyperthyroidism (Edinboro et al. 2004; Kass et al. 1999; 
Martin et al. 2000; Scarlett et al. 1988). Some studies have found increasing risk 
if the canned food was in a pop-top can (Edinboro et al. 2004), and increasing if 
the flavor was fish or liver and giblets (Martin et al. 2000). The consumption of 
canned cat food has also been identified world-wide as a risk factor for feline 
hyperthyroidism (Gójska-Zygner et al. 2014; Kohler et al. 2016; Olczak et al. 
2005; Wakeling et al. 2009). However, a single study conducted in Hong Kong 
did not report canned food as a significant risk factor. The sample size of this 
study was limited to 12 hyperthyroid cats (De Wet et al. 2009). With a lack of 
prospective studies, there have only been suggested hypotheses as to why the 
consumption of canned cat food is linked to an increase risk of hyperthyroidism.  
Isoflavones, selenium, and iodine are known to be incorporated into feline 
canned diets at highly variable concentrations (Court and Freeman 2002; 
Johnson et al. 1992; Simcock et al. 2005). These three dietary constituents are 
routinely hypothesized to contribute to the pathogenesis of feline hyperthyroidism 
(van Hoek et al. 2015). Simcock et al. (2005) reported canned cat food contains 
significantly higher concentrations of selenium than dry cat diets, with “seafood” 
and “chicken and seafood” flavored diets consistently containing the highest 
selenium concentrations. This association is of particular interest since 
consumption of fish, liver, and giblets-flavored canned cat food further increases 
risk of hyperthyroidism (Martin et al. 2000). Dietary selenium content has been 
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shown to influence the conversion of T4 to triiodothyronine (T3) through the 
selenoenzymes, iodothyronine deiodinase types I, II, and III (Wedekind et al. 
2003). It is unknown whether selenium directly alters the function of the 
hypothalamic-pituitary-thyroid axis.  
Most domestic pet cats are maintained on dry-expanded diets, canned 
diets, or a combination of both diets. It is unknown if the high dietary moisture 
content of canned diets alters the production, secretion, or metabolism of thyroid 
hormones. Water, as a nutrient, is often overlooked in research studies (Sawka 
et al. 2005), however water intake can have profound impacts on a variety of 
physiological processes including metabolism (Boschmann et al. 2003). Deng et 
al. (2014) demonstrated that a diet with 70% moisture content increased the 
activity of cats when compared to a diet with a moisture content of 8% w/w. The 
mechanism of this increased activity has not been determined, but perhaps the 
increased dietary water consumption altered the production of thyroid hormones 
resulting in the observed increase in activity level. Increased activity, or 
hyperactivity, is clinically observed in cats with hyperthyroidism (Thoday and 
Mooney 1992) which is also observed in rats rendered hyperthyroid through 
administration of T3. However the mechanism as to how thyroid hormones 
increase spontaneous physical activity is unknown (Levine et al. 2003). 
The present study sought to determine whether the dietary nutrients, 
selenium and water, alter the function of the hypothalamic-pituitary-thyroid axis. 
Encompassing this objective were three hypothesis. The first hypothesis was that 
a diet high in selenium would result in an increase in T3 production by the thyroid 
 15 
 
gland, and that this production would be revealed by a thyrotropin release 
hormone (TRH) stimulation test. The second hypothesis was that the moisture 
content of a typical feline canned diet (~75% w/w) would alter the function of the 
hypothalamic-pituitary-thyroid axis and cause an increase in T4 production. The 
third hypothesis was that the increase secretion of thyroid hormones from the 
dietary treatments would result in a significant increase in physical activity. 
Materials and Methods 
All procedures performed were approved by the University of Missouri 
Animal Care and Use Committee in accordance with the Guide for the Care and 
Use of Laboratory Animals (Institute for Laboratory Animal Research 2011), 
Public Health Service policy (Public Health Service 2015), and the Animal 
Welfare Act and Regulations (United States Department of Agriculture 2013). 
Animals: Six, adult (3-5 yr), lean (16-25% body fat [w/w] based upon 
deuterium oxide body composition and a BCS of 4-5/9), purpose bred, neutered 
male, domestic short-haired cats were deemed healthy on physical exam, 
complete blood cell count, and serum clinical biochemistry (University of Missouri 
Veterinary Diagnostic Laboratory, Columbia, MO, USA) findings. All cats had ad 
lib access to water and were socially housed in a room (3.2 x 4.8 m) with free 
access to four adjacent cubicles (1.1 x 1.6 x 2.4 m). Two cats were individually 
housed in stainless steel cages (0.9 x 0.7 x 1.2 m) and four cats were individually 
housed in cubicles during food presentation. All cats were consistently housed in 
the same cubicle or cage during food presentation.    
Diets: A commercially available feline adult maintenance dry-expanded 
diet (Purina Pro Plan Urinary Tract Health Formula, Nestlé Purina PetCare 
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Company, Saint Louise, MO, USA) that was nutritionally complete and balanced 
as substantiated from passage of feeding trials as described by American 
Association of Feed Control Officials (AAFCO) served as the base and control 
diet (Table 2.1). Reverse osmosis water which did not contain substantive 
amounts of selenium or iodine was continuously provided. The base/control diet 
contained selenium at 0.8 ppm and 10% moisture. There were two dietary 
nutrient variables, selenium and water. The increased-selenium content diet of 
1.25 ppm selenium was made by top-dressing the base diet with sodium selenite 
(Dyets Inc, Bethlehem, PA, USA) dispersed in dyetrose (Dyets Inc, Bethlehem, 
PA, USA) to ensure even distribution and coating of the kibble during batch 
mixing. The increased-moisture content diet of 75% (w/w) water was achieved by 
adding water purified by reverse osmosis to the base diet the evening before 
presentation. The food remained covered and refrigerated (4 ⁰C) overnight to 
allow the kibble to absorb the water. Selenium contents of the diets were 
determined by the South Dakota Agricultural Laboratories (Brookings, SD, USA) 
and proximate analysis of the diets was completed at the University of Missouri-
Columbia Agricultural Experiment Station Chemical Laboratories (Columbia, MO, 
USA). Iodine contents of the diets were determined by neutron activation 
analysis (Spate et al. 1995) by the University of Missouri-Columbia Research 
Reactor Center (Columbia, MO, USA).   
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Table 2.1 Proximate analysis and select nutrients of the control diet 
Nutrient Amount 
Crude protein g/100 g 31 
Crude fat g/100 g 14 
Crude fiber g/100 g 2 
Moisture g/100 g 10 
Ash g/100 g 6.2 
Selenium ppm* 0.857 
Iodine ppm† 2.27 
Ingredients: Corn gluten meal, chicken, wheat flour, brewers rice, ground 
yellow corn, animal fat preserved with mixed-tocopherols (form of Vitamin E), 
egg product, sodium caseinate, phosphoric acid, calcium carbonate, potassium 
chloride, animal digest, salt, L-Lysine monohydrochloride, dried whey, choline 
chloride, dicalcium phosophate, taurine, zinc sulfate, ferrous sulfate, 
manganese sulfate, Vitamin E supplement, niacin, citric acid, Vitamin A 
supplement, calcium pantothenate, thiamine mononitrate, copper sulfate, 
riboflavin supplement, Vitamin B-12 supplement, pyridoxine hydrochloride, folic 
acid, Vitamin D-3 supplement, calcium iodate, biotin, menadione sodium 
bisulfite complex (source of Vitamin K activity), and sodium selenite 
*As determined by the South Dakota Agricultural Laboratories Agricultural 
Experiment Station Chemical Lab, on a dry matter basis. †As determined by the 
University of Missouri-Columbia Research Reactor Center, on dry matter basis. 
 
Study design:  Using a Latin Square design, each cat was randomly 
assigned to one of three dietary treatments, 1) control (0.8 ppm selenium, 10% 
moisture), 2) high selenium (1.25 ppm, 10% moisture), or 3) high moisture (0.8 
pm, 75% moisture). Diet-presentation blocks were 28 days in duration. Following 
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each block were 14 day washout periods during which cats were presented with 
the base diet. Cats were presented daily an allotted amount of diet in order to 
maintain a stable weight and an ideal body condition score of 5/9 (Laflamme 
1997). The dry matter amount of diet offered to each cat was not changed during 
the study and dietary intake was recorded daily. Cats were weighed weekly. 
Jugular venous blood was collected on day 0, 14, and 28 of each dietary block. 
Blood was allowed to clot at room temperature for 1 hour prior to centrifugation at 
1200 x g for 10 min. Extracted serum was stored in 1 mL aliquots at -20°C until 
analyses.   
Thyroid Releasing Hormone (TRH) Stimulation Tests:  On day 28 of 
each diet block, a thyrotropin releasing hormone (TRH) stimulation test was 
conducted using previously described methods (Peterson et al. 1994; Sparkes et 
al. 1991). Briefly, jugular venous blood was collected prior to each cat 
intravenously receiving 0.1 mg/kg Proteirelin (TRH) (Wedgewood Pharmacy, 
Swedesboro, NJ, USA) (time 0). Jugular venous blood was thereafter collected at 
0.5, 1, 2, and 4 hours post-TRH injection. Blood was kept on ice for up to 2.5 
hours before being centrifuged at 1200 x g for 10 min to extract serum, which 
was stored at -20°C until analyses of thyroid hormones.  
Activity Monitoring:  Three weeks prior to the start of the study, all cats 
were habituated to wearing collars to which was attached an accelerometer 
(Actical Activity Monitoring Devices, Mini Mitter, Bend, OR, USA). The 
accelerometer devices were previously validated for use in measuring the 
physical activity of cats (Lascelles et al. 2008). Motion was registered as an 
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activity count, a unit-less measure. Activity counts were continuously logged at 
15 second intervals throughout each diet block on days 1 through 27. Each cat 
wore the same Actical unit for the duration of the study. Sums of activity counts 
per day was determined for each cat for each block with and without periods of 
human interaction. A period of human interaction was defined as when any 
husbandry staff or laboratory staff entered the housing room which was tracked 
by key card access and a room door sign-in sheet.   
Thyroid hormone and selenium analysis:  Serum samples were sent 
overnight on dry ice to Michigan State University’s Diagnostic Center for 
Population and Animal Health (DCPAH) for measurements of total T4 (TT4), and 
total T3 (TT3) on day 0 and 14; and TT4, TT3, TSH, free T4 (fT4), and free T3 
(fT3) on day 28. Day 0 and 28 serum samples were sent on dry ice to South 
Dakota Agricultural Laboratories (Brookings, SD, USA) for selenium analysis. 
Water consumption:  Water consumption was estimated using the 
deuterium oxide (D2O) washout method (Lifson and McClintock 1966). Body 
composition was determined as previously described (Backus et al. 2010). 
Briefly, on day 0 of each block, jugular venous blood was collected and 
subsequently cats received 0.7 g/kg of sterile filtered, salinated (9 g/L sodium 
chloride), D2O (99.8% Sigma-Aldrich, St. Louis, USA) subcutaneously. Jugular 
venous blood was collected 4-6 hours after injection of the D2O for determination 
of D2O enrichment in serum after equilibration. Jugular venous blood was 
collected again on day 14 and 28. Aliquots of serum were stored in 1.5 mL 
microcentrifuge screw top tubes (USA Scientific, Ocala, FL, USA) at -20°C until 
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analysis. In duplicate, deuterium oxide enrichment was determined in water 
distilled from serum using Fourier Transform infrared spectrophotometry 
(Jennings et al. 1999). A first-order wash-out curve was assumed to correctly 
model rate of water turnover of the cats. Water consumption during each block in 
milliliters per day was determined from the fractional change in D2O enrichment 
during blocks and from body water mass estimated from D2O dilution on day 1 of 
blocks. Body lean mass of cats was assumed to equal body water mass divided 
by 0.732, the fractional moisture mass of lean tissue reported applicable to many 
species. Body fat mass was assumed to equal body weight minus body lean 
mass.  
Statistical Analyses: We used SAS 9.3 software package (SAS Institute 
Inc., Cary, NC, USA) to perform all statistical analysis and significance was 
calculated at alpha=0.05. All outcome variables were determined to be normally 
distributed, except for the activity data which was transformed through log10. The 
Proc GLM procedure and differences of the least square means was used to 
compare the variables of interest: TT4, TT3, TSH, fT4, fT3, activity counts, water 
consumption, diet consumption, body weight, and cat and the interactions of 
cat*dietary treatment, dietary treatment*block, dietary treatment*block*time.   
Results 
The dietary treatments did not significantly (p > 0.05) alter the amount of 
diet consumed or weights throughout the study (Table 2.2). When the cats were 
given the high moisture diet, their total water consumption was significantly 
increased (p < 0.001) by a mean of 72.6 mL per day compared to the control diet. 
One cat consumed more water than the other cats (p < 0.01) when they were on 
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the high selenium and control diets (Figure 2.1). When data from this cat was 
excluded from analyses, the mean water consumption among the other cats was 
greater (p < 0.001) by a mean of 86.2 mL per day when they were when given 
the high moisture diet compared to when they were given the control diet. A 
urinalysis and serum chemistry analysis were repeated for the cat with 
extraordinary water consumption. Serum creatinine and urea nitrogen 
concentrations were within the reference interval of the clinical laboratory. 
Results of the urinalysis revealed a low urine osmolality with no bacteria or 
crystals observed in sediment. It is possible the cat with extraordinary water 
consumption was in a very early stage of chronic renal failure. Nevertheless, 
observations from this cat were included in all statistical analyses as removing 
his data did not change the outcomes of the study. 
Throughout each dietary block, serum selenium concentrations were 
highly variable within each cat. The mean serum selenium concentration did not 
significantly increase (p = 0.98) when the cats were on the selenium-added 
dietary treatment (Table 2.3).  The TT4 and TT3 serum concentrations of the cats 
were not significantly different (p > 0.05) between any of the dietary treatments 
on any of the sampling days during the treatment blocks (days 0, 14, and 28) 
(Table 2.3). 
 
2
2
 
Table 2.2  Feed intake, weight, and percent weight change over each dietary treatment block 
Dietary 
Treatment 
Dietary 
Moisture 
(% w/w) 
Dietary 
Se 
(ppm)* 
Food 
Intake 
(g DM/day) 
Metabolizable 
energy 
(kcal/day) 
Weight 
Day 0 
(kg) 
Weight 
Day 28 
(kg) 
Weight 
change 
(%) 
Control 10 0.8 52 ± 3.1 87 ± 5.1 4.7 ± 0.23 4.7 ± 0.28 -0.02 ± 0.03
Selenium 10 1.25 52 ± 3.0 87 ± 5.0 4.7 ± 0.35 4.8 ± 0.24 0.01 ± 0.04 
Moisture 75 0.8 52 ± 3.2 86 ± 5.3 4.8 ± 0.20 4.7 ± 0.27 -0.02 ± 0.02
*Provided as sodium selenite on a per dry matter basis.
Table 2.3 Serum Se, TT4, and TT3 over the duration of each dietary treatment block 
Dietary 
Treatment 
Serum Se 
Day 0 
(µmol/L) 
Serum Se 
Day 28 
(µmol/L) 
Serum TT4 
Day 0 
(nmol/L) 
Serum TT4 
Day 14 
(nmol/L) 
Serum 
TT4 Day 
28 
(nmol/L) 
Serum TT3 
Day 0 
(nmol/L) 
Serum TT3 
Day 14 
(nmol/L) 
Serum TT3 
Day 28 
(nmol/L) 
Control 6.6 ± 1.3 6.3 ± 0.93 18 ± 4.9 16± 4.5 20 ± 5.0 0.83 ± 0.39 0.73 ± 0.12 0.70 ± 0.09 
Selenium 6.6 ± 0.73 6.8 ± 0.75 18 ± 3.8 17 ± 1.9 17 ± 2.1 0.72 ± 0.14 0.75 ± 0.18 0.63 ± 0.05 
Moisture 6.6 ± 0.71 7.1 ± 0.93 17 ± 4.4 16 ± 3.9 18 ± 3.0 0.67 ± 0.12 0.73 ± 0.10 0.73 ± 0.14 
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Figure 2.1 Daily water consumption 
 
Daily water consumption of each cat as measured by deuterium oxide dilution 
method. The cats consumed significantly more water on the high moisture diet 
compared to the control (p<0.01) and high selenium (p<0.01) diets. Cat five 
consumed more water than all other cats (*, p<0.01). 
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On day 28 of dietary blocks, prior to TRH injection of TRH-stimulation 
tests, baseline serum concentrations of TT4, TT3, fT4, fT3, and TSH were not 
significantly different (p > 0.05) between the control, high selenium, and high 
moisture dietary treatments. Immediately after each cat received their dose of 
TRH for TRH stimulation test, the cats immediately began to exhibit ptyalism with 
one to two of the cats vomiting frothy fluid each block. During the first two hours 
all the cats exhibited lethargy and during the second two hours only two cats 
remained lethargic.   
When the cats were on the high dietary moisture treatment, serum TT3 
concentrations were greater (p < 0.001) post-TRH infusion (Figure 2.2) compared 
to when they were on the other diets (p < 0.01). Consumption of the high 
moisture diet resulted in a sixteen percent increase in serum TT3 area under the 
curve when compared to the control dietary treatment. There were no significant 
dietary treatment effects on the serum concentrations of TT4 (p = 0.94), fT4 (p = 
0.88), and fT3 (p = 0.68) following TRH injection (Figure 2.3).  
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Figure 2.2 TRH stimulation test mean circulating serum T3 concentrations 
Mean total T3 serum concentration prior to intravenous administrations of TRH 
and post-injection. There was a significant difference found between the high 
dietary moisture diet compared to the control diet (*, p<0.05). 
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Figure 2.3 TRH stimulation test T4, FT4, and FT3 circulating serum 
concentrations 
Mean total T4 (a), free T4 (b), and free T3 (c) serum concentration prior to 
intravenous administration of TRH and post-injection.  
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There was no significant dietary treatment effects seen with serum TSH 
concentrations (p = 0.80) following TRH injection. Each cat’s TSH concentrations 
peaked at 30 minutes post-TRH infusion, however there was great between-
individual variability in serum TSH concentrations among the cats with two cats 
consistently exhibiting the highest of serum TSH concentrations during each 
dietary block (Figure 2.4). 
Figure 2.4 TRH Stimulation test circulating serum TSH concentrations 
Figure 4: Individual serum TSH concentrations prior to intravenous administration 
of TRH and post-injection when cats were receiving the (a) control diet, (b) high 
selenium diet, and (c) high moisture diet.   
The cats accepted the Actical activity monitors on their collars. One 
monitor malfunctioned on day 14-28 of the high moisture dietary treatment, 
therefore only data from 5 cats were included for the activity analysis of this 
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dietary treatment. Additionally, there was one cat whose collar was found to be 
on the floor during an approximately 4 hour timespan. The data for all cats during 
this specific 4 hour timespan during each dietary block was eliminated prior to 
analysis. Activity counts were highly variable between cats and within cats, and 
activity counts greatly varied each day (p < 0.01). A significant increase in 
physical activity without human interaction was observed in the high moisture 
dietary treatment and the high dietary selenium treatment compared to the 
control dietary treatment (p < 0.05, Figure 2.5). Activity counts were not found to 
significantly vary with dietary treatment unless activity counts recorded during 
periods of human interaction were omitted from analyses. The authors would like 
to highlight that with our data, there was large variability between days and 
between cats which lead us to incorporate the entire block into our analysis 
rather than only the last week. We also chose to use the sum of the daily activity 
counts instead of the mean activity counts.  
Figure 2.5 Activity counts during each dietary treatment block 
Figure 5: Mean sum of the 
activity counts during the 
entire dietary treatment 
block. Control and high 
selenium dietary 
treatments n=6 whereas 
high dietary moisture n=5 
due to the malfunction of 
one of the units.   
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Discussion 
With nearly all epidemiological studies universally identifying commercial canned 
cat food as a risk factor for feline hyperthyroidism (Gójska-Zygner et al. 2014; 
Kohler et al. 2016), there has been much speculation on whether the increased 
risk is due to the nutrient composition of canned food or contaminants in the diet 
(van Hoek et al. 2015). It has been largely assumed that canned cat food is a 
“causation” factor whereas few have reflected on the possibility that it may be 
simply “guilty by association” rather than an actual cause of hyperthyroidism. 
Most studies that investigate possible causes of feline hyperthyroidism have 
focused on measuring blood biomarkers (nutrients or contaminants) in 
hyperthyroid and euthyroid cats. One such example is (Foster et al. 2001) who 
measured the plasma concentrations of selenium and glutathione peroxidase 
(GPX) activity. These studies are of limited value because they report on effects 
pre- and post-diagnosis rather than physiological changes that are occurring 
during the early pathogenesis of feline hyperthyroidism. 
Our study was unique as it examines potential nutritional etiologies of 
hyperthyroidism in a prospective investigation. The aims were to determine if 
high dietary selenium or high dietary moisture, equivalent to those typically found 
in canned cat foods (Simcock et al. 2005), alter the function of the hypothalamic-
pituitary-thyroid axis, leading to an increase in thyroid hormone production, and 
this increase in thyroid hormone would be reflected in the measurable outcome 
of increased physical activity, as increased activity is a commonly described 
clinical sign of feline hyperthyroidism. 
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Our hypothesis that the increase secretion of thyroid hormones from the 
dietary treatments would result in a significant increase in physical activity, was 
partially supported by our results as we observed a significant increase (p <0.05) 
in activity when the cats were on the high selenium and high dietary moisture 
treatments compared to the control treatment, but only when they were socially 
housed without human interaction (Figure 2.5). Including human interaction time 
along with when the cats were housed socially together, yielded results similar to 
Deng et al. (2014), who reported a trending increase in the mean activity of cats 
fed a 70% (w/w) high moisture diet compared to the control dry diet when fed 
twice daily. Since our cats’ personalities are highly variable, with only some of the 
cats seeking attention and playing with the care staff and laboratory staff, it was 
important to eliminate this uncontrollable variable by controlling access to the 
vivarium room and eliminating all data that was collected while there was a 
human in the room. This allowed us to find a difference between dietary 
treatments. A limitation of our study, was the lack of video recording to pair with 
the activity data in order to determine the type of physical activity the cats 
engaged in; however, with a 20% increase of total non-human interaction activity 
when the cats were on the high moisture diet, we do not believe it was solely due 
to increased litter box usage as Deng et al (2014) suggests. 
Our results warrant further investigation into the mechanisms underlying 
the increase in activity that was observed, particularly when cats consume a diet 
high in selenium as there was not a significant increase in T4 or T3 during the 
dietary treatment blocks nor did we detect an increase in serum selenium (table 
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2.3). While only TSH has been found to be impacted by food consumption in 
humans (Nair et al. 2014), in cat’s it has been shown that TT4 increases 4 hours 
postprandial, and TT3 increases postprandial 4, 8, 12, and 16 hours (Hooper SE 
2014). All of the thyroid hormones measured within this study, were done on 
fasted samples. Perhaps if we had measured postprandial samples, an increase 
in TT3 may have been recorded that could be directly linked to the increased 
activity level. 
Additionally, we did not observe any changes in the peripheral serum 
TT3:TT4 ratio when the cats were on the high dietary selenium treatment. This 
could reflect directly on the deiodinase activity not increasing due to the uptake of 
selenium, as detected by the selenium content of the blood, did not change 
significantly between day 0 and day 28 (table 2.3). Since we utilized sodium 
selenite which is absorbed through passive diffusion, the blood selenium content 
may have increased if an organically bound selenium was incorporated into the 
diet as this form is actively transported in the cat (Todd et al. 2012). Despite not 
observing an increase in serum content, the tissue selenium concentration could 
have been increased, resulting in increased TT3 cellular concentration, however 
the tissue levels were not measured. Alternatively, the lack of changes in TT3, 
could be attributed to the deiodinase enzymes already being fully activated on 
the control diet as our dietary selenium concentration of 0.8 mg/kg was greater 
than the breakpoint of 0.05 mg/kg for the TT4/TT3 ratio that is reported for kittens 
(Wedekind et al. 2003). The iodothyronine deiodinases are present in both the 
tissue and the thyroid gland (Salvatore et al. 1996). Iodothyronine deiodinase I 
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(IDI) is attributed to the main production source of plasma TT3 in human 
hyperthyroid patients and has been documented in the thyroid gland of some 
species (Bianco and Kim 2006). IDI has not been found in the feline thyroid gland 
(Foster et al. 2001) and could help explain why we did not detect an increase in 
circulating T3. Iodothyronine deiodinase II (IDII) mRNA has been detected in the 
thyroid gland of humans (Salvatore et al. 1996), but there have been no reports 
of the IDII enzyme detected in the feline thyroid gland and typically tissue only 
expresses one type of deiodinase at a given time (Arthur and Beckett 1999). 
Although since IDII is a major source of plasma T3 in euthyroid patients (Bianco 
and Kim 2006), it would be of value to determine if the feline thyroid contains IDII. 
Iodothyronine deiodinase III (IDIII) is not found in the thyroid gland but solely in 
the tissue, and is responsible for converting T4 to rT3 and T3 to T2 (Bianco and 
Kim 2006).   
To determine if selenium upregulated the deiodinases within the thyroid or 
altered the function of the hypothalamic-pituitary-thyroid axis, we conducted a 
TRH stimulation test at the end of each dietary block. This allowed differentiation 
between increased T3 production by the thyroid versus increased peripheral 
conversion of T4 to T3. Contrary to our hypothesis, the high dietary selenium 
treatment did not significantly affect the serum TT3 concentration during the TRH 
stimulation test (Figure 2.2). The selenium content of the thyroid is one of the 
highest out of all the organs in the body (Kohrle 1999), which may be due to its 
role as an anti-oxidant. In humans there is no correlation established between 
selenium content of thyroid tissues and the expression of functional IDI activities 
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(Kohrle 1999), which along with the lack of IDI enzymes within feline thyroids 
(Foster et al. 2001), could explain why there was no impact seen during the TRH 
stim test. Alternatively the lack of effect could be due to the excessive selenium 
promoting iodine excretion as has been shown in the mouse (Xu et al., 2010). If 
iodine was reduced in the thyroid, it may reduce the amount of thyroid hormone 
produced.  Future research on the interaction of iodine with other dietary 
nutrients such as selenium would be of value. 
One of the most interesting findings of this study was that the consumption 
of high dietary moisture resulted in a significant increase of TT3 production 
during the TRH stimulation test (Figure 2.2). The 16% difference in the TT3 AUC 
between the high moisture versus the control diet found during the TRH 
stimulation test, may provide a potential mechanism for the observed increased 
activity level (Figure 2.5), as only in the past few years has it become recognized 
that the thyroid hormones have a large role in the central nervous system, and do 
not just act peripherally (Lopez et al. 2013; Mullur et al. 2014). To the authors 
knowledge there are no known reports of increased water consumption altering 
the production or regulation of thyroid hormones. However, our results should be 
carefully interpreted. Our findings do not indicate that the high moisture diets 
induce feline hyperthyroidism, especially when considering cats consuming prey 
are consuming diets with a similar moisture content. Rather our results indicate 
future studies on the relationship between water consumption and feline 
physiology including the thyroid axis are needed.   
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In cats, increase production of T3 has been only attributed to an 
upregulation of the selenoenzymes iodothyronine deiodinases, which convert T4 
to T3 (Wedekind et al. 2003). Upregulation of these iodothyronine deiodinases 
have been solely attributed to increased dietary intake of selenium (Wedekind et 
al. 2003), as consumed selenium is metabolized by the body into hydrogen 
selenide, which in turn can be utilized for selenoprotein synthesis (Suzuki 2005), 
hence the hypothesis that increased dietary selenium would alter the function of 
the thyroid axis.    
Since our study was conducted in a high selenium area of the US (Survey 
2016), the water provided to the cats ad lib as well as the water added to the 
base diet, during creation of the high moisture diet, underwent filtering followed 
by reverse osmosis. Reverse osmosis water purification is routinely used 
effectively in mining operations to remove selenium (Santos et al. 2015), and 
ensured our cat’s did not consume any additional selenium. Therefore, our TRH 
stimulation test results showing an increase in TT3 production when the cats 
were fed a diet with high dietary moisture (Figure 2.2) were not likely due to 
increased selenium intake nor an upregulation of deiodinases secondary to 
selenium ingestion. Future studies should be conducted to determine what 
physiological alterations may be occurring both on the central as well as 
peripheral or cellular level with the increased water consumption. 
While no dietary treatment effects were found on the other thyroid 
parameters measured during the TRH stimulation test, the TSH results are of 
particular interest. There were significant inter-cat differences found as four of the 
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cats exhibited similar TSH levels throughout the test while two individuals had 
repeatedly higher TSH values (Figure 2.4, 2.S1). Although it is difficult to conduct 
long-term studies, it may be worthwhile to design a lifetime prospective study to 
determine if cats with high TSH values are at an increased risk for the 
development of hyperthyroidism. It is suspected that cats have a long subclinical 
state of hyperthyroidism, before developing overt hyperthyroidism (Wakeling et 
al. 2007). During this subclinical state, TT4 and TT3 will be within the normal 
range while TSH will be low or undetectable (Peterson 2014; Wakeling et al. 
2007).  However, due to the lack of available feline specific TSH assays 
(Peterson et al. 1994), laboratories use canine TSH assays since feline TSH has 
96% homology to canine TSH (Rayalam et al. 2006). These assays unfortunately 
lack sensitivity, and cause both hyperthyroid and some euthyroid cats to both 
have TSH below the limit of quantification (Wakeling et al. 2007) which the 
authors have experienced. As an attempt to avoid this, we predicted that the 
TRH stimulation test would to allow us to measure TSH in our research colony 
cats. While this was successful, our results also suggest cats may have 
individual set points for thyroid function similar to humans as it has been 
documented that individuals have different set points which result in unique 
thyroid functions (Andersen et al. 2002). There has been recent interest in using 
cats as an animal model for human thyroid research, particularly for toxic 
multinodular goiter as the subclinical, clinical, and histological progression of the 
human disease is nearly identical to feline hyperthyroidism (Peterson 2014; 
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Wakeling et al. 2007), and our results also provide further support that cats may 
be an excellent animal model for thyroid diseases. 
Since canned cat food diets are considered a risk factor for developing 
feline hyperthyroidism (Gójska-Zygner et al. 2014; Kohler et al. 2016), our study 
sought to provide insights into the role selenium and moisture may have into the 
etiopathogensis of feline hyperthyroidism. This study highlighted that high dietary 
moisture is capable of altering the thyroid hormone production in cats and could 
be the underlying mechanism explaining why increased dietary moisture has 
been linked to an increase in physical activity (Deng et al. 2014). Additionally, to 
the author’s knowledge, this is the first report of TSH being described during a 
TRH stimulation test in cats. Our results suggest cats may have individual set 
points for thyroid function, which should be investigated to determine if different 
set points can be attributed to an increased risk of hyperthyroidism or if high TSH 
indicates early stages of feline hyperthyroidism. Further studies into the 
mechanisms of this increased TT3 would also be of great value, including the 
risks of long term increased TT3 production since excessive T4 production, 
thyrotoxicosis, is attributed to multiple health conditions such as hypertension 
and osteoporosis (Bassett et al. 2007; Kobayashi et al. 1990). 
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Supporting Figure 2.1 
Individual serum TSH concentrations prior to intravenous administration of TRH 
when cats were receiving the high selenium diet.   
Supporting Figure 2.2 
Individual serum TSH concentrations prior to intravenous administration of TRH 
when cats were receiving the high moisture diet.   
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Abstract 
Research in animal models has demonstrated many beneficial effects of 
taurine supplementation.  These findings have generated much interest in 
supplementing humans with taurine, however it is unknown if high dietary taurine 
intake affects physiological processes.  We proposed that high levels of dietary 
taurine would affect the homeostasis of the hypothalamic-pituitary-thyroid axis by 
causing a proliferation of thyroid cells, leading to an increase in circulating thyroid 
hormones.  Using a parallel design of 12-week duration, 12 male and 12 female 
sexually mature Sprague Dawley rats were randomly assigned to a 0% taurine or 
a 0.7% taurine diet.  Plasma taurine and circulating serum thyroxine (T4), 
triiodothyronine (T3), thyroid stimulating hormone (TSH) were measured every 2 
to 4 weeks.  Thyroids were collected at week 12, with one thyroid from each rat 
undergoing analysis for taurine content and the other thyroid undergoing 
histological analysis.  Intra- and inter- individual variation was observed in all 
thyroid hormone parameters measured with the range for T3 in the female rats 
0.75 ± 0.06 (mean ± SEM) to 1.16 ± 0.17 ng/mL and in the male rats 0.47 ± 0.06 
to 0.84 ± 0.08 ng/mL; for T4 in the female rats 4.1 ± 0.32 to 5.4± 0.69 µg/dL and 
in the male rats 4.7 ± 0.43 to 8.4 ± 0.38 µg/dL, and for TSH in the female rats 
34.3 ± 4.8 to 70.8 ± 12.4 pg/mL and in the male rats 45.7 ± 4.3 to 90.6 ± 18.4 
pg/mL. There was a significant positive correlation (r = 0.55, p < 0.002) between 
serum T3 and plasma taurine concentrations in the female rats.  The female rats 
on the high dietary taurine gained 27.8 ± 4.3 grams which was significantly more 
weight than the 9.3 ± 3.6 grams the female control rats gained (p < 0.01).  It was 
also determined that thyroid glands need to be immediately removed and 
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preserved in formalin as follicular colloid loss and subsequent collapse begin to 
occur within 30 minutes post-euthanasia.  Our results indicate a larger study 
evaluating the effects of taurine on the female thyroid axis is warranted. 
Introduction 
Iodine deficiency is one of the best studied nutritional epidemiological risk 
factors for the development of nodular thyroid diseases (Krohn et al. 2005a). 
However thyroid diseases, including toxic multinodular goiter, a type of 
hyperthyroidism, occur in iodine replete areas in non-iodine deficient individuals 
(Vanderpump 2005).  Other dietary constituents such as selenium, thiocyanate, 
and flavonoids (Vanderpas 2006) have been investigated as potential risk factors 
for development of thyroid nodules and goiter since they are known to effect 
thyroid hormone metabolism through a variety of mechanisms (de Souza Dos 
Santos et al. 2011; Kohrle 1999; Vanderpas 2006).  However, epidemiologic and 
animal model studies focused on these nutritional risk factors have failed to 
provide a direct dietary link to the development of hyperthyroidism independent 
of iodine and the investigators have failed to explain why the prevalence of 
hyperthyroidism and other thyroid diseases are higher in women than men 
(Krohn et al. 2005a).   
Taurine, a sulfur-containing amino acid, is acquired directly through the 
diet or is synthesized by adults from dietary methionine and cysteine (Lourenco 
and Camilo 2002).  Once thought to be an inert waste product, taurine is now 
recognized to have a diversity of biological actions including modulation of 
neurotransmitters and hormone release (Huxtable 1992). In vitro work by Jhiang 
et al. (1993) identified a taurine transporter in thyroid cells and demonstrated that 
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the proliferation rate of thyroid cells from two human cell lines increased with 
increasing taurine uptake. Since taurine is found in high concentrations in tissues 
that generate free radicals and oxidants (Jacobsen and Smith 1968; Wright et al. 
1986) it has been suggested that taurine may be protective of thyroid cellular 
proliferation through its role in membrane stabilization, detoxification, anti-
oxidation, and osmoregulation (Jhiang et al. 1993).  Through the use of rodent 
animal models, taurine has been shown to be protective within other cells such 
as pancreatic beta cells in type 1 diabetic animal models (Chang and Kwon 
2000; Gavrovskaya et al. 2008; Ito et al. 2012) and has been shown to reduce 
insulin resistance. These findings have generated much interest in 
supplementing humans with large amounts of taurine when suffering from certain 
disease such as diabetes to help manage insulin resistance, diabetic 
nephropathy, and other complications (Ito et al. 2012). 
Food manufacturers have begun supplementing various products with 
taurine, particularly those produced for infants and young children, such as baby 
formula and complete nutrition beverages, because taurine biosynthesis from 
dietary methionine and cysteine is poor to absent in infants (Lambert et al. 2015).  
Additionally, taurine is routinely added to dietary food supplements for adults 
such as protein bars as it is well established that adult biosynthesis capability is 
low (Ito et al. 2012), whereas other products, such as energy drinks, contain 
tremendous amounts of taurine as it is touted to have beneficial effects such as 
improving mental performance (Alford et al. 2001). 
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Consumption of a single 16 ounce energy drink, such as Red Bull or 
Monster, typically provides 2000 mg of taurine (Higgins et al. 2010).  In contrast, 
it has been reported the average taurine intake by European adults on an 
omnivore diet is 58 mg per day, with a range of 9 to 372 mg per day (Schaffer et 
al. 2014).  The variation is dependent upon the dietary consumption of animal 
proteins, as meat and seafood contain high levels of taurine whereas the taurine 
content of fruits and vegetables is typically below detection limits (Lourenco and 
Camilo 2002). It remains unknown whether a high dietary taurine intake or an 
exceptionally low taurine intake (e.g. vegan diets) affect physiological processes 
(Lambert et al. 2015).  
We propose that high levels of dietary taurine could affect thyroid axis 
homeostasis, because in vitro evidence suggests that thyroid cells exposed to 
higher levels of taurine will have increased proliferation rates (Jhiang et al. 1993).  
Additionally, nuclear magnetic resonance studies have revealed that malignant 
thyroid tumors contain relatively higher concentrations of taurine compared to 
benign thyroid tumors (Torregrossa et al. 2012). With the prevalence of 
hyperthyroidism and thyroid diseases higher in women, there is evidence in 
rodent animal models, specifically in the rat, that female thyroid glands contain 
significantly higher concentrations of taurine compared to male thyroid glands 
(Jacobsen and Smith 1968).   Therefore, our study incorporated both sexes to 
determine if taurine exerted any sex-specific effects on the function of the thyroid 
axis which could help to explain the increased incidence of hyperthyroidism in 
females. We hypothesized that excessive dietary taurine would result in a 
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proliferation of thyroid cells.  This cellular proliferation would result in the 
formation of hyperfunctioning thyroid nodules which would lead to a rise in the 
production of the circulating thyroid hormones triiodothyronine (T3) and thyroxine 
(T4).  
Materials and Methods 
Ethical Statement 
This study was conducted at an animal facility accredited by AAALAC 
International. All procedures performed were under an approved University of 
Missouri Animal Care and Use Committee Protocol and adhered to the Guide for 
the Care and Use of Laboratory Animals (National Institutes of Health 2011).   
Animals 
Twelve male, ten-week-old sexually mature Sprague Dawley rats and 
twelve, seventeen-week-old sexually mature female Sprague Dawley rats (Hsd: 
Sprague Dawley rats, Envigo, USA) were pair housed in a temperature-
controlled rodent housing facility under a 12 hr light-dark cycle. Rats were 
requested from Harlan Laboratories Inc. (now Envigo, Indianapolis, Indiana, 
USA) to be at the top of the growth curve, therefore different ages were used.  To 
minimize stress that could alter the biological parameters measured, rats were 
acclimated to handling, restraint, and meal feeding for a minimum of 8 days prior 
to the start of the study.  At the end of the study, animals were anesthetized with 
isoflurane and euthanized by cardiac exsanguination.    
Diets and study design 
All rats underwent an adaptation period to meal-feeding using standard 
rodent chow (Lab Diet Rat Diet 5012, St. Louis, MO, USA). After their body 
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weight stabilized, rats were randomly assigned to 2 dietary treatment groups, 
AIN-93M purified diet (Reeves et al. 1993) with 0% taurine (control) (Modified 
AIN-93M 0.7% cornstarch Dyets #103967, Dyet’s Inc., Bethlehem, PA, USA) or 
0.7% DM taurine (high taurine) (Modified AIN-93M 0.7% taurine Dyets #103968, 
Dyets Inc., Bethlehem, PA, USA). Crude protein and taurine analyses of the diets 
were completed by the University of Missouri Experimental Station Chemical 
Laboratories (Columbia, MO, USA), results of which are shown in table 3.1. 
Dietary treatment groups were balanced for sex and starting body weight. Using 
a parallel design of 12-week duration, the rats were individually housed from 800 
to 1200 hr and presented with ~50 grams of diet to simulate meal feeding—
defined as a fixed window of time in which animals receive the entirety of their 
daily food ration (Vahl et al. 2014). At all other times, rats were housed in pairs. 
Food intake was determined daily from the weight of the diet presented minus 
weight of the diet remaining after individual housing. The cage litter was manually 
sifted by hand to ensure all feed was weighed after removal. The amount of 
taurine consumed was calculated every two weeks (weeks 2, 4, 6, 8, 10, 12) by 
multiplying the amount of food consumed by the amount of taurine in the diet 
using the as is basis values reported for the proximate and taurine analyses. 
Table 3.1: Crude protein and taurine content of diets. 
Diet 
Crude protein 
(w/w) 
Taurine 
(w/w) 
AIN-93 0.7% Taurine 12.8% 0.59% 
AIN-93 0.7% Cornstarch 13.0% 0.00% 
           Crude protein and taurine content reported on an as is basis. 
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Blood collection 
On day 0, 14, 28, 42, 56, 70, and 84, between 600 and 800 hr rats were 
briefly restrained in a DecapiCone (Braintree Scientific Inc., Braintree, MA) to 
allow pre-feeding blood collection from the saphenous vein. Two hours after 
removal of the daily feed allotment (1400 hrs), rats were anesthetized using 
isoflurane and up to 7% of each animals’ blood volume was collected from the 
jugular vein. Two-hundred and fifty microliter lithium heparin Terumo Capiject© 
capillary blood collection tubes (Terumo Medical, Elkton, MD, USA) were used to 
allow extraction of plasma. Plain five-hundred microliter Terumo Capiject© 
capillary blood collection tubes were used to allow extraction of serum. All blood 
samples were allowed to clot for a minimum of one hour prior to centrifugation at 
2000 x g. All samples were frozen at -20°C until analysis. 
Thyroid hormones 
T4 and thyroid stimulating hormone (TSH) were measured in duplicate on 
pre-feeding (fasted) serum samples using the Milliplex Map Rat Thyroid Magnetic 
Bead Panel (RTHYMAG-30K EMD Millipore, Billerica, MA, USA). T3 was 
measured using a human I125 radioimmunoassay kit (MP Biomedicals, Irvine, CA, 
USA). All samples were run according to each manufacturer’s directions.  
Taurine analysis 
Plasma taurine was measured on day 0, 14, 28, 42, 56, 70, and 84 post-
prandial blood samples. Taurine concentration of a single thyroid gland of each 
rat was determined. For this, one whole thyroid gland was homogenized in 1 mL 
of distilled water, and homogenates were frozen and thawed three times to help 
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ensure lysis of the cells. Taurine concentration in all samples was measured 
using high pressure liquid chromatography (HPLC) method modified from Sarwar 
and Botting (1990). Reagents were HPLC grade purchased from Sigma Aldrich 
(St. Louis, MO, USA) unless otherwise noted. Prior to HPLC analysis, samples 
were deproteinized by adding 50 µL of acetonitrile to 50 µL of plasma or tissue 
homogenate with trans-4-hydroxy-L-proline at a concentration of 100 ng/mL 
added for internal standard. After thoroughly mixing, samples were centrifuged 
for 15 min at 16,000 x g and 50 µL of the supernatant was transferred to a 13 x 
100 mm glass tube. Samples were evaporated to dryness at 35°C in a centrifugal 
evaporator (SpeedVac®Concentrator, Savant® SPD 111V, Thermo Electron 
Corp., Milford, MA, USA). Derivatization was performed in two steps. First, 50 µL 
of a coupling solution (1:1:1, v/v, triethylamine:water:methanol) was added to the 
dried residue, mixed, and then evaporated to dryness in the evaporator. 
Subsequently, 50 µL of derivatization solution (20:5:5:2, v/v, 
methanol:water:triethylamine:phenylisothiocyanate) was added to each tube, 
covered with parafilm, and left for 20 minutes at ambient temperature (20-24°C). 
Samples were then evaporated to dryness and redisolved in 200 µL (thyroid) or 
400 µL (plasma) of sample diluent (710 mg disodium hydrogen phosphate, 950 
mL water, 5 mL acetonitrile, adjusted to pH 5.4 with phosphoric acid). Samples 
were transferred to an Eppendorf tube with a 0.2 µm centrifuge tube filter 
(Corning®Costar® SpinX centrifuge tube filters, Sigma Aldrich, St. Louis, MO, 
USA) and centrifuged for 15 min at 15,000 x g. Five µL was injected onto a 
heated (45°C) column (Microsorb-MV™ 100-5 C18, 250 x 4.6 mm Varian Inc, 
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Lake Forest, CA, USA) equilibrated with buffer A at 1.0 mL/min. The 
phenylisothiocyanate derivatives of taurine and the internal standard were 
detected by UV absorbance at 254 nm as eluted with an increasing amount of 
Buffer “B” (1:1, v/v, acetonitrile:water). Buffer “A” was prepared by adding 11.45 g 
sodium acetate, 900 mL water, 15 mL acetonitrile (Optima™ LC/MS, Fisher 
Chemical, Waltham, MA, USA), and 0.5 mL of trimethylamine adjusted to pH 5.4 
with glacial acetic acid. The buffer gradient was 0% B from 0 to 5 min, 10% B for 
5 to 9 min, 48% B for 9 to 17 min, 100% B for 17 to 20, 100% B for 20-35 min, 
0% B for 35 to 38 min, and 0% B for 38 to 45 min. Intra-assay variation was 
6.05%. 
Tissue protein analysis 
Protein was measured in the thyroid homogenate solutions by Bradford 
assay (Bradford 1976) (BioRad USA  Microplate BSA Hercules, California 
94547). Lyophilized, essentially fat free, bovine serum albumin (Sigma Aldrich, 
St. Louis, MO, USA) was used to establish the standard curve from 0 to 1000 
µg/mL. Samples were diluted to ensure protein analysis was conducted between 
200-600 µg/mL. Samples were processed according to the manufacturer’s 
directions for the standard microplate assay. 
Histological analysis 
One thyroid gland of each rat was fixed in 10% buffered formalin. The 
fixed tissues were submitted to a commercial laboratory (IDEXX Bioresearch, 
Columbia, MO, USA) for embedding and hematoxylin and eosin staining. Using a 
light microscope with built-in software, 3 photographs at 20x magnification were 
 56 
 
taken to capture the entire longest diameter of the thyroid gland. Follicles were 
numbered and the follicular diameter was measured using NIH ImageJ 1.50b 
(National Institutes of Health, Bethesda, MD, USA).  
Statistical analysis 
We used SAS 9.3 (SAS Institute Inc., Cary, NC, USA) to perform all 
statistical analysis and significance was calculated at alpha = 0.05. Data was 
tested for normality using the Shapiro-Wilk, Kolmogorov-Smirnov, and Anderson-
Darling tests. Non-normally distributed data was transformed using log10 or 
square root. The Proc GLM and GLMMix procedure with repeated measures, 
and differences of the least square means was used to compare the variables of 
interest (time, treatment, sex) and the interactions. The Proc Correlation 
procedure and Pearson correlation coefficients were used to examine any 
potential correlations between the circulating thyroid hormone serum 
concentrations, taurine consumed every 2 weeks, and plasma taurine 
concentrations. 
Results 
Thyroid hormones  
Over the 12 weeks, the rats exhibited intra- and inter-individual variation of serum 
T3, T4, and TSH concentrations, with sex-effects found for T3 (p < 0.001), T4 (p < 
0.001), and TSH (p < 0.001) (Fig 3.1, tables 3.2-3.4). There were no dietary treatment 
effects found for T3 (p = 0.21), T4 (p = 0.28) and TSH (p = 0.54) (Fig. 3.2-3.3) and there 
were no sex*treatment effects for T3 (p = 0.35), T4 (p = 0.87), TSH (p = 0.36).  
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Figure 3.1 Circulating serum thyroid hormones 
Circulating serum concentrations of (A) T4 and (B) T3 were measured at weeks 0, 4, 8, and 12. 
Circulating serum concentration of (C) TSH were measured at weeks 0, 2, 4, 6, 8, 10, 12. Each sample 
time point for each individual is represented by ♦ for females and ● for males Circulating serum 
concentrations of T4 and TSH were significantly higher than in the male rats compared to the female 
rats (p < 0.001).  Circulating serum concentrations of T3 were significantly higher in the female rats 
compared to the male rats (p < 0.001). 
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Table 3.2 Circulating serum TT3 concentrations 
Sex 
Dietary 
treatment 
Week 0 
(ng/mL) 
Week 2 
(ng/mL) 
Week 4 
(ng/mL) 
Week 6 
(ng/mL) 
Week 8 
(ng/mL) 
Week 10 
(ng/mL) 
Week 12 
(ng/mL) 
Dietary 
treatment 
p-value
Sex 
effect p-
value 
Female Control 0.87 ± 0.14 0.76 ± 0.19 0.97 ± 0.09 0.86 ± 0.22 0.90 ± 0.12 0.82 ± 0.20 0.85 ± 0.10 
0.21 < 0.001 
Female Taurine 0.75 ± 0.06 0.90 ± 0.19 0.88 ± 0.12 1.16 ± 0.17 0.90 ± 0.25 1.07 ±0.18 0.78 ± 0.08 
Male Control 0.66 ± 0.07 0.57 ± 0.06 0.46 ± 0.04 0.59 ± 0.12 0.58 ± 0.07 0.70 ± 0.08 0.50 ± 0.06 
Male Taurine 0.50 ± 0.03 0.84 ± 0.08 0.47 ± 0.06 0.94 ± 0.07 0.42 ± 0.04 0.80 ± 0.06 0.48 ± 0.08 
Circulating serum TT3 mean ± SEM concentrations measured in non-anesthetized rats (n=6 per sex per treatment group). 
Table 3.3 Circulating serum TT4 concentrations 
Sex 
Dietary 
treatment 
Week 0 
(µg/dL) 
Week 4 
(µg/dL) 
Week 8 
(µg/dL) 
Week 12 
(µg/dL) 
Dietary 
treatment 
p-value
Sex 
effect 
p-value
Female Control 5.4 ± 0.5 5.4 ± 0.69 4.7 ± 0.43 4.9 ± 0.51 
0.28 <0.001 
Female Taurine 4.7 ± 0.32 4.6 ± 0.40 4.1 ± 0.32 4.8 ± 0.21 
Male Control 8.4 ± 0.38 8.3 ± 0.33 4.7 ± 0.43 7.9 ± 0.30 
Male Taurine 7.0 ± 0.38 8.1 ± 0.27 7.7 ± 0.38 7.6 ± 0.37 
Circulating serum TT4 mean ± SEM concentrations measured in non-anesthetized rats (n=6 per sex per treatment group). 
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Table 3.4 Circulating serum TSH concentrations 
Sex 
Dietary 
treatment 
Week 0 
(pg/mL) 
Week 4 
(pg/mL) 
Week 8 
(pg/mL) 
Week 12 
(pg/mL) 
Dietary 
treatment 
p-value
Sex 
effect p-
value 
Female Control 64.80 ± 9.81 57.25 ± 8.92 52.14 ± 2.98 57.38 ± 5.63 
0.54 <0.001 
Female Taurine 70.82 ± 12.47 35.03 ± 7.04 34.32 ± 4.78 58.51 ± 7.12 
Male Control 90.56 ± 18.42 45.68 ± 4.31 52.14 ± 11.51 76.21 ± 12.73 
Male Taurine 86.21 ± 15.70 58.18 ± 7.04 68.38 ± 15.91 84.04 ± 11.00 
Circulating serum TSH mean ± SEM concentrations measured in non-anesthetized rats (n=6 per sex per treatment 
group). 
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Figure 3.2 Circulating serum concentrations of T3 
Circulating serum concentrations of T3 at weeks 0, 4, 8, and 12 in (A) the control 
(CF) (n=6) and high dietary taurine (TF) (n=6) females and in (B) the control 
(CM) (n=6) and high dietary taurine (TM) (n=6) males.  There were no significant
dietary treatment effects over the twelve weeks (p=0.21). 
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Figure 3.3 Circulating serum concentrations of T4 
 
Circulating serum concentrations of T4 at weeks 0, 4, 8, and 12 in (A) the control 
(CF) (n=6) and high dietary taurine (TF) (n=6) females and in (B) the control 
(CM) (n=6)  and high dietary taurine (TM) (n=6) males.  There were no significant 
dietary treatment effects over the twelve weeks (p=0.28). 
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There was a positive correlation found between serum T3 and taurine 
consumed every two weeks (r = 0.55, p < 0.002) and serum T3 and plasma 
taurine concentrations (r = 0.50, p < 0.001) for the female rats, but not for the 
male rats (r = 0.02, p = 0.91; r = 0.04, p = 0.079).  There were no correlations 
found between serum T4 and taurine consumed every 2 weeks (females r = 0.19, 
p = 0.27; males r =-0.21, p = 0.22) and between serum T4 and plasma taurine 
concentration (females r = -0.01, p = 0.94; males r = -0.25, p = 0.09).  There 
were also no correlations between serum TSH and taurine consumed every two 
weeks (females r = 0.43, p = 0.22; males r = 0.09, p = 0.58) and serum TSH and 
plasma taurine concentration (females r = -0.19, p = 0.19, males r = -0.11, p = 
0.44). 
Taurine concentrations 
The amount of taurine consumed correlated with the plasma taurine 
concentrations (females r = 0.88, p < 0.001; males r = 0.80, p < 0.001).  Taurine 
post-prandial plasma concentrations were significantly higher in the female high 
dietary taurine treatment group (p <0.001) and male high dietary taurine 
treatment group (p <0.001) when compared to the control groups (Fig 3.4). There 
were no significant treatment effects found in the taurine content of the thyroid 
gland when normalized by the wet organ weight (p = 0.18) and the protein 
concentration (p = 0.43)(Fig 3.5).   
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Figure 3.4 Post-prandial plasma taurine concentrations 
Post-prandial plasma taurine concentrations in control females (CF) (n=6), control males 
(CM) (n=6), high dietary taurine females (TF) (n=6), and high dietary taurine males (TM)
(n=6). 
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Figure 3.5 Thyroid gland taurine concentrations 
There were no significant treatment effects found in the taurine content of the thyroid 
gland when normalized by (A) the wet organ weight (p = 0.18) and (B) the protein 
concentration (p = 0.43). 
Feed intake 
Over the entire 12-week study, the female high dietary taurine rats 
consumed 855 ± 12.9 grams (SEM) which was significantly more than the female 
control rats who consumed an average of 795 ± 26.9 grams (p < 0.05) (table 
3.5).  The female high dietary taurine rats body mass significantly increased 
compared to the body mass of the female control rats (p < 0.01).  There was not 
a significant difference (p = 0.68) between the feed consumption of the control 
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males compared to the male high dietary taurine treatment group (table 3.5) nor 
a significant difference in weight gain (p = 0.44; control 98.0 ± 4.7 grams; taurine 
107.0 ± 8.2 grams).    
Table 3.5 Summary of weights, feed intake, and feed conversion 
Treatment Control Taurine Control Taurine 
Treatment 
p-value
Sex-
effect 
p-value
Sex Female 
(n=6) 
Female 
(n=6) 
Male 
(n=6) 
Male 
(n=6) 
Starting 
weight (g) 
207 ± 10.6 202 ± 8.33 319 ± 8.50 315 ± 4.83 0.35 0.001 
Ending 
Weight (g) 
216 ± 5.54* 230 ± 8.29* 417 ± 15.5 422 ± 24.1 0.02 0.001 
Weight 
Gain (%) 
4.68 ± 0.05* 13.9 ± 0.06* 30.1 ± 0.04 34.0 ± 0.06 0.001 0.001 
Feed 
intake (g) 
795 ± 26.9* 854 + 12.9* 1267 ± 63.8 1310 ± 71.4 0.03 0.001 
* Denotes significance difference in females only.  Dietary taurine treatment
resulted in an increase ending weight, an increase in percent weight gain, and an 
increase in feed intake.   
Histology 
All 24 thyroid glands examined had evidence of partial or complete 
follicular collapse which altered the follicular diameter and sometimes caused 
indistinct margins of the follicular cells, prohibiting measurement of the follicular 
diameter and epithelium height.  To determine if this was autolysis, another 
investigator euthanized 8 adult, male, Wistar rats (Crl:WI Charles River, 
Wilmington, MA, USA) and allowed us to collect the thyroid glands from 2 rats at 
each of the following time points: 0, 30, 60, or 90 minutes post-euthanasia.  The 
glands were immediately fixed in 10% buffered formalin and submitted as 
previously described for periodic acid-Schiff staining. The thyroids among the 8 
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rats harvested at 0, 30, 60, and 90 minutes after euthanasia had evidence of 
partial follicular collapse with loss of colloid at 30 minutes post-euthanasia with 
carbon dioxide (Fig 3.6). Due to unexpectedly rapid autolysis affecting the thyroid 
glands, histological analysis of the follicles was not continued as the observer 
could not differentiate between morphological changes caused by autolysis or 
possible treatment effects. 
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Figure 3.6 Periodic acid-Schiff stained thyroid glands 
(A) Photomicrograph of a PAS stained Wistar rat thyroid gland, collected 30 minutes after euthanasia. An example of a large follicle
filled with colloid designated by (      ).  The arrowhead points to a small amount of colloid that is left in a follicle as it begins to 
collapse.  (B) A PAS stained Wistar rat thyroid gland collected 90 minutes after euthanasia.  There is no colloid in the follicles, and 
they are partially to completely collapsed. 
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Discussion 
Rodent animal models are heavily utilized in thyroid research including 
studies focused on the effects of dietary constituents on the hypothalamic-
pituitary-thyroid axis (Gallaher 1992; Vanderpas 2006). Animal models are also 
utilized in nutrition research, and most of our knowledge on tolerance of amino 
acid excess has come from animal studies (Baker 2008).  Rats in particular have 
been heavily utilized in taurine research (Huxtable 1992). Since rats readily 
consume purified diets and our control rats would not become taurine deficient, 
as rodents can adequately synthesize taurine from dietary methionine and 
cysteine (Huxtable 1992; Ito et al. 2012), we selected to use the rat as an animal 
model to test our hypothesis that excessive dietary taurine would alter the 
homeostasis of the thyroid axis.  Furthermore, we selected a rat model because 
it is considered a sensitive mammalian model for detecting changes in the thyroid 
axis when screening for endocrine disrupting compounds that alter the 
production of thyroid hormones (Pickford 2010).  The underlying physiology of 
the rat including high numbers of sodium iodide symporters on thyroid follicular 
cells (Josefsson et al. 2002), low amounts of colloid stores in the thyroid gland 
(McClain 1995), and short half-lives of the thyroid hormones due to thyroid 
binding globulin transporter being absent in rats age 2 – 7 months old 
(Lewandowski et al. 2004) are all thought to contribute to the sensitivity of the rat 
by limiting their ability to compensate for compounds that disrupt the thyroid axis 
(Pickford 2010).  
Our rats exhibited inter- and intra-individual variation of circulating serum 
thyroid hormone concentrations (Fig 3.1) similar to the variation reported in 
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humans (Maes et al. 1997).  This finding was unexpected due to the low amount 
of colloid store in the rat thyroid gland and the reported limited ability of rats to 
compensate for thyroid axis disruptions (Pickford 2010).  While rats on the high 
taurine diet had significantly increased post-prandial concentrations of taurine 
(Fig 3.4), we did not detect an increased uptake of taurine by the thyroid gland 
(Fig 3.5) nor did taurine elucidate a treatment effect on the circulating 
concentrations of T4, T3, and TSH (Fig 3.2-3.3). However, the biological variation 
in our thyroid hormone data may be masking a dietary treatment effect, and 
therefore future studies should have a larger sample size. 
Typically, most rodent studies only measure circulating concentrations of 
thyroid hormones at the endpoint of a study, as to the authors’ knowledge, there 
are no reports of rodent studies evaluating variation in concentrations of 
circulating levels of thyroid hormones over time (Pickford 2010).  Even 
established guidelines set forth by the US Environmental Protection Agency 
(EPA) pertaining to pesticide-induced alterations of the thyroid axis and the 
guidelines set forth by the Organization for Economic Co-operation and 
Development (OECD) for reproduction/developmental toxicity screening of 
endocrine disruptors do not address the biological variation we observed and 
only recommend measuring thyroid hormones at the terminal endpoints.  
Additionally, the guidelines dedicate a section to hormone analysis, with both 
organizations highlighting only the importance of drawing blood at the same time 
of day due to circadian rhythm of thyroid hormones and recommend to minimize 
any stress that could affect circulating thyroid hormones (OECD 2015; EPA 
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2005).  EPA also mentions that if animals are anesthetized, then documentation 
should be provided that anesthetic does not exert an effect on the circulating 
thyroid hormones (EPA 2005).   
Our study addressed the factors outlined in the EPA and OECD guidelines 
by collecting blood samples for each animal at the same time of day, not using 
anesthesia while collecting blood samples used for thyroid hormone analysis, 
and the animals were acclimated to handling and the restraint prior to the start of 
the study.  If we had selected only a single time point for measuring the 
circulating thyroid hormones as other studies, our data could have shown a 
significant effect between groups (Fig. 3.2-3.3) which clearly would have been 
the natural variation of the individuals rather than a true effect.  Therefore, the 
biological variability in circulating thyroid hormones is important to consider when 
designing studies aimed at detecting treatment effects in the functioning of the 
thyroid axis. Well-designed human clinical studies provide additional support for 
this concept as the goal of most animal model studies are to identify endocrine 
disrupting compounds that could cause effects in humans. Of particular note are 
the human clinical studies that focused on how biological variation affects 
interpretation of thyroid function tests (Andersen et al. 2003; Benhadi et al. 
2010), as it is well recognized within the population that large inter- and intra-
individual variation of serum T3, T4, and TSH exists in healthy human subjects.  
These studies have resulted in some physicians developing “rule of thumbs” for 
assessing changes in circulating thyroid hormone concentrations, such as a 
change of 40 nmol/L in T4 is needed to achieve a beta of 0.90 (Andersen et al. 
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2003).  Changes in circulating thyroid hormones, considered to represent a true, 
clinically significant change, should be established for rodent studies where 
circulating thyroid hormones are a measured outcome. 
Despite the high biological variation that we observed, effects of sex were 
found. The circulating serum concentrations of T4 and TSH in the male rats were 
significantly higher than in the female rats, and the circulating serum T3 
concentrations in the female rats were significantly higher than in the male rats 
(Fig 3.1).  These sex differences have been previously reported in many other 
studies (Marassi et al. 2007; Rapp and Pyun 1974) and it has been suggested 
that greater hepatic sulfotransferase activity in males (Gong et al. 1992) could 
explain why the serum T3 in males is lower (Marassi et al. 2007). There are 
additional, well established sex-related differences in thyroid function such as 
increased T3 and TRH receptors in the adenohypophysis of female rats (Donda 
et al. 1990). Unfortunately, none of these sex-related differences have provided 
insight into why there is a higher prevalence of hyperthyroidism and thyroid 
diseases in females (Krohn et al. 2005a).   
Our study incorporated both sexes to determine if taurine exerted any sex-
specific effects on the function of the thyroid axis which could help to explain the 
increased incidence of hyperthyroidism in females. In other studies investigating 
taurine supplementation, sex-specific effects have been found.  One such study 
by Roysommuti et al. (2009) found that supplementing Sprague-Dawley rats with 
taurine alters arterial blood pressure control depending upon the sex of the rat 
(Roysommuti et al. 2009).   
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Interestingly, only in the female rats was there a significant correlation 
between circulating serum T3 and the amount of taurine consumed.  This was 
also true for the correlation between circulating serum T3 and circulating plasma 
taurine concentrations. While sex hormones influence the deiodinase enzymes 
that are responsible for converting T4 to T3 (Marassi et al. 2007), it is unknown if 
taurine has any regulation of deiodinase activity.  It could be that taurine alters 
the gene expression of the deiodinases found within the thyroid gland as it has 
been shown that gene expression can be influenced through high dietary taurine 
consumption (Yokogoshi et al. 1999). Since the thyroid gland is responsible for 
40% of daily T3 production in the rat (Bianco et al. 2002), perhaps with larger 
samples sizes, we could have clearly detected an increased concentration of 
taurine in the female thyroids.  Increased taurine content in female thyroid glands 
has been reported in a larger study (Jacobsen and Smith 1968) and could help 
explain as to why circulating T3 concentrations in the female rats are correlated 
with taurine.  The sex difference found in taurine content could also help explain 
why circulating T3 concentrations are significantly higher in female rats 
compared to the male rats.  
Another sex-specific taurine effect in our study was the significant 
increase in feed intake and body weight gain in the female high dietary taurine 
treated rats.  Taurine has been shown to improve growth and feed conversion 
efficiency in a variety of species within the aquaculture industry (Johnson et al. 
2015; Matsunari et al. 2008), although the mechanism remains unknown.  
Dietary taurine has been shown to increase amylase, lipase, trypsin, and pepsin 
 73 
 
enzyme activity in larval cobia which has led to the thought perhaps taurine 
increases the nutrient availability within the diet (Salze et al. 2012).  Another 
possible mechanism is that dietary taurine alters the bile acid composition 
leading to an alteration in the microbial community in the gut. It is thought that 
bile acids are responsible for controlling some aspects of the microbial 
community (Ridlon et al. 2014).  
Another important study finding was how quickly the post-mortem changes 
altered the morphology of the thyroid glands. Multiple studies have indicated that 
histopathological analysis in mammalian models is one of the most sensitive 
outcomes for evaluation of changes in the thyroid axis (Pickford 2010). None of 
these studies discuss how quickly autolysis affects the thyroid glands of rats.  
Several studies have utilized human thyroids collected during autopsies for 
histological studies including one report by De Jongh et al. (2001) that showed 
there were no changes in follicular diameter of the thyroid gland up to 48 hours 
post-mortem (De Jongh et al. 2001). The post-mortem collapse of the follicular 
cells and loss of distinct cellular borders that we observed (Fig 3.6) may have 
been due to a species differences. Rats have cuboidal follicular epithelium and 
small amounts of colloid compared to those in the thyroid glands of primates who 
have large amounts of colloid and a thin cuboidal follicular epithelium (McClain 
1995).  The post-mortem changes in the rats prohibited us from being able to 
detect histopathologically identifiable treatment effects such as follicular 
hypertrophy.  In rats, there are few studies that incorporate histopathological data 
at the endpoints (Pickford 2010). This absence of reporting may reflect on the 
 74 
 
challenge of preserving the thyroid glands without artefactual post-mortem 
changes. Many researchers, including our laboratory group, specifically harvest 
tissue for immediate freezing to measure time-sensitive biomarkers such as 
mRNA. Similar expedience appears to be needed for histological evaluation of 
the thyroid glands of rats. 
Conclusion 
 Our study sought to determine if the consumption of high levels of dietary 
taurine affected the homeostasis of the thyroid axis.  While there was a 
significant positive correlation between serum T3 and plasma taurine 
concentrations in the female rats, we did not observe this in the male rats.  
Additionally, the female high dietary taurine rats exhibited a significant increase 
in body weight and food consumption compared to the control female rats.  With 
the unexpectedly large intra- and inter-individual variation of serum T3, T4, and 
TSH, our results indicate a larger study evaluating the effects of taurine on the 
female thyroid axis is warranted.   
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Abstract  
High doses of oral taurine, a β-amino acid, are recommended to help 
mitigate certain diseases; however, little is known about possible negative side 
effects of these large doses.  The purpose of our study was to determine if 
taurine-induced increases in the body weight of female rats was due to an 
increase in muscle mass, an increase fat mass, or both.  We hypothesized that 
dietary taurine would cause an increase in circulating insulin-like growth factor-1 
(IGF-1) yielding to an increase in lean muscle mass.  Furthermore, we 
hypothesized that taurine would cause an increase in Firmicutes and decrease in 
Bacteroides and the changes could be correlated to an increase in body fat. To 
test these hypothesis, 12 male and 12 female sexually mature Sprague Dawley 
rats were randomly assigned to a 0% taurine or a 0.7% taurine diet for 12 weeks.  
Circulating IGF-1 concentrations were measured at day 0, 14, 28, 42, 56, 70, and 
84.  Fecal microbiome analysis was completed on fecal pellets collected on Day 
0 and Day 84.  On Day 85, dual x-ray absorptiometry (DXA) scans were 
completed and revealed a trend of increased fat (p = 0.09) and lean + bone 
mineral content (p = 0.10) in female rats consuming the high taurine diet. The 
female rats consuming the high dietary taurine diet had an increase in Firmicutes 
and a decrease in Bacteroidetes phyla (p < 0.05).  The β-diversity at the OTU 
level was different between males and females at day 0 (p < 0.001), but the sex-
difference was lost by day 84 (p = 0.12).  Taurine did not increase the circulating 
serum IGF-1 concentrations (p = 0.42), but sex- effects were observed (p < 
0.001) with mean circulating concentrations of IGF-1 with 863 ± 24.1 ng/mL in 
the females and 1284 ± 21.95 ng/mL in the males.  Our results suggest that the 
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AIN-93 purified diet and high levels of dietary taurine may promote an increase in 
Firrmicutes phylum and a decrease in Bacteroides phylum that is associated with 
obesity. 
Introduction 
Amino acids, once considered simply building blocks for proteins, are now 
recognized to have funcational roles in metabolism such as lipid and glucose 
metabolic pathways, anti-oxidative reactions, and generation of physiologically 
important peptides and nitrogenous substances (Wu et al. 2014).  This new 
perception of amino acids challeges the traditional classifications of essential or 
nonessential amino acids.  Amino acids classified as essential must be acquired 
in the diet as they are not synthesized de novo or cannot be synthesized in 
adequate amounts to meet the animal or human’s needs (Wu 2009). 
Nonessential amino acids are synthesized de novo in adequate amounts and are 
not required to be consumed in the diet (Wu 2009). A third category, conditionally 
essential amino acids, are synthesized de novo; however, there are limits to the 
rate at which they can be synthesized (Reeds 2000).   
Taurine, a β-amino acid, is classified as a conditionally essential amino 
acid in some species while in other species it is either nutritionally essential or 
non-essential (Jacobsen and Smith 1968).  Healthy adult individuals in some 
species can biosynthesize adequate amounts of taurine to meet their needs from 
dietary cysteine and methionine (Jacobsen and Smith 1968; Wu et al. 2014) 
while individuals undergoing certain stresses (e.g. severe infection) or during 
certain life stages (e.g. neonates) cannot adequately synthesize taurine to meet 
the body’s biological needs (Lourenco and Camilo 2002).  Therefore, taurine 
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must be acquired through the diet under these conditions.  With the recognition 
of the functional roles of amino acids beyond their nutritional essentiality (Wu 
2010) there is a developing interest in providing taurine to optimize health in 
adults and treat diseases.  Clinicians have recommended supplemental oral 
taurine to help mitigate certain diseases such as hypertension (Militante and 
Lombardini 2002),and are beginning to recommend taurine to treat secondary 
disease complications such as endothelial dysfunction in diabetes (Ito et al. 
2012).  Clinical research evaluating taurine supplementation in diseased 
individuals have evaluated oral doses of up to 10 grams per day (Durelli et al. 
1983). These taurine doses are much higher than the average dietary taurine 
consumption of 58 mg per day in Europe (Schaffer et al. 2014) or 123 mg per 
day in America (Laidlaw et al. 1990).   It is largely unknown if there are risks 
associated with these high doses of taurine as clinical studies have been short 
duration, and typically data provided for evaluating possible negative side effects 
of taurine administration is limited to self-reporting within these studies (Shao and 
Hathcock 2008).  
Recently, using a rat model, our laboratory sought to test the hypothesis 
that extraordinary high dietary taurine could alter the activity of the hypothalamic-
pituitary-thyroid axis.  Our hypothesis stemmed from in-vitro evidence that taurine 
increases proliferation rates of thyroid cells when cultured in taurine-containing 
media (Jhiang et al. 1993).  In our study, we determined that there was a positive 
correlation between circulating concentrations of plasma taurine and serum 
triiodothyronine (T3), but only in female rats (Hooper et al. 2017). Interestingly, 
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we also observed that the female rats consuming high dietary taurine diet gained 
significantly more weight compared to the control females.  The weights of the 
male rats consuming high dietary taurine were not significantly different 
compared to the control rats (Hooper et al. 2017).  Therefore, the purpose of our 
study presented here was to determine if the taurine-induced increase in body 
weight among the female rats was due to increased lean muscle mass or 
increased fat mass and to investigate two alternative mechanisms that could 
explain the observed gain in body weight.   
We hypothesized that the rats given high dietary taurine would have 
increased lean muscle mass and that the effect may be caused by an increase in 
circulating insulin-like growth factor-1 (IGF-1).  Both IGF-1 and growth hormone 
are recognized to play a role in post-natal growth (Lupu et al. 2001), and 
intravenous taurine has been shown to increase circulating IGF-1 (Ikuyama et al. 
1988).  Additionally, IGF-1 is known to play a role in thyroid function (Ock et al. 
2013), and could help explain the correlation between circulating T3 and plasma 
taurine.  
Furthermore, liver taurine concentration is known to be elevated with high 
dietary taurine intake (Satsu et al. 2002).  It is also known that taurine 
conjugation of bile acids is strongly correlated to the taurine content in the liver 
(Martin et al. 2007), and that alterations in bile acid composition leads to an 
alteration in the microbial community in the gut (Ridlon et al. 2014).  Therefore, 
our second mechanistic hypothesis was that rats consuming the high taurine diet 
would have an alteration in the composition of bacteria in the gut, causing an 
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increase in bacterial phyla associated with weight gain (e.g. an increase in 
Firmicutes and decrease in Bacteroides) (Holmes et al. 2011) that could help 
explain the increase in weight gain.   
Materials and Methods 
Descriptions of animals, study design, blood collection methods, and 
taurine analysis are described in brief.  Detailed descriptions are in the 
companion report Hooper et al. (2017). 
Ethics statement 
This study was carried out in an AALAAC accredited animal facility in 
accordance to the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health.  All activities were conducted under an approved 
University of Missouri-Columbia Animal Care and Use Committee animal use 
protocol. 
Animals 
Twelve male, ten-week-old Sprague Dawley rats and twelve, seventeen-
week-old female Sprague Dawley rats (Hsd: Sprague Dawley rats, Envigo, USA) 
were acclimated to handling, restraint, and meal feeding prior to the start of the 
study. The male rats were younger, as rats were requested from Harlan 
Laboratories Inc. (now Envigo, Indianapolis, Indiana, USA) to be at the top of the 
growth curve rather than a specific age. Rats were pair housed in an animal 
facility that was temperature controlled and under a 12 hr light-dark cycle (light 
600 to 1800 hrs).   
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Diets and study design 
The study began after all rats underwent adaption to a daily 4-hour period 
during which a standard rodent chow was presented for ad libitum consumption 
(Lab Diet Rat Diet 5012, St. Louis, MO, USA). Once body weights stabilized, the 
rats were randomly assigned to one of two dietary treatment groups that were 
balanced for sex and starting body weight.  Using a parallel design of 12 weeks 
duration (84 days), the rats were individually housed from 800 to 1200 hrs and 
presented with ~50 grams of their assigned diet, which was either a purified diet 
with 0% taurine (no taurine diet) (Modified AIN-93M 0.7% cornstarch Dyets 
#103967, Dyet’s Inc., Bethlehem, PA, USA) or 0.7% of the dry matter (DM) 
weight in which corn starch was substituted with a weight equivalence in taurine 
(high taurine diet) (Modified AIN-93M 0.7% taurine Dyets #103968, Dyets Inc., 
Bethlehem, PA, USA). During the 4-hour feeding periods, each rat was placed in 
a solid-bottom, plastic cage with a wire-bar lid fashioned with a hopper for diet 
pellets and mount for a water bottle (static interchangeable plastic rat cage, 
Allentown Inc, Allentown, NJ, USA). Cage litter was hand-sifted to ensure all feed 
that was not consumed was removed.  The difference between weight of food 
presented and removed was counted as food intake.   
Blood collection 
Between 600 and 800 hrs on days 0, 14, 28, 42, 56, 70, and 84, the rats 
were briefly restrained without anesthesia for blood collection from a saphenous 
vein. A second, post-prandial blood sample was collected from the jugular vein 
between 1400 and 1700 hrs while the animals were anesthetized using 
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isoflurane.  Blood samples were allowed to clot for a minimum of one hour prior 
to serum extraction. Serum samples were frozen at -20°C until analysis. 
Fecal collection 
On days 0 and 84, the rats were individually housed in clean cages from 
600 to 1800 for fecal pellet collection. Samples were immediately placed into a -
20°C freezer, and were moved to a -80°C freezer after the collection window. 
Some animals did not defecate during the collection window.  As a result, these 
animals were excluded from the analysis of the specific time point. 
Dual energy X-ray absorptiometry 
The rats were anesthetized with isoflurane on day 85, and were 
euthanized through exsanguination. Immediately after euthanasia, all rats had 
duplicate dual energy X-ray absorptiometry (DXA) scans (Hologic Discovery A, 
Hologic Company, Bedford, USA) performed from the tip of the nose to the end 
of the tail (Rose et al. 1998). The rats were positioned on a bare scan table in 
ventral recumbancy using a laser for positioning guidance. Quality control checks 
were performed prior to completion of the scans using a spine and rat step 
phantom as recommended by the manufacturer. Analysis for whole body bone 
mineral content (BMC), bone mineral density (BMD), fat mass, lean mass plus 
BMC, total mass, and percent fat was completed using built-in Hologic software. 
Tissue collection 
Subsequently to the DXA scan, the following organs of the rats were 
removed and weighed: liver, fat pads, heart, lungs, kidney, adrenal glands, 
spleen, brain, ovary, uterus, testis, epididymis, thyroid, thymus, extensor muscle, 
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and soleus muscle. Immediately after weighing, liver and kidney was flash frozen 
using liquid nitrogen. Quadriceps muscle was removed and samples stored at -
20°C until analysis. Liver and kidney samples were stored at -80°C. 
IGF-1 serum concentrations 
IGF-1 was measured in duplicate in morning-collected serum samples 
when the rats were briefly restrained without use of anesthesia. For the IGF-1 
measurements, a R&D Systems Mouse/Rat IGF-1 Quantikine ELISA kit (R&D 
Systems, Minneapolis, MN, USA) was used following the kit directions. 
Tissue and whole blood taurine concentrations 
Taurine concentration was measured on day 84 post-prandial blood 
samples. To ensure cells were lysed the whole blood samples were frozen and 
thawed 3 times before extraction for taurine analysis. For taurine analysis, 
approximately 50 milligrams of thawed liver or kidney samples were 
homogenized in 1.5 mL of distilled water, and approximately 25 milligrams of 
thawed quadriceps muscle was homogenized in 500 µL of distilled water. The 
homogenates were frozen and thawed three times, deproteinized, and their 
taurine concentration measured using high pressure liquid chromatography 
(HPLC) methods described by Hooper et al. (2017). In brief, the samples were 
deproteinized by adding 50 µL of acetonitrile to 50 µL of plasma, whole blood, or 
tissue homogenate.  Prior to the extraction to remove protein trans-4-hydroxy-L-
proline was added as internal standard. Samples were centrifuged for 15 min at 
16,000 x g.  Fifty microliters of resulting supernatant were transferred to a 13 x 
100 mm glass tube and evaporated by centrifugal evaporation. Fifty microliters of 
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a coupling solution (1:1:1, v/v, triethylamine:water:methanol) was added to the 
dried residue, and subsequently evaporated to dryness.  Then, 50 µL of 
derivatization solution (20:5:5:2, v/v, 
methanol:water:triethylamine:phenylisothiocyanate) was added to each tube and 
tubes were covered with parafilm and left at ambient temperature.  After 20 
minutes, samples were evaporated to dryness and redisolved in 400 µL of 
sample diluent (710 mg disodium hydrogen phosphate, 950 mL water, 5 mL 
acetonitrile, adjusted to pH 5.4 with phosphoric acid). The reconstituted samples 
were transferred to centrifuge tube with a 0.2 µm centrifuge tube filter 
(Corning®Costar® SpinX centrifuge tube filters, Sigma Aldrich, St. Louis, MO, 
USA) and spun for 15 min at 15,000 x g. Samples were injected into a C18 
column (Microsorb 100-5 C18, 250 x 4.6 mm Varian Inc. Lake Forest, CA, USA) 
and the UV265nm absorbance of the phenylisothiocyanate derivatives of taurine 
and internal standard were quantified. 
Tissue protein determination 
Protein was measured in the liver, kidney, and muscle homogenate 
solutions by Bradford assay (Bradford 1976)(BioRad USA  Microplate BSA 
Hercules, California 94547) following the manufacturer’s directions for the 
standard microplate assay.  Lyophilized, essentially fat free, bovine serum 
albumin (Sigma Aldrich, St. Louis, MO, USA) was used to establish the standard 
curve from 0 to 1000 µg/mL. All homogenate solutions were diluted to ensure 
protein analysis was conducted between 400-800 µg/mL, a linear range found for 
the assay.  
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Fecal DNA extraction and sequencing 
DNA extraction was modified from the methods described by Ericson et al. 
(2015). One fecal pellet was placed into a sterile 2 mL round-bottom tube with a 
0.5 cm diameter stainless steel bead. Eight-hundred microliters of 37°C lysis 
buffer (500 mM NaCl, 50 mM Tris-HCl pH 8.0, 50 mM EDTA, and 4% sodium 
dodecyl sulfate) was placed into each tube and homogenized for 3 minutes at 30 
Hz in TissueLyser II (Qiagen, Venlo, Netherlands). Tissue samples were 
incubated for 70°C for 20 minutes with periodic vortexing. After incubation, 
samples were centrifuged at room temperature for 5 min at 5,000 x g. The 
supernatant was transferred to a new sterile 1.5 mL Eppendorf tube before 
adding 200 µL of 10 mM ammonium acetate. The mixture was vortexed, 
incubated on ice for 5 min, and centrifuged at room temperature for 5 min at 
5,000 x g. Seven-hundred and fifty microliters of supernatant was transferred to a 
new 1.5 mL Eppendorf tube containing 750 µL of ice-chilled isopropanol. The 
samples were incubated for a minimum of 30 min on ice, and subsequently 
centrifuged at 4C° for 15 min at 16,000 x g. The supernatant was aspirated and 
discarded. The resulting DNA pellet was washed with 150 µL of 70% ethanol, 
and resuspended with 150 µL of Tris-EDTA (10 mM Tris and 1 mM EDTA). 
Occasionally incubation of DNA pellets in a 37°C water bath for 20 min with 
intermittent vortexing was required to fully resuspend pellet. After pellet 
resuspension, 15 µL of proteinase K and 200 µL of AL Buffer (Qiagen DNeasy 
Blood and Tissue kit, Qiagen) were added to the mixture and thoroughly 
vortexed. The mixture was incubated at 70°C for 10 min before adding 200 µL of 
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100% ethanol and mixing by gently aspirating and eluting of the contents multiple 
times in a pipette. Subsequently, the contents were transferred to a spin column 
in the DNeasy kit and centrifuged at room temperature for 1 min at 16,000 x g. 
Using the Qiagen kit reagents, the flow-through and collection tube were 
discarded, the column retained, and 500 µL of Buffer AW1 was added before 
spinning for 1 min at 16,000 x g. The flow through-and collection tube were 
discarded, the column retained, and 500 µL of Buffer AW2 was added before 
spinning for 3 min at 16,000 x g. The column was transferred to a clean 1.5 mL 
Eppendorf tube and 200 µL of EB buffer was added. Samples were incubated at 
room temperature for 2 min prior to centrifuging for 1 min at 16,000 x g. DNA 
concentrations were determined fluorometrically (Qubit dsDNA BR assay, Life 
Technologies, Carlsbad CA).  
The DNA was submitted to the University of Missouri Metagenomics 
Center for 16S rRNA sequencing and informatics analysis as previously 
described (Ericsson et al. 2015; Hart et al. 2015). In summary, DNA 
concentrations were normalized to 3.51 ng/µl in EB buffer at a volume of 60 µl. 
The University of Missouri DNA Core facility performed the library construction 
and sequencing. Bacterial 16S rDNA amplicons were constructed by the 
amplification of the V4 hypervariable region of the 16s rRNA with universal 
primers (U515F/806R) (Caporaso et al. 2011; Walters et al. 2011) flanked by 
Illumina standard adapter sequences. Amplicons were pooled for sequencing 
with an Illumina MiSeq platform and V2 chemistry with 2 x 250 bp paired-end 
reads. The University of Missouri Informatics Research Core Facility assembled, 
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binned, and annotated the DNA sequences. Contiguous DNA sequences are 
assembled using FLASH software (Magoc and Salzberg 2011), with sequences 
eliminated from analysis if they had a base quality less than 31 after trimming. 
Representative operational taxonomic sequences (OTUs) were selected using 
Qiime v1.8. Selected OTUs were annotated to the Greengenes database 
(DeSantis et al. 2006) of 16S rRNA gene sequences using BLAST (Altschul et al. 
1997) and taxonomy assigned. Relative abundance of OTU data was 
transformed by using ¼ root before principal component analysis (PCAs) were 
performed in PAST (Hammer 2001). 
Statistical analysis 
We used SAS 9.3 (SAS Institute Inc., Cary, NC, USA) and PAST 3.14 
(Øyvind Hammer, University of Oslo, Norway) to perform all statistical analysis 
and significance was calculated at alpha = 0.05.  Alpha values of 0.06 - 0.10 
were considered indicative of a trend. Data was tested for normality using the 
Shapiro-Wilk, Kolmogorov-Smirnov, and Anderson-Darling tests. Non-normally 
distributed data was transformed using log10, square root, or ¼ root.  The Proc 
GLM and Proc GLMMix procedure and differences of the least square means 
was used to compare the variables of interest, the interactions, and for alpha-
diversity of phyla and OTUs. For beta-diversity of phyla and OTUs, two-way 
PERMANOVA using the Bray-Curtis Similarity Index was completed for time vs 
diet and diet vs sex at day 0 and day 84. 
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Results  
Body weight and feed intake 
Body weights and feed intakes were previously reported by Hooper et al 
(2017) are summarized in Table 4.1.  In brief, both male and female rats, 
irrespective of diet, were heavier on day 84 compared to day 0 (p < 0.05).  The 
female rats consuming the high taurine diet gained significantly more weight 
compared to the control females (p < 0.02). The mean feed intake was 7% 
greater compared to the dietary control females (p < 0.001).  In the male rats, 
there were no dietary treatment effects observed on food intake and body weight. 
Table 4.1 Summary of weights, and feed intake 
Treatment Control Taurine Control Taurine Treatment 
Sex-
effect 
Sex Female 
(n=6) 
Female 
(n=6) 
Male 
(n=6) 
Male 
(n=6) 
p-value p-value 
Starting 
weight (g) 
207 ± 10.6 202 ± 8.33 319 ± 8.50 315 ± 4.83 0.35 0.001 
Ending 
Weight (g) 
216 ± 5.54* 230 ± 8.29* 417 ± 15.5 422 ± 24.1 0.02 0.001 
Weight 
Gain (%) 
4.68 ± 0.05* 13.9 ± 0.06* 30.1 ± 0.04 34.0 ± 0.06 0.001 0.001 
Feed 
intake (g) 
795 ± 26.9* 854 + 12.9* 1267 ± 63.8 1310 ± 71.4 0.03 0.001 
* Denotes significance difference in females only 
Summary of data from Hooper et al 2017.  Dietary taurine treatment resulted in 
an increase in ending weight, an increase in percent weight gain, an increase in 
feed intake, and a decrease in feed conversion ratio.  
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Organ weight 
All organs except the brain and thymus were of significantly greater weight 
in the male rats compared to the female rats (Table 4.2). The weights of the high 
dietary taurine female rats’ spleens were greater compared to the control females 
(p < 0.02). The high dietary taurine female rats’ ovaries were trending towards 
being heavier than those in control rats (p = 0.06).  
9
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Table 4.2 Summary of organ weights 
Organ 
Control Taurine Control Taurine Treatment 
Sex-
effect 
Female Female Male Male p-value p-value
Adrenal gland (mg) 62.9 ± 58 57.3 ± 65.1 83.1 ± 67.1 61.2 ± 70.5 0.96 0.03 
Brain (g) 1.71 ± 0.03 1.75 ± 0.03 1.92 ± 0.02 1.65 ± 0.29 0.46 0.71 
Epididymus (g) 1.22 ± 0.05 1.24 ± 0.09 0.83 
Fat pads (g) 4.07 ± 0.46 4.70 ± 0.26 12.13 ± 0.86 12.70 ± 2.00 0.6 0.001 
Heart (g) 0.79 ± 0.03 0.83 ± 0.03 1.31 ± 0.04 1.33 ± 0.55 0.48 0.001 
Kidney (g) 1.17 ± 0.04 1.20 ± 0.04 2.15 ± 0.06 2.23 ± 0.07 0.28 0.001 
Liver (g) 5.495 ± 0.19 5.97 ± 0.37 12.66 ± 0.41 12.41 ± 0.46 0.90 0.001 
Lungs (g) 0.99 ± 0.03 1.08 ± 0.08 1.36 ± 0.07 1.40 ± 0.07 0.33 0.001 
Ovary (mg) 101.8 ± 90.7 124.9 ± 15.0 0.06 
Spleen (g) 0.40 ± 0.01* 0.49 ± 0.01* 0.66 ± 0.02 0.68 ± 0.03 0.02 0.001 
Thyroid (mg) 15.3 ± 0.64 14.8 ± 0.75 19.1  ± 0.77 19.08 ± 1.56 0.79 0.001 
Testis (g) 3.72 ± 0.08 3.77 ± 0.12 0.75 
Thymus (mg) 0.16 ± 0.02 0.20 ± 0.03 0.25 ± 0.04 0.24 ± 0.07 0.90 0.14 
Uterus (g) 0.54 ± 0.16 0.56 ± 0.06 0.65 
*Denotes significant difference in females only.
Gross organ weights by sex and treatment (n=6 per treatment per sex).  High dietary taurine significantly increased spleen 
weight in the females and the high dietary taurine rats’ ovaries were trending towards being heavier than the control rats.
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DXA 
There were significant sex-effect differences in all DXA parameters, 
except percent fat (Table 4.3). Males compared to females had greater (p < 
0.001) lean and fat masses as well as bone mineral content (BMC). Although 
there was a trend for greater fat mass (p = 0.09) and lean mass + BMC (p = 0.1) 
in the high dietary taurine female rats compared to the controls, there was no 
significant dietary treatment effects on DXA variables found in females and 
males.   
Table 4.3 Summary of DXA variables by sex and treatment 
DXA 
parameter 
Control Taurine Control Taurine Treatment 
Sex-
effect 
Female 
(n=6) 
Female 
(n=6) 
Male 
 (n=6) 
Male 
(n=6) 
p-value
p-
value 
Area 
(cm2) 
43.3 ± 0.33 43.5 ± 0.61 61.5 ± 0.74 61.26 ± 1.04 0.98 0.001 
BMC (g)1 8.02 ± 0.07 8.14 ± 0.09 12.5 ± 0.22 12.5 ± 0.22 0.75 0.001 
BMD 
(g/cm2)2 
0.19 ± 0.001 0.19 ± 0.002 0.20 ± 0.003 0.20 ± 0.003 0.62 0.001 
Fat (g) 19.27 ± 1.83 21.7 ± 1.33 46.0 ± 3.50 44.6 ± 6.9 0.09 0.001 
Lean + 
BMC (g) 
197 ± 2.83 210 ± 2.69 374 ± 4.61 377 ± 6.42 0.1 0.001 
Total 
mass (g) 
217 ± 2.90 231± 3.14 420 ± 6.44 421 ± 9.10 0.23 0.001 
% fat 8.87 ± 0.81 9.33 ± 0.47 10.9 ± 0.72 10.5 ± 1.44 0.98 0.1 
1 bone mineral content 
2 bone mineral density 
DXA variables were measured post-euthanasia on day 85.  Fat and lean + bone 
mineral content (BMC) were trending towards significantly different in the female 
high dietary taurine rats. 
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Whole blood and tissue taurine concentrations 
Day 85, post-prandial whole blood taurine concentrations were 
significantly higher in the female high dietary taurine treatment group (344 ± 42.8 
µmol/mL) and male high dietary taurine treatment group (264.81 ± 31.3 µmol/mL) 
when compared to their respective control groups (124 ±14.0 µmol/mL females, 
120 ± 17.6 µmol/mL males; p < 0.001) (Fig 4.1). The liver taurine concentrations 
were significantly higher in the male and female high taurine dietary treatment 
groups when compared to the controls (p = 0.01) (Fig 4.2). The quadriceps 
muscle taurine content was significantly greater in the female and male high 
taurine compared to control when normalized by wet weight (p < 0.001) and 
protein concentration (p < 0.01) (Fig4. 3). There was an interaction trend 
between sex and treatment for the muscle taurine content normalized by wet 
weight (p = 0.08), but not when normalized by protein concentration (p = 0.48). 
There were trends of greater taurine content in the kidney in the high taurine 
compared to control male and female rats when normalized by the wet organ 
weight (p = 0.07) and the protein concentration (p = 0.10) (Fig 4.4).   
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Figure 4.1 Whole blood taurine concentrations 
On day 84, the whole blood taurine concentration in the male (n=6) and female (n=6) 
rats on the high taurine dietary treatment were significantly higher than the control rats 
(n=6 per sex) (p < 0.001). 
*
*
101 
Figure 4.2 Liver taurine concentrations 
The liver taurine concentration when normalized by (A) wet weight (p = 0.01) and 
(B) protein concentration (p < 0.01) was significantly increased in the high dietary
taurine treated rats compared to the controls (n=6 per sex per treatment). 
*
*
* *
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Figure 4.3 Quadriceps muscle taurine concentrations 
The quadriceps muscle taurine concentration when normalized by (A) wet weight 
and (B) protein concentration was significantly increased in the high dietary 
taurine treated rats compared to the controls (wet weight p < 0.001; protein 
concentration p <0.003) (n=6 per sex per treatment). 
**
*
*
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Figure 4.4 Kidney taurine concentrations 
The kidney taurine concentration when normalized by (A) wet weight and (B) 
protein concentration was not increased in the high dietary taurine treated rats 
compared to the controls (wet weight p = 0.07; protein concentration p = 0.10) 
(n=6 per sex per treatment). 
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IGF-1 
There was no dietary treatment effect (p = 0.42) or interaction between 
dietary treatment and sex (p = 0.49) on serum concentrations of IGF-1.  However 
all male IGF-1 concentrations (mean 1284 ± 21.95 ng/mL) were significantly 
higher than all female IGF-1 concentrations (mean 863 ± 24.1 ng/mL) (p < 0.001) 
(Fig 4.5). 
Figure 4.5 Circulating serum IGF-1 concentrations 
All male (n=6 per diet) IGF-1 serum concentrations were significantly higher than 
all female (n=6 per diet) IGF-1 concentrations (p < 0.001). 
Microbiome  
Within the 12 hour window for fecal collection, 1 female rat in the high 
taurine dietary treatment group did not did not defecate on day 0 or day 84 and 1 
male rat in the high taurine dietary treatment group did not defecate on day 0.  A 
total of 45 fecal samples were collected.  Over 3.75 million 16S rRNA gene 
sequences were obtained from bacterial DNA extracted from the feces using 
from Illumina MiSeq sequencing. A total of 124 OTUs were identified from the 
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sequences representing 13 bacterial phyla and 51 bacterial families (Fig 4.6-4.7, 
Table S4.1).  Four of the bacteria phyla, Bacteroidetes, Firmicutes, 
Proteobacteria, and Tenericutes, accounted for 98.3% of the sequences obtained 
from both males and females.   
The rats given the high taurine diet had an altered abundance of 9 
bacteria including 6 within the Bacteroidetes phylum and 2 within the Firmicutes 
phylum (p < 0.05; Table 4.4-4.7) compared to the rats on the control diet. While 
taurine altered the abundance of Bacteroidetes phylum (p = 0.02) and the 
Firmicutes phylum (p = 0.03), there was a significant change in the abundance of 
Actinobacteria, Spirochaetes, TM7, and Tenericutes phyla caused by transition 
from the standard rodent chow to the purified diet (Table 4.4-4.5).  An interaction 
between diet and time was found to affect the abundance of the Barnesiellaceae 
family (p < 0.05) within Bacteroidetes phyla and Gracilibacter genus (p < 0.01) 
and Allobaculum genus (p < 0.001) within the Firmicutes family.   An interaction 
between diet and sex was found to affect the abundance of 9 Bacteroidetes (p 
<0.001), 1 Cyanobacteria (p = 0.05), 9 Firmicutes (p < 0.05), and 2 
Proteobacteria (p < 0.05; Table S4.2).  The abundance of 56 OTUs were altered 
by the transition of the rats from the standard rodent chow to the purified diet and 
the subsequent twelve weeks of consuming the purified diet (p < 0.05, Table 
S4.3).  There were 41 OTUs affected by the sex of the animal (p < 0.05, S4.4). 
An interaction between time, diet, and sex were found to affect the abundance of 
21 OTUs representing Bacteroidetes, Firmicutes, Proteobacteria, Spirochaetes, 
and Tenericutes phylum (p < 0.05, S4.5).  
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Figure 4.6 Relative abundance at taxonomic level of phyla 
Bacterial phyla in fecal samples collected from day 0 (n = 6, female 0% taurine and male 0% taurine; n = 5, female 0.7% taurine and 
male 0.7% taurine) and day 84 (n = 6, female 0% taurine, male 0% taurine, and male 0.7% taurine; n = 5, female 0.7% taurine).  
Bacteroidetes and Firmicutes were the most abundant phyla, and their relative abundance was altered by dietary taurine (p < 0.05). 
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Figure 4.7 Relative abundance at taxonomic level of OTU 
Bacterial OTUs collected in fecal samples collected from day 0 (n = 6, female 0% taurine and male 0% taurine; n = 5, female 0.7% taurine and 
male 0.7% taurine) and day 84 (n = 6, female 0% taurine, male 0% taurine, and male 0.7% taurine; n = 5, female 0.7% taurine).  The abundance 
of nine OTUs including Family S24-7, Genus Bacteroides, Genus Allobaculum, and Genus Clostridium were altered by dietary taurine. The 
abundance of 56 OTUs including Order Clostridiales were affected by the transition onto the purified diet (p < 0.001) and the abundance of 41 
OTUs including Family Ruminococca were different based upon the sex of the rat (p < 0.03).  
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Table 4.4 Relative abundance at the taxonomic level of phyla in female rats 
Phylum 
Female 
Dietary taurine Sex Time 
Day 0 Day 84 Day 84 
Control Taurine 
F-
value 
P-
value 
F-
value 
P-
value 
F-
value P-value
Euryarchaeota 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.28 0.27 1.28 0.27 1.43 0.24 
Actinobacteria 0.60 ± 0.00 0.20 ± 0.00 0.14 ± 0.00 1.09 0.30 4.65 0.04 23.99 <0.001 
Bacteroidetes 24.40 ± 0.01 21.50 ± 0.02 18.86 ± 0.03 6.12 0.02 11.60 < 0.01 1.27 0.27 
Cyanobacteria 0.15 ± 0.00 0.10 ± 0.00 0.10 ± 0.00 0.65 0.43 3.53 0.07 0.29 0.6 
Deferribacteres 0.06 ± 0.00 0.02 ± 0.00 0.20 ± 0.00 0.38 0.54 0.55 0.46 0.52 0.47 
Firmicutes 69.07 ± 0.02 71.48 ± 0.03 71.60 ± 0.04 5.20 0.03 9.38 < 0.01 0.02 0.9 
Lentisphaerae 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.14 0.29 0.95 0.34 0.43 0.52 
Proteobacteria 1.55 ± 0.00 0.95 ± 0.00 0.70 ± 0.00 0.07 0.8 1.64 0.21 1.37 0.25 
Spirochaetes 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.26 0.61 1.62 0.21 5.88 0.02 
TM7 0.51 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.50 0.49 0.40 0.53 60.44 < 0.001 
Tenericutes 3.26 ± 0.01 5.60 ± 0.01 7.00 ± 0.01 0.94 0.34 0.03 0.87 14.31 < 0.001 
Verrucomicrobia 0.35 ± 0.00 0.15 ± 0.00 1.40 ± 0.01 0.82 0.37 0.21 0.65 2.15 0.15 
WPS-2 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.43 0.24 0.00 0.96 0.63 0.43 
Relative abundance at the taxonomic level of phyla of female rats on day 0 [n = 6, female control (0% taurine); n = 5, female 
0.7% taurine] and day 84 (n = 6, female control; n = 5, female 0.7% taurine).  Dietary taurine altered the relative abundance of 
Bacteroidetes.  The relative abundance of Actinobacteria was significantly different between the male and female rats and was 
altered by the transition between standard chow to the purified diet. The relative amount of Spriochaetes, TM7, and 
Tenericutes was significantly altered by the transition between standard chow to the purified diet.  
Interactions reported in the supplementary tables. Complete dataset available through the MOspace Institutional Repository.  
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Table 4.5 Relative abundance at the taxonomic level of phyla in male rats 
Phylum 
Male 
Dietary taurine Sex Time 
Day 0 Day 84 Day 84 
Control Taurine 
F-
value 
P-
value 
F-
value 
P-
value 
F-
value 
P- 
value 
Euryarchaeota 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.28 0.27 1.28 0.27 1.43 0.24 
Actinobacteria 1.00 ± 0.00 0.30 ± 0.00 0.17 ± 0.00 1.09 0.30 4.65 0.04 23.99 <0.001 
Bacteroidetes 16.60 ± 0.03 16.13 ± 0.02 16.57 ± 0.02 6.12 0.02 11.60 < 0.01 1.27 0.27 
Cyanobacteria 0.03 ± 0.00 0.02 ± 0.00 0.03 ± 0.00 0.65 0.43 3.53 0.07 0.29 0.6 
Deferribacteres 0.00 ± 0.00 0.00 ± 0.00 0.02 ± 0.00 0.38 0.54 0.55 0.46 0.52 0.47 
Firmicutes 77.47 ± 0.03 72.50 ± 0.03 77.78 ± 0.02 5.20 0.03 9.38 < 0.01 0.02 0.9 
Lentisphaerae 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.14 0.29 0.95 0.34 0.43 0.52 
Proteobacteria 1.13 ± 0.00 0.88 ± 0.00 1.65 ± 0.00 0.07 0.8 1.64 0.21 1.37 0.25 
Spirochaetes 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.26 0.61 1.62 0.21 5.88 0.02 
TM7 0.44 ± 0.00 0.03 ± 0.00 0.00 ± 0.00 0.50 0.49 0.40 0.53 60.44 < 0.001 
Tenericutes 3.10 ± 0.00 9.83 ± 0.02 2.67 ± 0.01 0.94 0.34 0.03 0.87 14.31 < 0.001 
Verrucomicrobia 0.16 ± 0.00 0.27 ± 0.00 1.10 ± 0.01 0.82 0.37 0.21 0.65 2.15 0.15 
WPS-2 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.43 0.24 0.00 0.96 0.63 0.43 
Relative abundance at the taxonomic level of phyla of male rats on day 0 [male control (0% taurine); n = 5, male 0.7% 
taurine] and day 84 (n = 6, male control, and male 0.7% taurine).  Dietary taurine altered the relative abundance of 
Firmicutes in the male rats.  The relative abundance of Actinobacteria was significantly different between the male and 
female rats and was altered by the transition between standard chow to the purified diet. The relative amount of 
Spriochaetes, TM7, and Tenericutes was significantly altered by the transition between standard chow to the purified diet. 
Interactions reported in the supplementary tables. Complete dataset available through the MOspace Institutional 
Repository.   
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Table 4.6 Relative abundance at the taxonomic level of OTU that were altered by high dietary taurine in the female 
rats 
Phylum Family 
Operational 
taxonomic unit (OTU) 
Female 
Day 0 Day 84 
F-
value 
p-
value 
Control Taurine 
Actinobacteria Coriobacteriaceae 
Family 
Coriobacteriaceae 
0.14 ± 0.06 0.02 ± 0.01 0.00 ± 0.00 6.48 0.02 
Bacteroidetes Bacteroidaceae 
Bacteroides 
acidifaciens 
0.13 ± 0.02 0.20 ± 0.02 0.18 ± 0.04 5.42 0.03 
Bacteroidetes Bacteroidaceae Genus Bacteroides 3.18 ± 0.45 8.02 ± 0.93 7.98 ± 2.16 5.63 0.02 
Bacteroidetes Porphyromonadaceae 
Genus 
Parabacteroides 
0.15 ± 0.04 0.12 ± 0.01 0.12 ± 0.02 4.00 0.05 
Bacteroidetes Prevotellaceae Prevotella copri 1.22 ± 0.29 0.00 ± 0.00 0.00 ± 0.00 5.36 0.03 
Bacteroidetes Rikenellaceae Family Rikenellaceae 0.36 ± 0.05 0.42 ± 0.04 0.26 ± 0.02 7.95 <0.01 
Bacteroidetes S24-7 Family S24-7 17.29 ± 1.07 11.45 ± 1.14 9.50 ± 1.06 5.03 0.03 
Firmicutes Clostridiaceae Genus Clostridium 0.75 ± 0.11 0.00 ± 0.00 0.00 ± 0.00 12.77 0.001 
Firmicutes Erysipelotrichaceae Genus Allobaculum 0.67 ± 0.28 0.48 ± 0.18 0.20 ± 0.08 13.63 <0.001 
The relative abundance at the taxonomic level of OTU of fecal samples collected from female rats on day 0 [n = 6, female 
control (0% taurine); n = 5, female 0.7% taurine] and day 84 (n = 6, female control; n = 5, female 0.7% taurine).  Nine 
OTUs were altered by the presence of taurine in the diet. Interactions for diet and time are reported in the supplementary 
tables. Complete dataset available through the MOspace Institutional Repository. 
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Table 4.7 Relative abundance at the taxonomic level of OTU that were altered by high dietary taurine in the male 
rats 
Phylum Family 
Operational taxonomic 
unit (OTU) 
Male 
Day 0 Day 84 
F-
value 
p-value
Control Taurine 
Actinobacteria Coriobacteriaceae 
Family 
Coriobacteriaceae 
0.28 ± 0.05 0.02 ± 0.02 0.02 ± 0.02 6.48 0.02 
Bacteroidetes Bacteroidaceae 
Bacteroides 
acidifaciens 
0.16 ± 0.03 0.08 ± 0.03 0.08 ± 0.02 5.42 0.03 
Bacteroidetes Bacteroidaceae Genus Bacteroides 2.41 ± 0.46 6.53 ± 0.76 6.92 ± 0.61 5.63 0.02 
Bacteroidetes Porphyromonadaceae 
Genus 
Parabacteroides 
0.02 ± 0.01 0.07 ± 0.02 0.10 ± 0.04 4.00 0.05 
Bacteroidetes Prevotellaceae Prevotella copri 0.01 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 5.36 0.03 
Bacteroidetes Rikenellaceae Family Rikenellaceae 0.44 ± 0.12 0.08 ± 0.03 0.22 ± 0.05 7.95 <0.01 
Bacteroidetes S24-7 Family S24-7 13.09 ± 2.29 8.82 ± 1.21 8.65 ± 1.30 5.03 0.03 
Firmicutes Clostridiaceae Genus Clostridium 3.09 ± 0.43 0.00 ± 0.000 0.00 ± 0.00 12.77 0.001 
Firmicutes Erysipelotrichaceae Genus Allobaculum 5.75 ± 1.29 0.17 ± 0.076 0.17 ± 0.08 13.63 <0.001 
The relative abundance at the taxonomic level of OTU of fecal samples collected from male rats on day 0 [n = 6, male 
control (0% taurine); n = 5, male 0.7% taurine] and day 84 (n = 6).  Nine OTUs were altered by the presence of taurine in 
the diet. Complete dataset available through the MOspace Institutional Repository.
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The principal component analysis (PCA) visually revealed the β-diversity 
at the OTU level was different between males and females at day 0 and the loss 
of the sex-difference by day 84 (Fig 4.8).  Principal component 1 (PC1) 
accounted for 59.02% variance and principal component 2 (PC2) accounted for 
8.69% of the variance.  At day 0, when the rats were on the standard rodent 
chow, a two-way PERMANOVA of sex and diet, showed a significant difference 
between the male and female rats (p < 0.01, F = 6.80) and no diet effect (p = 
0.17, F = 1.39) at the OTU level. At day 84, the sex effect on β-diversity was lost 
(p = 0.12, F = 1.46) and there was not a diet effect (p = 0.33, F = 0.97), but there 
was a sex and diet interaction (p < 0.01, F = 0.55) at the OTU level.   A 
PERMANOVA looking at the effects of time and diet showed a significant time 
difference (p < 0.001, F = 39.72), but there were no diet effects (p = 0.16, F = 
1.55) at the OTU level. 
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Figure 4.8 Principal component analysis 
Principal component analysis for all rats at Day 0 showed a visible sex-effect (p < 
0.01) (n = 6, female 0% taurine and male 0% taurine; n = 5, female 0.7% taurine 
and male 0.7% taurine) whereas on Day 84 the sex-effect was lost (p = 0.12) (n 
= 6, female 0% taurine and male 0% taurine; n = 5, female 0.7% taurine and 
male 0.7% taurine). 
Discussion 
Researchers and clinicians from a variety of medical disciplines are 
considering the use of supplemental taurine to optimize health and to help 
mitigate a variety of health problems such as diabetes (Ito et al. 2012) and 
coronary heart disease (Wójcik et al. 2010); however, there is a lack of 
knowledge on potential risks or “side effects” of high supplementation doses.  
During an investigation of taurine’s effect on the thyroid, it was found that high 
levels of dietary taurine supplementation caused an increase in the body weight 
of female adult, 17 week-old, rats (Hooper et al. 2017).   
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The DXA results of this present study indicate the observation of 
increased body weight of the female rats on the high taurine diet was likely due 
to an increase in both fat and lean masses—evidenced by the trend that was 
observed in these two parameters.  Therefore, the rats appeared to become 
physically larger (Table 4.1, 4.3) while consuming less food than the control rats.  
To the authors’ knowledge, it has never been reported that taurine 
supplementation can alter the growth of sexually mature rats. Oral maternal 
taurine supplementation has been shown to significantly increase the body 
weight of rat pups during the first 12 weeks post-parturition (Hultman et al. 2007).  
Hultman et al. (2007) suggested the taurine-induced effect on growth of the pups 
was the result of simulation of the GH/IGF-1 axis. 
Transgenic mice deficient in growth hormone receptors (GHR), IGF-1, or 
both GHR and IGF-1 confirm that GH and IGF-1 have independent and 
overlapping functions of growth (Lupu et al. 2001).  Lupu et al (2001) estimated 
that the GH/IGF-1 axis contribute to 83% of post-natal growth with 34% being 
attributed to overlapping functions, 35% to IGF-1 independent actions, and 14% 
to GH independent actions.  Intravenously administered taurine has been shown 
to increase growth hormone (Ikuyama et al. 1988), and an increase in growth 
hormone will directly raise the circulating serum IGF-1 concentrations (Kalu et al. 
1998).  Because Dawson et al. (1999) reported that a trend was observed in 
taurine’s ability to attenuate the age-related decline of circulating serum IGF-1 
concentrations in 28 month old rats (Dawson et al. 1999), we expected to see 
high dietary taurine would cause an increase in circulating IGF-1 and thereby 
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explain greater body size in rats given the diet. However, no significant dietary 
taurine treatment effects on serum IGF-1 concentration in the females or males 
was detected (Fig 4.5).  Our results are similar to those reported by Hultman et al 
(2007) who also predicted an increase in circulating IGF-1 in rats orally 
supplemented with taurine, but did not detect an increase.  Hultman et al (2007) 
suggested that IGF-1 was not altered in the larger pups whose mother receive 
taurine supplementation, because IGF-1 was only measured once and the 
increase could have occurred prior to the study endpoint.  In an effort to capture 
potential fluxuations in IGF-1, our study measured fasting circulating serum IGF-
1 concentrations over the duration of the study, when the female rats on the high 
dietary taurine diet were actively increasing in body weight during 17 to 29 weeks 
of age.  We also chose to measure IGF-1 rather than GH, because GH has a 
half-life of approximately 12 minutes (Bright et al. 1999) and is secreted in a 
pulsatile manner that is highly variable within and between individuals 
(Tannenbaum and Martin 1976).  Whereas, IGF-1 has a fifteen-hour half-life and 
is not secreted in a pulsatile manner (Brabant 2003) allowing a single time point 
measurement to be able to more accurately capture a potential effect of taurine 
on IGF-1.  It is possible that taurine caused an increase in circulating serum IGF-
1 during the 4-hour period of food intake and that we did not detect the rise it as 
our blood sampling occurred 20 hours later, well past the 15 hours half-life of 
IGF-1.  However, this seems unlikely because the rats receiving taurine 
compared to the control rats had a significantly greater taurine concentration of 
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the liver (Fig 2), and the liver produces the majority of the circulating IGF-1 
(Brabant 2003). 
Approximately 17% of growth relies on other physiological processes that 
are independent of the GH/IGF-1 axis (Lupu et al. 2001).  The ending age of the 
rats in our study were 5.5 months for males and 7.25 months for females.  The 
functional closing of epiphyseal growth plates does not occur until 8 months of 
age in male rats and 10 month of age in female rats (Shim 2015). Our 
observation of the increase in mass and the trend observed in lean and BMC as 
measured by DXA (Table 4.3) indicates that taurine may stimulate osteoblast 
activity, causing an increase in size. This is further supported by cell culture 
studies in which taurine has been shown to increase proliferation of human 
osteoblasts (Jeon et al. 2007) and to promote mesenchymal stem cells to 
differentiate into osteoblasts (Zhou et al. 2014).   
While it is well recognized that the pituitary-hypothalamic-thyroid axis 
contributes to growth (Gothe et al. 1999), the gut microbiome is beginning to be 
recognized as another factor contributing to growth (Cardinelli et al. 2015), 
particularly in neonates (Arboleya et al. 2017).  The majority of gut microbiome 
studies on growth have been descriptive studies linking a decrease of the 
Bacteroidetes phylum and an increase in Firmicutes phylum to weight gain, or 
more specifically to obesity (Cardinelli et al. 2015).  A single study has been 
completed on the contribution of the alteration of the microbiome and in particular 
an increase in relative abundance of Acidaminoccocus sp. bacteria that impedes 
linear growth (Gough et al. 2015).  Our study sought how to understand how 
 117 
 
taurine altered the microbiome to determine if alterations of specific phyla and 
OTUs could provide be linked to an increase in both lean muscle as well as fat 
mass in our female rats on the high taurine diet. 
The dietary taurine concentration used was shown to decrease the ratio of 
Bacteroidetes to Firmicutes in the females but not the male rats (Table 4.4-4.5).  
While a similar ratio change has been linked to obesity in humans and rats 
(Cláudia Marques 2016; Ley et al. 2006), it remains poorly understood how the 
fluctuation of individual OTUs, such as Family S24-7 or Bacteroides acidifaciens, 
affect physiological processes (Ormerod et al. 2016).  For example, we observed 
that Family S24-7 in the Bacteroidetes phylum decreased in relative abundance 
to being almost undetectable in the female dietary taurine group, but not the 
female control group and both male treatment groups (Table 4.6-4.7).  
Bacteroides acidifaciens increased in the female dietary taurine group, but not in 
the female control or either male group (Table 4.6-4.7).  While both dietary 
taurine and potentially sex or age influenced the abundance of these OTUs 
future studies measuring specific biomarkers are needed to understand how 
Bacteroides acidifaciens and other bacteria contributes to metabolic processes.  
Such future studies could help to explain the observed beneficial (Ito et al. 2012) 
or detrimental effects of taurine supplementation (Hultman et al. 2007).  Because 
we did not see an increase in percent fat mass or difference in fad pads weights 
between dietary treatment groups, the ratio of Bacteroidetes to Firmicutes may 
not be as important as to how individual OTUs within the Bacteroidetes and 
Firmicutes phyla fluctuate (Table 4.4-4.6). Alternatively, since oral taurine has 
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been linked to promoting obesity (Hultman et al. 2007) it is possible that we did 
not observe a difference in fat mass due to the rats not having ab lib access to 
the diet.   
 The Family Coriobacteriaceae appeared to decline in all groups when the 
rats were placed on the purified diet, however dietary taurine attenuated the 
decline in the female rats compared to the female control rats (Table 4.6-4.7).  
Coriobacteriaceae is within the Actinobacteria phylum, and has previously been 
shown to stimulate triglyceride synthesis and glycogenesis in the liver in germ 
free mice (Claus et al. 2011).  However, this contradicts the positive clinical 
outcome of decreased serum triglycerides in taurine treated individuals (Ito et al. 
2012) as well in diabetic rats (Goodman and Shihabi 1990).  This suggests that 
both the diet and other gut microbes can play a direct role in the metabolic 
functions of gut bacteria and germ free mice may be of limited value when 
determining these complicated relationships. 
While the purified diet appeared to have an effect on the Family 
Coriobacteriaceae, it also appeared to alter the abundance of 55 other bacteria 
(Table S4.3).  Interestingly, transitioning the female rats onto a purified diet also 
caused a decrease in Bacteroidetes and an increase in Firmicutes (Table 4.4-
4.5).  We only completed DXA scans on day 85, however it would be of value to 
have conducted DXA scans prior to the start of the study to determine if the 
purified diet caused a change in the percent fat mass.   Future studies should 
determine if the purified diet pre-disposes rats to exhibit an obesity phenotype.   
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Purified diets, specifically the composition of the American Instituted of 
Nutrition (AIN) purified diets, are defined in detail to allow mechanistic studies of 
a particular nutrient of interest (e.g. taurine) that can be mixed into the diet 
(Reeves 1997; Reeves et al. 1993).  These diets were formulated prior to the 
ability of scientists to study the gut microbiome with high-throughput sequencing. 
Our study suggests that scientists should consider how the gut microbiome may 
be altered on a purified diet.  This is especially important to consider with the new 
NIH mandate that both sexes should be represented in animal studies as not 
only was the α-diversity altered by the purified diet, but also the β-diversity.  
There were clear sex-differences in beta diversity prior to the start of the 
experiment that were lost when the rats were on the purified diet (Fig 4.8).  This 
elimination of diversity could be detrimental when trying to determine underlying 
mechanisms that are sex-specific.   
We did not observe an effect of high dietary taurine on fecal microbiome 
β-diversity, the diversity between samples.  The observation is of particular 
interest since the female rats consuming the taurine diet gained increased mass.  
With a dietary taurine-induced increase in lean and likely muscle mass as well as 
fat mass, it is difficult to correlate particular phyla or OTUs identified within our 
study that could have caused the increase in lean mass.  Because we did see an 
increase in taurine content in the quadriceps muscle (Fig 4.3), it may be the 
increase in muscle mass was due to an effect of taurine within the muscle tissue 
itself.  Goodman et al (2009) reported that taurine supplementation did not 
increase body mass or extensor digital longus muscle mass in rats that were 
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similarly aged to the males in this study. However, these investigators found a 
trend toward higher muscle mass-to-body mass ratio with taurine 
supplementation (Goodman et al. 2009). Of note, taurine depletion in transgenic 
mice with disrupted taurine transporter genes have been shown to have poor 
skeletal muscle function (Warskulat et al. 2004).  Additionally, upon histological 
examination of knock-out TauT transgenic mice the tibial anterior muscle 
exhibited atrophy and necrotic cells (Ito et al. 2010), so it appears taurine does 
play a role in skeletal muscle health.  It could be taurine has a greater effect in 
gaining muscle mass in older rats, and a future study should examine the effect 
of taurine on muscle mass in older animals to determine if a diet rich in taurine 
could help reverse sarcopenia.    
Conclusion 
Our study is the first to show that dietary taurine may increase both the 
lean muscle mass and fat mass of sexually mature female rats.  Both the 
inclusion of taurine in the diet, and the purified diet itself, caused a decrease in 
Bacteroidetes phylum and an increase in Firmicutes phylum, likely resulting in 
the increase in fat mass.  Additionally, future studies incorporating AIN-93 
purified diets should investigate possible physiologic changes that are caused by 
the loss fecal microbiota β-diversity between sexes and the alteration of 
microbiota α-diversity. 
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Supplemental Table 4.1 
Phyla 
Female 
Diet Sex Time 
Day 0 Day 84 Day 84 
Control Taurine 
F-
value 
P-
value 
F-
value 
P-
value 
F-
value P-value
Euryarchaeota 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.28 0.27 1.28 0.27 1.43 0.24 
Actinobacteria 0.60 ± 0.00 0.20 ± 0.00 0.14 ± 0.00 1.09 0.3 4.65 0.04 23.99 <0.001 
Bacteroidetes 24.40 ± 0.01 21.50 ± 0.02 18.86 ± 0.03 6.12 0.02 11.60 < 0.01 1.27 0.27 
Cyanobacteria 0.15 ± 0.00 0.10 ± 0.00 0.10 ± 0.00 0.65 0.43 3.53 0.07 0.29 0.6 
Deferribacteres 0.06 ± 0.00 0.02 ± 0.00 0.20 ± 0.00 0.38 0.54 0.55 0.46 0.52 0.47 
Firmicutes 69.07 ± 0.02 71.48 ± 0.03 71.60 ± 0.04 5.20 0.03 9.38 < 0.01 0.02 0.9 
Lentisphaerae 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.14 0.29 0.95 0.34 0.43 0.52 
Proteobacteria 1.55 ± 0.00 0.95 ± 0.00 0.70 ± 0.00 0.07 0.8 1.64 0.21 1.37 0.25 
Spirochaetes 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.26 0.61 1.62 0.21 5.88 0.02 
TM7 0.51 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.50 0.49 0.40 0.53 60.44 < 0.001 
Tenericutes 3.26 ± 0.01 5.60 ± 0.01 7.00 ± 0.01 0.94 0.34 0.03 0.87 14.31 < 0.001 
Verrucomicrobia 0.35 ± 0.00 0.15 ± 0.00 1.40 ± 0.01 0.82 0.37 0.21 0.65 2.15 0.15 
WPS-2 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.43 0.24 0.00 0.96 0.63 0.43 
The relative abundance at the taxonomic level of OTU of fecal samples collected from female rats on day 0 [n = 6, female 
control (0% taurine); n = 5, female 0.7% taurine] and day 84 (n = 6, female control; n = 5, female 0.7% taurine).   
Complete dataset available through the MOspace Institutional Repository.
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Phyla 
Female 
Diet*Sex Time*Diet Time*Sex Time*Diet*Sex 
Day 0 Day 84 Day 84 
Control Taurine 
F-
value 
P-
value 
F-
value 
P-
value 
F-
value 
P-
value 
F-
value 
P-
value 
Euryarchaeota 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.28 0.27 0.01 0.92 0.06 0.81 0.7 0.41 
Actinobacteria 0.60 ± 0.00 0.20 ± 0.00 0.14 ± 0.00 0.02 0.88 1.21 0.28 1.55 0.22 0.00 0.99 
Bacteroidetes 24.40 ± 0.01 21.50 ± 0.02 18.86 ± 0.03 10.55 < 0.01 2.12 0.15 1.81 0.19 7.62 < 0.01 
Cyanobacteria 0.15 ± 0.00 0.10 ± 0.00 0.10 ± 0.00 1.32 0.26 0.61 0.44 0.12 0.73 0.83 0.37 
Deferribacteres 0.06 ± 0.00 0.02 ± 0.00 0.20 ± 0.00 0.25 0.62 1.90 0.18 0.24 0.63 1.69 0.20 
Firmicutes 69.07 ± 0.02 71.48 ± 0.03 71.60 ± 0.04 8.57 0.01 0.98 0.33 1.76 0.19 2.19 0.15 
Lentisphaerae 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.91 0.35 3.67 0.06 0.48 0.49 0.59 0.45 
Proteobacteria 1.55 ± 0.00 0.95 ± 0.00 0.70 ± 0.00 2.66 0.11 0.12 0.74 3.27 0.08 4.86 0.03 
Spirochaetes 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.26 0.61 0.71 0.40 0.75 0.39 5.78 0.02 
TM7 0.51 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 2.67 0.11 0.09 0.76 0.25 0.62 1.57 0.22 
Tenericutes 3.26 ± 0.01 5.60 ± 0.01 7.00 ± 0.01 0.01 0.93 1.09 0.30 0.01 0.94 6.29 0.02 
Verrucomicrobia 0.35 ± 0.00 0.15 ± 0.00 1.40 ± 0.01 0.13 0.72 1.19 0.28 0.03 0.85 0.01 0.91 
WPS-2 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0 0.96 2.92 0.10 0.71 0.40 0.01 0.91 
The relative abundance at the taxonomic level of OTU of fecal samples collected from female rats on day 0 [n = 6, female 
control (0% taurine); n = 5, female 0.7% taurine] and day 84 (n = 6, female control; n = 5, female 0.7% taurine).   
Complete dataset available through the MOspace Institutional Repository.
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Phyla 
Male 
Diet Sex Time 
Day 0 Day 84 Day 84 
Control Taurine F-value P-value F-value P-value F-value P-value
Euryarchaeota 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.28 0.27 1.28 0.27 1.43 0.24 
Actinobacteria 1.00 ± 0.00 0.30 ± 0.00 0.17 ± 0.00 1.09 0.3 4.65 0.04 23.99 <0.001 
Bacteroidetes 16.60 ± 0.03 16.13 ± 0.02 16.57 ± 0.02 6.12 0.02 11.60 < 0.01 1.27 0.27 
Cyanobacteria 0.03 ± 0.00 0.02 ± 0.00 0.03 ± 0.00 0.65 0.43 3.53 0.07 0.29 0.6 
Deferribacteres 0.00 ± 0.00 0.00 ± 0.00 0.02 ± 0.00 0.38 0.54 0.55 0.46 0.52 0.47 
Firmicutes 77.47 ± 0.03 72.50 ± 0.03 77.78 ± 0.02 5.20 0.03 9.38 < 0.01 0.02 0.9 
Lentisphaerae 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.14 0.29 0.95 0.34 0.43 0.52 
Proteobacteria 1.13 ± 0.00 0.88 ± 0.00 1.65 ± 0.00 0.07 0.8 1.64 0.21 1.37 0.25 
Spirochaetes 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.26 0.61 1.62 0.21 5.88 0.02 
TM7 0.44 ± 0.00 0.03 ± 0.00 0.00 ± 0.00 0.50 0.49 0.40 0.53 60.44 < 0.001 
Tenericutes 3.10 ± 0.00 9.83 ± 0.02 2.67 ± 0.01 0.94 0.34 0.03 0.87 14.31 < 0.001 
Verrucomicrobia 0.16 ± 0.00 0.27 ± 0.00 1.10 ± 0.01 0.82 0.37 0.21 0.65 2.15 0.15 
WPS-2 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.43 0.24 0.00 0.96 0.63 0.43 
The relative abundance at the taxonomic level of OTU of fecal samples collected from male rats on day 0 [n = 6, male 
control (0% taurine); n = 5, male 0.7% taurine] and day 84 (n = 6).   Complete dataset available through the MOspace 
Institutional Repository.
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Phyla 
Male 
Diet*Sex Time*Diet Time*Sex Time*Diet*Sex 
Day 0 Day 84 Day 84 
Control Taurine 
F-
value 
P-
value 
F-
value 
P-
value 
F-
value 
P-
value 
F-
value 
P-
value 
Euryarchaeota 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.28 0.27 0.01 0.92 0.06 0.81 0.7 0.41 
Actinobacteria 1.00 ± 0.00 0.30 ± 0.00 0.17 ± 0.00 0.02 0.88 1.21 0.28 1.55 0.22 0.00 0.99 
Bacteroidetes 16.60 ± 0.03 16.13 ± 0.02 16.57 ± 0.02 10.55 < 0.01 2.12 0.15 1.81 0.19 7.62 < 0.01 
Cyanobacteria 0.03 ± 0.00 0.02 ± 0.00 0.03 ± 0.00 1.32 0.26 0.61 0.44 0.12 0.73 0.83 0.37 
Deferribacteres 0.00 ± 0.00 0.00 ± 0.00 0.02 ± 0.00 0.25 0.62 1.90 0.18 0.24 0.63 1.69 0.20 
Firmicutes 77.47 ± 0.03 72.50 ± 0.03 77.78 ± 0.02 8.57 0.01 0.98 0.33 1.76 0.19 2.19 0.15 
Lentisphaerae 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.91 0.35 3.67 0.06 0.48 0.49 0.59 0.45 
Proteobacteria 1.13 ± 0.00 0.88 ± 0.00 1.65 ± 0.00 2.66 0.11 0.12 0.74 3.27 0.08 4.86 0.03 
Spirochaetes 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.26 0.61 0.71 0.40 0.75 0.39 5.78 0.02 
TM7 0.44 ± 0.00 0.03 ± 0.00 0.00 ± 0.00 2.67 0.11 0.09 0.76 0.25 0.62 1.57 0.22 
Tenericutes 3.10 ± 0.00 9.83 ± 0.02 2.67 ± 0.01 0.01 0.93 1.09 0.30 0.01 0.94 6.29 0.02 
Verrucomicrobia 0.16 ± 0.00 0.27 ± 0.00 1.10 ± 0.01 0.13 0.72 1.19 0.28 0.03 0.85 0.01 0.91 
WPS-2 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0 0.96 2.92 0.10 0.71 0.40 0.01 0.91 
The relative abundance at the taxonomic level of OTU of fecal samples collected from male rats on day 0 [n = 6, male 
control (0% taurine); n = 5, male 0.7% taurine] and day 84 (n = 6).   Complete dataset available through the MOspace 
Institutional Repository.
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Supplemental Table 4.2 
Phylum Family 
Operational taxonomic 
unit (OTU) 
Female Diet*Sex 
Day 0 Day 84 Day 84 F-
value 
p-
value Control Taurine 
Bacteroidetes Order Bacteroidales 0.06 ± 0.02 0.35 ± 0.05 0.02 ± 0.02 5.14 0.03 
Bacteroidetes Bacteroidaceae Genus Bacteroides 3.18 ± 0.45 8.02 ± 0.93 7.98 ± 2.16 8 0.01 
Bacteroidetes Bacteroidaceae Bacteroides acidifaciens 0.13 ± 0.02 0.20 ± 0.02 0.18 ± 0.04 17.61 <0.001 
Bacteroidetes Bacteroidaceae Bacteroides uniformis 0.29 ± 0.05 0.17 ± 0.02 0.16 ± 0.02 8.68 0.005 
Bacteroidetes Porphyromonadaceae Genus Parabacteroides 0.15 ± 0.04 0.12 ± 0.01 0.12 ± 0.02 10.31 0.002 
Bacteroidetes Porphyromonadaceae 
Parabacteroides 
distasonis 
0.10 ± 0.02 0.07 ± 0.02 0.12 ± 0.02 6.97 0.01 
Bacteroidetes Rikenellaceae Family Rikenellaceae 0.36 ± 0.05 0.42 ± 0.04 0.26 ± 0.02 13.27 <0.001 
Bacteroidetes Rikenellaceae Genus AF12 0.04 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 5.4 0.03 
Bacteroidetes S24-7 Family S24-7 17.29 ± 1.07 11.45 ± 1.14 0.00 ± 0.00 6.73 0.014 
Cyanobacteria Order Streptophyta 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.21 0.05 
Firmicutes Streptococcaceae Genus Lactococcus 0.01 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 4.39 0.04 
Firmicutes Class Clostridia 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 16.08 <0.001 
Firmicutes Order Clostridiales 31.25 ± 1.14 18.48 ± 0.74 21.22 ± 2.36 4.95 0.03 
Firmicutes Clostridiaceae Genus Clostridium 0.75 ± 0.11 0.00 ± 0.00 0.00 ± 0.00 6.25 0.02 
Firmicutes Dehalobacteriaceae 
Family 
Dehalobacteriaceae 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 3.97 0.05 
Firmicutes Peptostreptococcaceae 
Family 
Peptostreptococcaceae 
0.70 ± 0.11 0.66 ± 0.19 0.54 ± 0.22 4.42 0.04 
Firmicutes [Mogibacteriaceae] Family Mogibacteriaceae 0.39 ± 0.03 0.08 ± 0.02 0.00 ± 0.00 9.62 0.004 
Firmicutes Erysipelotrichaceae Genus Allobaculum 0.67 ± 0.28 0.20 ± 0.08 0.12 ± 0.02 9.58 0.004 
Firmicutes Erysipelotrichaceae 
Clostridium 
saccharogumia 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 8.17 0.007 
Proteobacteria Alcaligenaceae Genus Sutterella 0.98 ± 0.26 0.18 ± 0.04 0.00 ± 0.00 4.83 0.03 
Proteobacteria Desulfovibrionaceae Desulfovibrio C21_c20 0.07 ± 0.03 0.04 ± 0.02 0.10 ± 0.00 7.27 0.01 
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Phylum Family 
Operational taxonomic 
unit (OTU) 
Male Diet*Sex 
Day 0 Day 84 Day 84 F-
value 
p-
value Control Taurine 
Bacteroidetes Order Bacteroidales 0.12 ± 0.06 0.22 ± 0.04 0.17 ± 0.03 5.14 0.03 
Bacteroidetes Bacteroidaceae Genus Bacteroides 2.41 ± 0.46 6.53 ± 0.76 6.92 ± 0.61 8 0.01 
Bacteroidetes Bacteroidaceae Bacteroides acidifaciens 0.16 ± 0.03 0.08 ± 0.03 0.08 ± 0.02 17.61 <0.001 
Bacteroidetes Bacteroidaceae Bacteroides uniformis 0.13 ± 0.03 0.13 ± 0.02 0.12 ± 0.02 8.68 0.005 
Bacteroidetes Porphyromonadaceae Genus Parabacteroides 0.02 ± 0.01 0.07 ± 0.02 0.10 ± 0.04 10.31 0.002 
Bacteroidetes Porphyromonadaceae 
Parabacteroides 
distasonis 
0.04 ± 0.01 0.05 ± 0.02 0.08 ± 0.02 6.97 0.01 
Bacteroidetes Rikenellaceae Family Rikenellaceae 0.44 ± 0.12 0.08 ± 0.03 0.22 ± 0.05 13.27 <0.001 
Bacteroidetes Rikenellaceae Genus AF12 0.01 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 5.4 0.03 
Bacteroidetes S24-7 Family S24-7 13.09 ± 2.29 8.82 ± 1.21 8.65 ± 1.30 6.73 0.014 
Cyanobacteria Order Streptophyta 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.21 0.05 
Firmicutes Streptococcaceae Genus Lactococcus 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.39 0.04 
Firmicutes Class Clostridia 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 16.08 <0.001 
Firmicutes Order Clostridiales 29.85 ± 1.40 22.57 ± 3.27 20.82 ± 1.76 4.95 0.03 
Firmicutes Clostridiaceae Genus Clostridium 3.09 ± 0.43 0.00 ± 0.00 0.00 ± 0.00 6.25 0.02 
Firmicutes Dehalobacteriaceae 
Family 
Dehalobacteriaceae 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 3.97 0.05 
Firmicutes Peptostreptococcaceae 
Family 
Peptostreptococcaceae 
0.40 ± 0.08 0.25 ± 0.07 0.48 ± 0.13 4.42 0.04 
Firmicutes [Mogibacteriaceae] Family Mogibacteriaceae 0.46 ± 0.03 0.12 ± 0.08 0.08 ± 0.02 9.62 0.004 
Firmicutes Erysipelotrichaceae Genus Allobaculum 5.75 ± 1.29 0.17 ± 0.08 0.17 ± 0.08 9.58 0.004 
Firmicutes Erysipelotrichaceae 
Clostridium 
saccharogumia 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 8.17 0.007 
Proteobacteria Alcaligenaceae Genus Sutterella 0.58 ± 0.23 0.22 ± 0.05 0.23 ± 0.10 4.83 0.03 
Proteobacteria Desulfovibrionaceae Desulfovibrio C21_c20 0.42 ± 0.09 0.00 ± 0.00 0.00 ± 0.00 7.27 0.01 
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Supplemental Table 4.3 
Phylum Family 
Operational taxonomic 
unit (OTU) 
Female Time 
Day 0 Day 84 Day 84 F-
value 
p-value
Control Taurine 
Actinobacteria Bifidobacteriaceae Genus Bifidobacterium 0.31 ± 0.11 0.10 ± 0.02 0.06 ± 0.04 11.73 0.001 
Actinobacteria Coriobacteriaceae 
Family 
Coriobacteriaceae 
0.14 ± 0.06 0.02 ± 0.01 0.00 ± 0.00 19.48 <0.001 
Actinobacteria Coriobacteriaceae Genus Adlercreutzia 0.14 ± 0.01 0.07 ± 0.02 0.06 ± 0.02 37.7 <0.001 
Bacteroidetes Order Bacteroidales 0.06 ± 0.02 0.35 ± 0.05 0.02 ± 0.02 6.73 0.01 
Bacteroidetes Bacteroidaceae Genus Bacteroides 3.18 ± 0.45 8.02 ± 0.93 7.98 ± 2.16 49.39 
< 
0.0001 
Bacteroidetes Bacteroidaceae Bacteroides uniformis 0.29 ± 0.05 0.17 ± 0.02 0.16 ± 0.02 5.54 0.02 
Bacteroidetes Prevotellaceae Genus Prevotella 0.86 ± 0.12 0.07 ± 0.03 0.10 ± 0.08 29.01 <0.0001 
Bacteroidetes Prevotellaceae Prevotella copri 1.22 ± 0.29 0.00 ± 0.00 0.00 ± 0.00 16.31 <0.001 
Bacteroidetes Rikenellaceae Family Rikenellaceae 0.36 ± 0.05 0.42 ± 0.04 0.26 ± 0.02 6.55 0.01 
Bacteroidetes Rikenellaceae Genus AF12 0.04 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 40.56 <0.0001 
Bacteroidetes S24-7 Family S24-7 17.29 ± 1.07 11.45 ± 1.14 9.50 ± 1.06 16.21 <0.001 
Bacteroidetes [Odoribacteraceae] Genus Butyricimonas 0.03 ± 0.01 0.13 ± 0.02 0.14 ± 0.02 35.99 <0.0001 
Bacteroidetes [Odoribacteraceae] Genus Odoribacter 0.07 ± 0.03 0.00 ± 0.00 0.00 ± 0.00 4.57 0.04 
Bacteroidetes [Paraprevotellaceae] Genus Paraprevotella 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 12.58 0.001 
Bacteroidetes Cryomorphaceae Genus Fluviicola 0.06 ± 0.02 0.00 ± 0.00 0.00 ± 0.00 16.18 <0.001 
Firmicutes Lactobacillaceae Genus Lactobacillus 2.94 ± 0.66 0.02 ± 0.01 0.08 ± 0.08 22.28 <0.001 
Firmicutes Streptococcaceae Genus Lactococcus 0.01 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 11.03 0.002 
Firmicutes Streptococcaceae Genus Streptococcus 0.00 ± 0.00 0.02 ± 0.01 0.02 ± 0.02 7.19 0.01 
Firmicutes Turicibacteraceae Genus Turicibacter 0.15 ± 0.02 0.02 ± 0.01 0.02 ± 0.02 23.04 <0.0001 
Firmicutes Class Clostridia 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 9.96 0.003 
Firmicutes Order Clostridiales 31.25 ± 1.14 18.48 ± 0.74 21.22 ± 2.36 47.16 <0.0001 
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Firmicutes Christensenellaceae 
Family 
Christensenellaceae 
0.15 ± 0.02 0.20 ± 0.00 0.24 ± 0.04 8.29 0.007 
Firmicutes Christensenellaceae 
Genus 
Christensenellaceae 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 8.2 0.007 
Firmicutes Clostridiaceae Family Clostridiaceae 0.17 ± 0.02 0.10 ± 0.04 0.06 ± 0.02 36 <0.0001 
Firmicutes Clostridiaceae 
Genus Candidatus 
Arthromitus 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 5.09 0.03 
Firmicutes Clostridiaceae Genus Clostridium 0.75 ± 0.11 0.00 ± 0.00 0.00 ± 0.00 78.61 <0.0001 
Firmicutes Clostridiaceae Genus SMB53 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 10.16 0.003 
Firmicutes Dehalobacteriaceae 
Family 
Dehalobacteriaceae 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 27.9 <0.0001 
Firmicutes Dehalobacteriaceae Genus Dehalobacterium 0.20 ± 0.03 0.08 ± 0.01 0.12 ± 0.02 4.7 0.04 
Firmicutes Eubacteriaceae Genus Anaerofustis 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.47 0.04 
Firmicutes Gracilibacteraceae Genus Gracilibacter 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 6.53 0.01 
Firmicutes Lachnospiraceae Genus Anaerostipes 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 33.96 <0.0001 
Firmicutes Lachnospiraceae Genus Coprococcus 1.83 ± 0.46 1.08 ± 0.26 4.62 ± 1.55 5.68 0.02 
Firmicutes Lachnospiraceae Genus Roseburia 0.42 ± 0.06 0.08 ± 0.03 0.06 ± 0.02 28.46 <0.0001 
Firmicutes Lachnospiraceae Genus Ruminococcus 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 5.97 0.02 
Firmicutes Lachnospiraceae Ruminococcus gnavus 0.32 ± 0.06 0.03 ± 0.02 0.06 ± 0.02 17.21 <0.001 
Firmicutes Ruminococcaceae 
Family 
Ruminococcaceae 
11.23 ± 0.79 41.30 ± 2.00 34.06 ± 4.25 176.38 <0.0001 
Firmicutes Ruminococcaceae Genus Anaerotruncus 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 13.66 <0.001 
Firmicutes Ruminococcaceae Genus Oscillospira 7.77 ± 0.74 2.02 ± 0.25 4.18 ± 0.50 35.62 <0.0001 
Firmicutes Ruminococcaceae Genus Ruminococcus 4.39 ± 0.51 2.70 ± 0.45 2.26 ± 0.34 16.22 <0.001 
Firmicutes Ruminococcaceae 
Ruminococcus 
flavefaciens 
1.03 ± 0.14 0.98 ± 0.46 0.50 ± 0.30 6.69 0.01 
Firmicutes [Mogibacteriaceae] Family Mogibacteriaceae 0.39 ± 0.03 0.08 ± 0.01 0.08 ± 0.02 122.2 <0.001 
Firmicutes Order SHA-98 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 23.38 <0.0001 
Firmicutes Erysipelotrichaceae Genus Allobaculum 0.67 ± 0.28 0.48 ± 0.18 0.20 ± 0.08 27.59 <0.0001 
Firmicutes Erysipelotrichaceae 
Clostridium 
saccharogumia 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 29.75 <0.0001 
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Firmicutes Erysipelotrichaceae Genus L7A_E11 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.84 0.03 
Proteobacteria Alcaligenaceae Genus Sutterella 0.98 ± 0.26 0.50 ± 0.19 0.18 ± 0.04 6.24 0.02 
Proteobacteria Desulfovibrionaceae 
Family 
Desulfovibrionaceae 
0.04 ± 0.01 0.10 ± 0.02 0.16 ± 0.04 38.37 <0.0001 
Proteobacteria Desulfovibrionaceae Genus Desulfovibrio 0.28 ± 0.08 0.13 ± 0.02 0.10 ± 0.00 4.96 0.03 
Proteobacteria Desulfovibrionaceae Desulfovibrio C21_c20 0.07 ± 0.03 0.02 ± 0.01 0.04 ± 0.02 22.08 <0.0001 
Proteobacteria Pasteurellaceae 
Aggregatibacter 
pneumotropica 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 12.84 0.001 
Proteobacteria Moraxellaceae Psychrobacter sanguinis 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 5.34 0.03 
Spirochaetes Spirochaetaceae Genus Treponema 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 5.88 0.02 
TM7 F16 Family F16 0.51 ± 0.10 0.00 ± 0.00 0.00 ± 0.00 60.44 <0.0001 
Tenericutes Anaeroplasmataceae Genus Anaeroplasma 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 12.88 0.001 
Tenericutes Order RF39 3.25 ± 0.47 5.60 ± 0.97 6.96 ± 0.89 14.18 <0.001 
The relative abundance at the taxonomic level of OTU of fecal samples collected from female rats on day 0 [n = 6, female 
control (0% taurine); n = 5, female 0.7% taurine] and day 84 (n = 6, female control; n = 5, female 0.7% taurine).   
Complete dataset available through the MOspace Institutional Repository.
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Supplemental Table 4.4 
Phylum Family 
Operational taxonomic 
unit (OTU) 
Female Sex 
Day 0 Day 84 Day 84 F-
value 
p-value
Control Taurine 
Actinobacteria Coriobacteriaceae 
Family 
Coriobacteriaceae 
0.14 ± 0.06 0.02 ± 0.01 0.00 ± 0.00 3.97 0.05 
Bacteroidetes Bacteroidaceae Bacteroides uniformis 0.29 ± 0.05 0.17 ± 0.02 0.16 ± 0.02 16.88 <0.001 
Bacteroidetes Porphyromonadaceae Genus Parabacteroides 0.15 ± 0.04 0.12 ± 0.01 0.12 ± 0.02 22.69 <0.0001 
Bacteroidetes Porphyromonadaceae 
Parabacteroides 
distasonis 
0.10 ± 0.02 0.07 ± 0.02 0.12 ± 0.02 7.98 0.008 
Bacteroidetes Prevotellaceae Genus Prevotella 0.86 ± 0.12 0.07 ± 0.03 0.10 ± 0.08 48.63 <0.0001 
Bacteroidetes Prevotellaceae Prevotella copri 1.22 ± 0.29 0.00 ± 0.00 0.00 ± 0.00 31.25 <0.0001 
Bacteroidetes Rikenellaceae Genus AF12 0.04 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 23.66 <0.001 
Bacteroidetes Rikenellaceae Alistipes indistinctus 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.15 0.05 
Bacteroidetes S24-7 Family S24-7 17.29 ± 1.07 11.45 ± 1.14 9.50 ± 1.06 5.96 0.02 
Bacteroidetes [Barnesiellaceae] Family Barnesiellaceae 0.07 ± 0.02 0.03 ± 0.02 0.08 ± 0.02 14.67 <0.001 
Bacteroidetes [Odoribacteraceae] Genus Odoribacter 0.07 ± 0.03 0.00 ± 0.00 0.00 ± 0.00 10.63 0.002 
Bacteroidetes [Paraprevotellaceae] Genus CF231 0.23 ± 0.11 0.37 ± 0.08 0.24 ± 0.09 6.37 0.02 
Bacteroidetes [Paraprevotellaceae] Genus Paraprevotella 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 8.61 0.006 
Bacteroidetes [Paraprevotellaceae] Genus Prevotella 0.24 ± 0.10 0.02 ± 0.01 0.00 ± 0.00 8.35 0.006 
Bacteroidetes Cryomorphaceae Genus Fluviicola 0.06 ± 0.02 0.00 ± 0.00 0.00 ± 0.00 6.35 0.02 
Firmicutes Bacillaceae Family Bacillaceae 0.37 ± 0.21 0.00 ± 0.00 0.00 ± 0.00 4.92 0.03 
Firmicutes Class Clostridia 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 17.94 <0.001 
Firmicutes Clostridiaceae 
Genus Candidatus 
Arthromitus 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 18.14 <0.0001 
Firmicutes Clostridiaceae Genus Clostridium 0.75 ± 0.11 0.00 ± 0.00 0.00 ± 0.00 61.25 <0.0001 
Firmicutes Dehalobacteriaceae Genus Dehalobacterium 0.20 ± 0.03 0.08 ± 0.01 0.12 ± 0.02 25.92 <0.0001 
Firmicutes Lachnospiraceae Genus Anaerostipes 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 21.47 <0.0001 
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Firmicutes Lachnospiraceae Genus Blautia 0.11 ± 0.03 0.25 ± 0.06 0.18 ± 0.04 5.33 0.03 
Firmicutes Lachnospiraceae Genus Roseburia 0.42 ± 0.06 0.08 ± 0.03 0.06 ± 0.02 59.62 <0.0001 
Firmicutes Lachnospiraceae Ruminococcus gnavus 0.32 ± 0.06 0.03 ± 0.02 0.06 ± 0.02 10.93 0.002 
Firmicutes Peptococcaceae Family Peptococcaceae 0.28 ± 0.06 0.25 ± 0.04 0.26 ± 0.04 25.4 <0.0001 
Firmicutes Peptostreptococcaceae 
Family 
Peptostreptococcaceae 
0.70 ± 0.11 0.90 ± 0.13 0.66 ± 0.19 6.09 0.02 
Firmicutes Ruminococcaceae 
Family 
Ruminococcaceae 
11.23 ± 0.79 41.30 ± 2.00 34.06 ± 4.25 4.92 0.03 
Firmicutes Ruminococcaceae Genus Anaerotruncus 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 11.51 0.002 
Firmicutes Ruminococcaceae Genus Oscillospira 7.77 ± 0.74 2.02 ± 0.25 4.18 ± 0.50 15.38 <0.001 
Firmicutes Ruminococcaceae Genus Ruminococcus 4.39 ± 0.51 2.70 ± 0.45 2.26 ± 0.34 8.08 0.007 
Firmicutes Veillonellaceae 
Genus 
Phascolarctobacterium 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.77 0.04 
Firmicutes Veillonellaceae Veillonella dispar 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.19 0.05 
Firmicutes [Mogibacteriaceae] 
Family 
Mogibacteriaceae 
0.39 ± 0.03 0.08 ± 0.01 0.08 ± 0.02 4.53 0.04 
Firmicutes Erysipelotrichaceae Genus Allobaculum 0.67 ± 0.28 0.48 ± 0.18 0.20 ± 0.08 39.64 <0.0001 
Firmicutes Erysipelotrichaceae Genus Holdemania 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 9.07 0.005 
Firmicutes Erysipelotrichaceae Genus L7A_E11 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.66 0.04 
Proteobacteria Desulfovibrionaceae Genus Bilophila 0.05 ± 0.03 0.00 ± 0.00 0.08 ± 0.02 12.32 0.002 
Proteobacteria Desulfovibrionaceae Genus Desulfovibrio 0.28 ± 0.08 0.13 ± 0.02 0.10 ± 0.00 3.39 0.07 
Proteobacteria Desulfovibrionaceae Desulfovibrio C21_c20 0.07 ± 0.03 0.02 ± 0.01 0.04 ± 0.02 27.69 <0.001 
Proteobacteria Moraxellaceae 
Psychrobacter 
sanguinis 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 11.34 0.002 
Tenericutes Anaeroplasmataceae Genus Anaeroplasma 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 6.79 0.01 
The relative abundance at the taxonomic level of OTU of fecal samples collected from female rats on day 0 [n = 6, female 
control (0% taurine); n = 5, female 0.7% taurine] and day 84 (n = 6, female control; n = 5, female 0.7% taurine).  Complete 
dataset available through the MOspace Institutional Repository. 
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Phylum Family 
Operational taxonomic 
unit (OTU) 
Male Sex 
Day 0 Day 84 Day 84 
F-value p-value
Control Taurine 
Actinobacteria Coriobacteriaceae 
Family 
Coriobacteriaceae 
0.28 ± 0.05 0.02 ± 0.02 0.02 ± 0.02 
3.97 0.05 
Bacteroidetes Bacteroidaceae Bacteroides uniformis 0.13 ± 0.03 0.13 ± 0.02 0.12 ± 0.02 16.88 <0.001 
Bacteroidetes Porphyromonadaceae Genus Parabacteroides 0.02 ± 0.01 0.07 ± 0.02 0.10 ± 0.04 22.69 <0.0001 
Bacteroidetes Porphyromonadaceae 
Parabacteroides 
distasonis 
0.04 ± 0.01 0.05 ± 0.02 0.08 ± 0.02 
7.98 0.008 
Bacteroidetes Prevotellaceae Genus Prevotella 0.08 ± 0.04 0.00 ± 0.00 0.02 ± 0.02 48.63 <0.0001 
Bacteroidetes Prevotellaceae Prevotella copri 0.01 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 31.25 <0.0001 
Bacteroidetes Rikenellaceae Genus AF12 0.01 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 23.66 <0.001 
Bacteroidetes Rikenellaceae Alistipes indistinctus 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.15 0.05 
Bacteroidetes S24-7 Family S24-7 13.09 ± 2.29 8.82 ± 1.21 8.65 ± 1.30 5.96 0.02 
Bacteroidetes [Barnesiellaceae] Family Barnesiellaceae 0.01 ± 0.01 0.05 ± 0.02 0.12 ± 0.02 14.67 <0.001 
Bacteroidetes [Odoribacteraceae] Genus Odoribacter 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 10.63 0.002 
Bacteroidetes [Paraprevotellaceae] Genus CF231 0.00 ± 0.00 0.07 ± 0.05 0.03 ± 0.03 6.37 0.02 
Bacteroidetes [Paraprevotellaceae] Genus Paraprevotella 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 8.61 0.006 
Bacteroidetes [Paraprevotellaceae] Genus Prevotella 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 8.35 0.006 
Bacteroidetes Cryomorphaceae Genus Fluviicola 0.04 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 6.35 0.02 
Firmicutes Bacillaceae Family Bacillaceae 0.00 ± 0.00 0.00 ± 0.00 0.07 ± 0.07 4.92 0.03 
Firmicutes Class Clostridia 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 17.94 <0.001 
Firmicutes Clostridiaceae 
Genus Candidatus 
Arthromitus 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
18.14 <0.0001 
Firmicutes Clostridiaceae Genus Clostridium 3.09 ± 0.43 0.00 ± 0.00 0.00 ± 0.00 61.25 <0.0001 
Firmicutes Dehalobacteriaceae Genus Dehalobacterium 0.06 ± 0.01 0.08 ± 0.02 0.10 ± 0.00 25.92 <0.0001 
Firmicutes Lachnospiraceae Genus Anaerostipes 0.03 ± 0.01 0.00 ± 0.00 0.00 ± 0.00 21.47 <0.0001 
Firmicutes Lachnospiraceae Genus Blautia 0.32 ± 0.06 0.23 ± 0.14 0.18 ± 0.03 5.33 0.03 
Firmicutes Lachnospiraceae Genus Roseburia 0.03 ± 0.01 0.00 ± 0.00 0.02 ± 0.02 59.62 <0.0001 
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Firmicutes Lachnospiraceae Ruminococcus gnavus 0.14 ± 0.02 0.07 ± 0.03 0.05 ± 0.03 10.93 0.002 
Firmicutes Peptococcaceae Family Peptococcaceae 0.01 ± 0.01 0.03 ± 0.02 0.05 ± 0.02 25.4 <0.0001 
Firmicutes Peptostreptococcaceae 
Family 
Peptostreptococcaceae 
0.40 ± 0.08 0.25 ± 0.07 0.48 ± 0.13 
6.09 0.02 
Firmicutes Ruminococcaceae 
Family 
Ruminococcaceae 
16.58 ± 1.02 29.63 ± 2.55 43.02 ± 3.25 
4.92 0.03 
Firmicutes Ruminococcaceae Genus Anaerotruncus 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 11.51 0.002 
Firmicutes Ruminococcaceae Genus Oscillospira 4.81 ± 0.34 3.75 ± 0.90 2.58 ± 0.26 15.38 <0.001 
Firmicutes Ruminococcaceae Genus Ruminococcus 6.82 ± 0.55 4.53 ± 1.11 3.20 ± 0.95 8.08 0.007 
Firmicutes Veillonellaceae 
Genus 
Phascolarctobacterium 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
4.77 0.04 
Firmicutes Veillonellaceae Veillonella dispar 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.19 0.05 
Firmicutes [Mogibacteriaceae] 
Family 
Mogibacteriaceae 
0.46 ± 0.03 0.12 ± 0.08 0.08 ± 0.02 
4.53 0.04 
Firmicutes Erysipelotrichaceae Genus Allobaculum 5.75 ± 1.29 0.17 ± 0.08 0.17 ± 0.08 39.64 <0.0001 
Firmicutes Erysipelotrichaceae Genus Holdemania 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 9.07 0.005 
Firmicutes Erysipelotrichaceae Genus L7A_E11 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.66 0.04 
Proteobacteria Desulfovibrionaceae Genus Bilophila 0.00 ± 0.00 0.03 ± 0.02 0.07 ± 0.03 12.32 0.002 
Proteobacteria Desulfovibrionaceae Genus Desulfovibrio 0.03 ± 0.01 0.30 ± 0.11 0.88 ± 0.27 3.39 0.07 
Proteobacteria Desulfovibrionaceae Desulfovibrio C21_c20 0.42 ± 0.09 0.00 ± 0.00 0.00 ± 0.00 27.69 <0.001 
Proteobacteria Moraxellaceae Psychrobacter sanguinis 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 11.34 0.002 
Tenericutes Anaeroplasmataceae Genus Anaeroplasma 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 6.79 0.01 
The relative abundance at the taxonomic level of OTU of fecal samples collected from male rats on day 0 [n = 6, male 
control (0% taurine); n = 5, male 0.7% taurine] and day 84 (n = 6).   Complete dataset available through the MOspace 
Institutional Repository.
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Supplemental Table 4.5 
Phylum Family 
Operational taxonomic 
unit (OTU) 
Female Time*Diet*Sex 
Day 0 Day 84 Day 84 F-
value 
p-
value Control Taurine 
Bacteroidetes Order Bacteroidales 0.06 ± 0.02 0.35 ± 0.05 0.02 ± 0.02 10.67 0.002 
Bacteroidetes Bacteroidaceae Genus Bacteroides 3.18 ± 0.45 8.02 ± 0.93 7.98 ± 2.16 4.83 0.03 
Bacteroidetes Bacteroidaceae Bacteroides acidifaciens 0.13 ± 0.02 0.20 ± 0.02 0.18 ± 0.04 15.64 <0.001 
Bacteroidetes Bacteroidaceae Bacteroides uniformis 0.29 ± 0.05 0.17 ± 0.02 0.16 ± 0.02 4.47 0.04 
Bacteroidetes Porphyromonadaceae Genus Parabacteroides 0.15 ± 0.04 0.12 ± 0.01 0.12 ± 0.02 8.87 0.005 
Bacteroidetes Rikenellaceae Family Rikenellaceae 0.36 ± 0.05 0.42 ± 0.04 0.26 ± 0.02 13.87 <0.001 
Bacteroidetes S24-7 Family S24-7 17.29 ± 1.07 11.45 ± 1.14 9.50 ± 1.06 4.81 0.03 
Bacteroidetes [Barnesiellaceae] Family Barnesiellaceae 0.07 ± 0.02 0.03 ± 0.02 0.08 ± 0.02 5.03 0.03 
Firmicutes Class Clostridia 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 8.84 0.005 
Firmicutes Order Clostridiales 31.25 ± 1.14 18.48 ± 0.74 21.22 ± 2.36 5.6 0.02 
Firmicutes Peptostreptococcaceae 
Family 
Peptostreptococcaceae 
0.70 ± 0.11 0.90 ± 0.13 0.66 ± 0.19 6.51 0.02 
Firmicutes Ruminococcaceae 
Family 
Ruminococcaceae 
11.23 ± 0.79 41.30 ± 2.00 34.06 ± 4.25 6.25 0.02 
Firmicutes Ruminococcaceae 
Papillibacter 
cinnamivorans 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.29 0.05 
Firmicutes Veillonellaceae 
Genus 
Phascolarctobacterium 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.45 0.05 
Firmicutes [Mogibacteriaceae] Family Mogibacteriaceae 0.39 ± 0.03 0.08 ± 0.01 0.08 ± 0.02 6.83 0.01 
Firmicutes Erysipelotrichaceae Genus Allobaculum 0.67 ± 0.28 0.48 ± 0.18 0.20 ± 0.08 4.4 0.04 
Proteobacteria Alcaligenaceae Genus Sutterella 0.98 ± 0.26 0.50 ± 0.19 0.18 ± 0.04 4.1 0.05 
Proteobacteria Desulfovibrionaceae Genus Desulfovibrio 0.28 ± 0.08 0.13 ± 0.02 0.10 ± 0.00 4.32 0.04 
Proteobacteria Desulfovibrionaceae Desulfovibrio C21_c20 0.07 ± 0.03 0.02 ± 0.01 0.04 ± 0.02 4.45 0.04 
Spirochaetes Spirochaetaceae Genus Treponema 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 5.78 0.02 
Tenericutes Order RF39 3.25 ± 0.47 5.60 ± 0.97 6.96 ± 0.89 6.29 0.02 
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Phylum Family 
Operational taxonomic 
unit (OTU) 
Male Time*Diet*Sex 
Day 0 Day 84 Day 84 F-
value 
p-
value Control Taurine 
Bacteroidetes Order Bacteroidales 0.12 ± 0.06 0.22 ± 0.04 0.17 ± 0.03 10.67 0.002 
Bacteroidetes Bacteroidaceae Genus Bacteroides 2.41 ± 0.46 6.53 ± 0.76 6.92 ± 0.61 4.83 0.03 
Bacteroidetes Bacteroidaceae Bacteroides acidifaciens 
0.16 ± 0.03 0.08 ± 0.03 0.08 ± 0.02 
15.64 
<0.00
1 
Bacteroidetes Bacteroidaceae Bacteroides uniformis 0.13 ± 0.03 0.13 ± 0.02 0.12 ± 0.02 4.47 0.04 
Bacteroidetes Porphyromonadaceae Genus Parabacteroides 0.02 ± 0.01 0.07 ± 0.02 0.10 ± 0.04 8.87 0.005 
Bacteroidetes Rikenellaceae Family Rikenellaceae 
0.44 ± 0.12 0.08 ± 0.03 0.22 ± 0.05 
13.87 
<0.00
1 
Bacteroidetes S24-7 Family S24-7 13.09 ± 2.29 8.82 ± 1.21 8.65 ± 1.30 4.81 0.03 
Bacteroidetes [Barnesiellaceae] Family Barnesiellaceae 0.01 ± 0.01 0.05 ± 0.02 0.12 ± 0.02 5.03 0.03 
Firmicutes Class Clostridia 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 8.84 0.005 
Firmicutes Order Clostridiales 
29.85 ± 1.40 22.57 ± 3.27 
20.8
2 
± 1.76 
5.6 0.02 
Firmicutes Peptostreptococcaceae 
Family 
Peptostreptococcaceae 
0.40 ± 0.08 0.25 ± 0.07 0.48 ± 0.13 
6.51 0.02 
Firmicutes Ruminococcaceae 
Family 
Ruminococcaceae 
16.58 ± 1.02 29.63 ± 2.55 
43.0
2 
± 3.25 
6.25 0.02 
Firmicutes Ruminococcaceae 
Papillibacter 
cinnamivorans 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
4.29 0.05 
Firmicutes Veillonellaceae 
Genus 
Phascolarctobacterium 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
0.45 0.05 
Firmicutes [Mogibacteriaceae] 
Family 
Mogibacteriaceae 
0.46 ± 0.03 0.12 ± 0.08 0.08 ± 0.02 
6.83 0.01 
Firmicutes Erysipelotrichaceae Genus Allobaculum 5.75 ± 1.29 0.17 ± 0.08 0.17 ± 0.08 4.4 0.04 
Proteobacteria Alcaligenaceae Genus Sutterella 0.58 ± 0.23 0.22 ± 0.05 0.23 ± 0.10 4.1 0.05 
Proteobacteria Desulfovibrionaceae Genus Desulfovibrio 0.03 ± 0.01 0.30 ± 0.11 0.88 ± 0.27 4.32 0.04 
Proteobacteria Desulfovibrionaceae Desulfovibrio C21_c20 0.42 ± 0.09 0.00 ± 0.00 0.00 ± 0.00 4.45 0.04 
Spirochaetes Spirochaetaceae Genus Treponema 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 5.78 0.02 
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Tenericutes Order RF39 3.10 ± 0.37 9.80 ± 2.18 2.65 ± 1.24 6.29 0.02 
The relative abundance at the taxonomic level of OTU of fecal samples collected from female rats on day 0 [n = 6, female 
control (0% taurine); n = 5, female 0.7% taurine] and day 84 (n = 6, female control; n = 5, female 0.7% taurine).  The 
relative abundance at the taxonomic level of OTU of fecal samples collected from male rats on day 0 [n = 6, male control 
(0% taurine); n = 5, male 0.7% taurine] and day 84 (n = 6).  Complete dataset available through the MOspace Institutional 
Repository.
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CHAPTER 5 
Dietary taurine and the feline thyroid axis 
 
Introduction  
Approximately 10% of domestic cats over 10 years of age are estimated to 
be afflicted by feline hyperthyroidism (Peterson 2012), making the disease the 
most commonly diagnosed endocrine disorder of domestic cats in the US 
(Broussard et al. 1995; Peterson 2012).  Worldwide, feline hyperthyroidism 
continues to increase in prevalence.  Eight countries including Canada (Taylor et 
al. 1989), the United Kingdom (Thoday and Mooney 1992), and Germany (Kohler 
et al. 2016) also now recognize feline hyperthyroidism as the most commonly 
occurring spontaneous endocrine disorder of domestic cats. 
Feline hyperthyroidism is caused by hyperplastic, autonomously 
functioning thyroid nodules (Hoenig et al. 1982; Peterson and Ward 2007).  
These nodules, unresponsive to thyroid stimulating hormone (TSH), continuously 
produce the thyroid hormones thyroxine (T4) and triiodothyronine (T3) (Gerber et 
al. 1994; Peterson et al. 1987). This excessive thyroid hormone production 
causes circulating serum T4 to be elevated above the laboratory reference range 
in over 90% of cats diagnosed with feline hyperthyroidism and approximately 
75% of these cats concurrently have elevated circulating serum T3 (Broussard et 
al. 1995; Peterson et al. 2001); therefore, an elevation of circulating serum T4 or 
T3 above the reference range is considered diagnostic for feline hyperthyroidism 
as no false positives have ever been reported (Peterson 2006).  When 
hyperthyroidism is suspected, but circulating T4 and T3 are within reference 
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range, then circulating serum concentrations of free T4 (FT4) can be used as a 
companion diagnostic test (Peterson 2006; Peterson et al. 2001).  However, FT4 
is not as sensitive as T4.  FT4 is elevated in 98.5% of hyperthyroid cats, but FT4 
can also be elevated in cats with non-thyroidal illness (Peterson et al. 2001).   
The incidence rate of spontaneously occurring feline hyperthyroidism has 
skyrocketed since the initial case report in 1979 (Edinboro et al. 2004; Peterson 
et al. 1979; Scarlett et al. 1988).  The ever increasing prevalence rate has 
caused many epidemiological studies to be undertaken to determine the risk 
factors associated with feline hyperthyroidism.  Consistently, all epidemiological 
studies conducted in North America and Europe have identified consumption of 
canned cat food to be a significant risk factor for the development of feline 
hyperthyroidism (Edinboro et al. 2004; Gójska-Zygner et al. 2014; Kass et al. 
1999; Martin et al. 2000; Olczak et al. 2005; Scarlett et al. 1988; Wakeling et al. 
2009).  The flavors fish and liver and giblets as well as those canned diets in 
pop-top cans have been found to further increase the risk of the development of 
hyperthyroidism (Edinboro et al. 2004; Martin et al. 2000).   
Due to the lack of prospective studies on the matrix and constituents 
contained within canned food, the veterinary community has only been able to 
speculate the link between canned food and the development of hyperthyroidism.  
Thyroid-disruption contaminants such as bisphenol-A (BPA) (Peterson 2012; 
Schecter et al. 2010), phyto-estrogens such as isoflavones, and nutrients such 
as selenium (van Hoek et al. 2015) have all been implicated as causative factors 
within canned cat foods.  
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Taurine, a β-amino acid, has not previously been speculated to be 
involved in the etiopathogensis of feline hyperthyroidism; however, it is found in 
canned cat food at concentrations as high as 7000 mg/kg dry matter (Purina 
Nutrition 2015). Taurine was determined to be a nutritionally essential amino acid 
for felines in the mid to late 1970’s when feline central retinal degeneration was 
determined to be caused by taurine deficiency (Hayes et al. 1975; National 
Research Council 1978).  Through the use of sulfate and cysteine radioisotopes, 
it was concluded that domestic cats could not adequately produce taurine via the 
cysteine sulfinic acid decarboxylase pathway; therefore, cats must consume 
adequate levels of taurine in the diet (Knopf et al. 1978).  Subsequently, a series 
of studies determined that the taurine requirement for cats depended upon the 
dietary matrix, the quality of the protein, and processing of the diet (Backus et al. 
1998; Morris et al. 1994).   
Taurine is found in high concentrations in the thyroid gland and other 
tissues that generate free radicals and oxidants (Jacobsen and Smith 1968; 
Wright et al. 1986).  It has been suggested that taurine may be protective of 
thyroid cellular proliferation through its role in membrane stabilization, 
detoxification, anti-oxidation, and osmoregulation (Jhiang et al. 1993).  Nuclear 
magnetic resonance studies have revealed that malignant thyroid tumors contain 
relatively higher concentrations of taurine compared to benign thyroid tumors 
(Torregrossa et al. 2012) and in vitro work has demonstrated that the proliferation 
rate of thyroid cells from two human cell lines increased with increasing taurine 
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uptake (Jhiang et al. 1993). It is unknown if taurine causes a proliferation of 
thyroid cells in vivo or affects the production of thyroid hormones. 
The establishment of the essentiality of dietary taurine and subsequent 
supplementation of taurine in commercial cat foods occurred shortly before the 
first clinical description of feline hyperthyroidism (National Research Council 
1978; Peterson et al. 1979). Edinoboro et al. (2004) documented the increasing 
prevalence rate of feline hyperthyroidism from 1979 to 1997.  Concurrently, the 
National Research Council (NRC) changed the original recommended dietary 
taurine content of 500 mg/kg on a dry matter basis (National Research Council 
1981) to the current recommended minimum dietary taurine concentrations at 
500 mg/kg for purified diets, 1000 mg/kg for dry diets, and 2500 mg/kg for 
canned diets (National Research Council 2006).   However, most commercial cat 
diets commonly contain taurine concentrations that are double to triple the 
minimum recommended levels (Hill's Pet Nutrition Inc. 2017; Purina Nutrition 
2015).  Since it is unknown if high dietary taurine affects the hypothalamic-
pituitary-thyroid axis, the purpose of this study was to determine if excessive 
dietary taurine could alter the thyroid axis by leading to a rise in the production of 
circulating thyroid hormones T4, T3, FT4, and free T3 (FT3).  Additionally, 
because IGF-1 plays a role in the thyroid axis and is elevated in human 
hyperthyroid patients (Miell et al. 1993), the secondary aim of this study was to 
determine if excessive dietary taurine causes an increase in insulin-like growth 
factor 1 (IGF-1).  
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Materials and Methods 
Ethics: All procedures performed were approved by the University of 
Missouri Animal Care and Use Committee in accordance with the Guide for the 
Care and Use of Laboratory Animals (National Institutes of Health 2011) and the 
Animal Welfare Act and Regulations (United States Department of Agriculture 
2013). 
Animals: Ten, adult (7-11 yr), lean (BCS of 4-5/9), purpose bred, 
neutered male, domestic short-haired cats were deemed healthy on physical 
exam, complete blood cell count, and serum clinical biochemistry (University of 
Missouri Veterinary Diagnostic Laboratory, Columbia, MO, USA) findings prior to 
the start of the study. All cats were individually housed approximately 8 hours 
each day in individual 1.2 x 1.8 meter runs during food presentation.  After food 
presentation, cats were socially housed by allowing access among all runs. At all 
times, cats had ad lib access to water.  
Diets: A custom formulated purified diet was initially investigated for use 
because all commercially available feline diets were deemed to contain taurine in 
excess of that desired and the matrix of such diets unpredictably affect taurine 
bioavailability in cats. A nutritionally complete and balanced purified diet 
previously described by Backus et al. (2007) was adapted for this study (table 
5.1-5.3).  Seven of the ten cats did not consume the diet adequately to maintain 
their body weight.  Cats were transitioned from the purified diet to a commercially 
available canine adult, “weight management”, dry-expanded diet (Purina Pro 
Plan Focus Adult Weight Management Formula, Nestlé Purina Pet Care 
Company, Saint Louise, MO, USA) (Table 5.4).  The commercial diet was 
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nutritionally complete and balanced as substantiated from passage of feeding 
trials as described by American Association of Feed Control Officials (AAFCO).  
The diet was selected to serve as a base diet to which taurine would be added 
because the kibble size and palatability were uniformly accepted by the ten cats. 
Taurine in the diet was assumed to be low as it was not listed as an ingredient.  
The nutrient profile provided by the manufacturer was in excess of that 
recommended by AAFCO (2013) and NRC (2006). The batch of the base diet 
used served as a “control” diet which was determined to contain 0.25% taurine 
(2.5 g/kg DM) (Experimental Station Chemical Laboratory, University of Missouri, 
Columbia, MO, USA), an amount in excess of the AAFCO recommendation for 
feline extruded diets (American Association of Feed Control Officials 2013). The 
“high taurine” diet was the base diet supplemented to contain 0.7% taurine (7 
g/kg DM), and was prepared by top-dressing the base diet with finely milled 
crystalline taurine (Dyets Inc, Bethlehem, PA, USA) dispersed in a cornstarch 
hydrolysate powder, dyetrose (Dyets Inc, Bethlehem, PA, USA), to ensure even 
distribution and coating of the kibble during batch mixing.  The cats underwent an 
adaption period of 40 weeks on the diet prior to the start of the study.  During this 
adaption period it was determined that the base diet required a taurine content of 
0.35% (3.5 g/kg DM) to maintain adequate plasma taurine concentrations >40 
nmol/mL (Delaney et al. 2003; University of California-Davis Amino Acids 
Laboratory 2017) in all cats.  Cats were maintained on the base diet containing 
0.35% taurine for 12 weeks prior to the start of the study and during the washout 
period.  
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Table 5.1 Feline purified diet 
Ingredient Amount (g/kg) 
Casein (30 mesh) 180 
Soy protein isolate 180 
Maize starch 219 
Chicken fat 237 
L-Methionine 0.25 
L-Threonine 0.84 
Potassium  13 
Magnesium Sulfate 5.4 
Omega-3 fatty acids 
• Docosahexaenoic acid (DHA)
• Eicosapentaenoic acid (EPA)
0.327 
0.125 
0.114 
Calcium 5.4 
Trical 2.8 
Sucrose 46 
Sodium propionate 10 
Mineral mixture* 50 
Vitamin mixture† 50 
* See table 2 for ingredients. † See table 3 for ingredients.
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Table 5.2 Mineral mixture 
Ingredient  Amount (g/kg) 
Ferric citrate (17.3% Fe)  8.283 
Zinc carbonate (60.4% Zn)  2.724 
Cupric carbonate (57.47% Cu)  0.101 
Manganese carbonate (47.79% Mn)  0.245 
Sodium selenate (41.79% Se)  0.014 
Sucrose  988.633 
Custom mineral mixture for cats (Dyet# 270004, Dyets Inc, Bethlehem, PA, USA) 
Table 5.3 Vitamin mixture 
Ingredient  Amount (g/kg) 
Vitamin A Palmitate (500000 IU/g)  0.174 
Vitamin D3 (400000 IU/g)  0.018 
Vitamin E Acetate (500 IU/g)  2.088 
Vitamin K1/Dextrose Mix (10 mg/g)  2.100 
Thiamine HCl  0.142 
Riboflavin  0.100 
Niacin  1.002 
Folic Acid Premix (5 mg/g)  2.371 
Pyridoxine HCl  0.065 
Vitamin B12 (0.1%)  0.513 
Biotin Premix (1 mg/g)  0.660 
Calcium Pantothenate  0.142 
Sucrose  990.625 
Custom vitamin mixture for cats (Dyet# 370003, Dyets Inc, Bethlehem, PA, USA) 
154 
Table 5.4 Proximate and taurine analysis of the control (low taurine diet) 
Nutrient Amount (g/100 g) 
Crude protein 27.87 
Crude fat  4.68 
Crude fiber  2.68 
Moisture  8.83 
Ash 5.33 
Taurine 0.25 
Ingredients: Chicken, brewers rice, poultry by-product meal 
(source of glucosamine), whole grain corn, wheat flour, corn 
gluten meal, whole grain wheat, corn germ meal, animal fat 
preserved with mixed-tocopherols (form of Vitamin E), fish 
meal (source of glucosamine), animal digest, wheat bran, 
calcium carbonate, salt, potassium chloride, Vitamin E 
supplement, calcium phosphate, choline chloride, zinc 
sulfate, ferrous sulfate, L-ascorbyl-2-polyphosphate (source 
of Vitamin C), manganese proteinate, niacin, and Vitamin A 
supplement 
Proximate analysis performed at the University of Missouri-Columbia 
Experimental Station Chemical Laboratories on an as is basis.  Metabolizable 
energy is 3579 kcal/kg. 
Study design:  Using a cross-over design, each cat was randomly assigned to 
one of two dietary treatments, 1) control (0.25% taurine) or 2) high taurine 
(0.70% taurine). Diet-presentation blocks were 42 days (6 weeks) in duration. 
After the first block the washout period was 63 days (9 weeks) during which cats 
were presented with the base diet top-dressed to contain a taurine content of 
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0.35%. Prior to the start of the study, the cats were pre-fed the base diet top-
dressed with the same amount of taurine as that used in the washout period for 
more than 9 weeks.  During day 28 thru day 38 of the washout period all cats 
received a once daily 50 mg/kg oral dose of fenbendazole as part of a University 
wide treatment for Giardia despite the cats not testing positive nor exhibiting 
clinical signs of Giardia infection.  Daily, the cats were presented an allotted 
amount of diet in order to maintain a stable weight and an ideal body condition 
score of 5/9 (Laflamme 1997). The dry matter amount of diet offered to each cat 
was not changed during the study or washout period and dietary intake was 
recorded daily. Cats were weighed weekly. Jugular venous blood was collected 
in the morning (0830 to 1000 hours) on day 0, 14, 28, and 42 of each dietary 
block. Jugular venous blood was also collected approximately 4-5 hours after 
initial food presentation (1400 to 1500 hours) on day 0 and 42 of each dietary 
block. A 3-mL BD vacutainer containing lithium heparin (Becton, Dickinson, and 
Company, Franklin Lakes, NJ, USA) was used for obtaining whole blood and 
plasma samples. Ten milliliter plain (serum) BD vacutainers (Becton, Dickinson, 
and Company, Franklin Lakes, NJ, USA) were used to collect blood for obtaining 
serum samples.  Blood was allowed to clot at room temperature for 1 hour prior 
to centrifugation at 1200 x g for 10 min for extraction of serum. Whole blood, 
extracted serum, and extracted plasma was stored in 0.5 – 1.0 mL aliquots at -
20°C until analyses.   
Thyroid hormone analysis:  Fasting serum samples from day 0, 14, 28, and 42 
and post-prandial samples on day 0 and 42 of each dietary block were sent 
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overnight on dry ice to Michigan State University’s Diagnostic Center for 
Population and Animal Health (DCPAH) for measurements of total T4 (TT4), total 
T3 (TT3), free T4 (fT4), and free T3 (fT3). 
Insulin-like growth factor 1 (IGF-1) analysis: Fasting serum samples from day 
0 and 42 were sent overnight on dry ice to DCPAH for measurements of IGF-1 
using the assay described by Reusch et al. (2006). 
Plasma and whole blood taurine analysis: Plasma and whole blood taurine 
concentrations were measured on days 0, 14, 28, and 42 of each block using 
high pressure liquid chromatography (HPLC) methods described by Hooper et al. 
(2017).  In brief, whole blood samples were frozen and thawed 3 times before 
extraction for taurine analysis to help ensure cells were lysed.  Fifty microliters of 
plasma or whole blood were deproteinized by adding 50 µL of acetonitrile with 
100 ng/mL trans-4-hydroxy-L-proline added as internal standard. Samples were 
centrifuged for 15 min at 16,000 x g.  Fifty microliters of resulting supernatant 
were transferred to a 13 x 100 mm glass tube and evaporated by centrifugal 
evaporation. Fifty microliters of a coupling solution (1:1:1, v/v, 
triethylamine:water:methanol) was added to the dried residue, and subsequently 
evaporated to dryness.  Then, 50 µL of derivatization solution (20:5:5:2, v/v, 
methanol:water:triethylamine:phenylisothiocyanate) was added to each tube and 
tubes were covered with parafilm and left at ambient temperature.  After 20 
minutes, samples were evaporated to dryness and redisolved in 400 µL of 
sample diluent (710 mg disodium hydrogen phosphate, 950 mL water, 5 mL 
acetonitrile, adjusted to pH 5.4 with phosphoric acid). The reconstituted samples 
 157 
 
were transferred to centrifuge tube with a 0.2 µm centrifuge tube filter 
(Corning®Costar® SpinX centrifuge tube filters, Sigma Aldrich, St. Louis, MO, 
USA) and spun for 15 min at 15,000 x g. Samples were injected into a C18 
column (Microsorb 100-5 C18, 250 x 4.6 mm Varian Inc. Lake Forest, CA, USA) 
and the UV265nm absorbance of the phenylisothiocyanate derivatives of taurine 
and internal standard were quantified. 
Statistical Analyses: We used SAS 9.3 software package (SAS Institute Inc., 
Cary, NC, USA) to perform all statistical analysis and significance was calculated 
at alpha=0.05. All outcome variables were determined to be normally distributed. 
The Proc MIXED procedure with repeated measures and differences of the least 
square means was used to evaluate effect of dietary taurine concentration, 
sampling time, time-diet interactions on variables of interest: serum TT4, TT3, 
fT4, and fT3 concentrations; diet consumption; body weight; and plasma and 
whole blood taurine concentrations.   
Results 
During the period when the dietary taurine concentration to be used in the 
study was being determined, two cats developed feline lower urinary tract 
disease (feline idiopathic cystitis) and were not included in the study.  During the 
study, one cat, deemed healthy prior to the start of the study, developed clinical 
signs of renal failure including elevated creatinine and blood urea nitrogen (BUN) 
values which were above the laboratory reference range, lethargy, decreased 
grooming, and weight lost.  A retrospective review of serum creatinine and urea 
nitrogen concentrations annually determined for the prior 2 years indicated that 
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the values were within the reference range however showed a progressively 
diminishing kidney function.  His participation in the study was discontinued. 
Seven of the ten cats completed both dietary blocks and were included in 
the analysis.  The seven cats adapted to the commercial canine diet. There were 
no difference in feed intakes during the dietary blocks (p = 0.96, table 3). There 
was a trending increase in body weight when the cats were on the high taurine 
diet (p = 0.07).   
Table 5.3 Summary of food intake, metabolizable energy, and weight over 
the duration of the study 
Dietary 
Treatment 
Dietary 
taurine 
(DM) 
Food 
Intake 
(g /day) 
Metabolizable 
energy 
(kcal/day) 
Weight 
Day 0 
(kg) 
Weight 
Day 42 
(kg) 
Weight 
change 
(%) 
Control 0.25% 62.3 ± 
3.35 
222 ± 11.8 5.53 ± 
0.26 
5.53 ± 
0.25 
0.00% 
Taurine 0.70% 62.1 ± 
3.30 
223 ± 12.0 5.43 ± 
0.24 
5.51 ± 
0.23 
1.58%* 
*There is an interaction trend (p = 0.07) between the body weight and time when the 
cats were on the high taurine diet. 
 The 12 week adaption period and 9 week washout period prior to the start 
of the study were adequate as the plasma taurine and whole blood 
concentrations were not significantly different at week 0 (p = 0.40; p = 0.98).  By 
week 2, the cats on the high taurine diet had significantly higher plasma and 
whole blood taurine concentrations than when the cats were on the control diet (p 
< 0.001, Fig 5.1).   
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Figure 5.1 Plasma and whole blood taurine concentrations 
(A) Circulating plasma taurine concentrations (n=7) and (B) whole blood taurine
concentrations (n=7) were not significantly different at week 0 (p = 0.40; p = 
0.98).  By week 2, the circulating taurine concentrations were significantly 
different (p < 0.001) between the high taurine and control. * indicates significant 
difference (p < 0.001) 
Dietary taurine did not alter the thyroid hormone concentrations (Table 
5.4, Figure 5.2), however the circulating serum concentrations of TT4, TT3, and 
* 
* 
* 
* 
*
* 
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FT3 from the morning fasted samples varied each week for all treatment groups 
(Table 5.4).  The TT4, TT3, and FT4 concentrations were significantly elevated 4 
hours after initial food presentation compared to the morning fasted circulating 
thyroid hormones (p < 0.05, Figure 5.2) 
Table 5.4 Thyroid hormone concentrations of morning fasted samples 
Thyroid 
Hormone 
Day Control High Taurine 
Treatment 
p-value
Week 
p-value
Treatment*Week 
p-value
TT4 
(nmol/L) 
0 17.9 ± 1.2 18.4 ± 0.3 
0.84 <0.01 0.73 
14 17 ± 0.7 16.4 ± 1.3 
28 18 ± 0.8 17.3 ± 1.4 
42 19.6 ± 0.8 20.4 ± 1.9 
TT3 
(nmol/L) 
0 0.59 ± 0.04 0.63 ± 0.04 
0.65 <0.01 0.51 
14 0.60 ± 0.03 0.59 ± 0.03 
28 0.66 ± 0.04 0.63 ± 0.04 
42 0.56 ± 0.04 0.57 ± 0.05 
FT4 
(pmol/L) 
0 20.4 ± 1.0 21.4 ± 1.1 
0.81 0.25 0.64 
14 20.3 ± 1.3 18.7 ± 1.3 
28 20.1 ± 1.0 19.6 ± 1.5 
42 21.3 ± 0.6 21.4 ± 1.5 
FT3 
(pmol/L) 
0 1.2 ± 0.2 1.1 ± 0.2 
0.17 0.03 0.14 
14 0.8 ± 0.1 1.0 ± 0.1 
28 1.1 ± 0.1 1.1 ± 0.1 
42 1.1 ± 0.1 1.4 ± 0.1 
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Figure 5.2 Day 0 and 42 fasting and post-prandial thyroid hormone 
measurements 
Post-prandial thyroid hormone samples significantly increase for serum TT4, TT3, and 
FT4 concentrations (p < 0.05). 
Dietary taurine did not significantly alter the circulating IGF-1 
concentrations, however the mean for all samples were elevated about the 
reference range of the laboratory (12-92 nmol/L). 
Table 5.5 Circulating serum IGF-1 concentration 
Day 
Control 
(nmol/L) 
High 
Taurine 
(nmol/L) 
Treatment 
p-value
Week 
p-
value 
Treatment*Week 
p-value
0 95 ± 8.8 99 ± 11 
0.77 0.91 0.61 
42 98 ± 11 93 ± 10 
The reported reference range based upon 38 healthy cats is 12-92 nmol/L 
(Reusch et al. 2006).  
* * * * * * * *
* * * * 
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Discussion 
By the mid-1980’s, two commonly occuring domestic cat diseases, central 
retinal degeneration and dilated cardiac myopathy, were determined to be 
caused by taurine deficiency (Hayes et al. 1975; Pion et al. 1987).  The formation 
of taurine from the amino acid L-cysteine is dependent upon a series of reactions 
involving cysteine sulphinic acid decarboxylase (CSAD)(Earle and Smith 1992). 
The lack of CSAD activity in domestic cats prevents them from synthesizing 
adequate amounts; therefore, taurine is required in the diet of cats (de la Rosa 
and Stipanuk 1985; Earle and Smith 1992).  After taurine was determined to be 
an essential dietary nutrient for domestic cats, comercial pet food manufacturers 
began supplementing feline diets with taurine (National Research Council 1981).  
The emergence of hyperthyroidism began to occur in the late 1970’s and early 
1980’s (Edinboro et al. 2004; Peterson et al. 1979) which coincided with the start 
of supplementation of taurine into commercial cat food (National Research 
Council 1981). 
The purpose of this study was to determine if high dietary taurine alters 
the function of the hypothalamic-pituitary-thyroid axis, leading to an increase in 
thyroid hormone production.  We chose to supplement the base diet with taurine 
at 0.70% DM as this concentration is found within commercial canned diets (Hill's 
Pet Nutrition Inc. 2017; Purina Nutrition 2014).  This supplementation is 
approximately 300 – 700% of the recommendations set forth by both the National 
Research Council (NRC) and the American Association of Feed Control Officials 
(AAFCO) who recommend a dietary taurine level of 0.10% DM in commercial dry 
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diets and 0.25% DM in commercial canned diets (National Research Council 
2006; American Association of Feed Control Officials 2013).  The higher 
recommendation for canned diets is based the processing of the diet (Backus RC 
1998) and upon the increased microbial degradation of taurine in the 
gastrointestinal tract as the composition of the microflora is criticial in determining 
the taurine status of cats (Morris et al. 1994).  
The best clinical method to monitor taurine status is measuring both 
plasma and whole blood (Pacioretty et al. 2001).  Plasma taurine is used for 
monitoring acute depleting trends of taurine status whereas whole blood is better 
for monitoring acute repleting trends of taurine status (Pacioretty et al. 2001). 
Despite the cats being on a high taurine diet containing 0.70% taurine, the 
plasma and whole blood taurine concentrations in this study (Fig 5.1) were lower 
than expected during the dietary blocks.  Heinze et al (2009) reported the taurine 
blood concentrations of domestic cats fed commercial canned and dry extruded 
diets (taurine content unknown) were 80-120 nmol/mL for plasma taurine and 
300-600 nmol/mL for whole blood taurine concentration (Heinze et al. 2009).
Douglas et al. (1991) reported that cat’s fed dry commercial diets at 0.055% and 
0.14% taurine had a mean plasma taurine concentration of 51 µmol/L (51 
nmol/mL) and 107 µmol/L (107 nmol/mL) at 7 weeks (Douglass et al. 1991).  
These same cats at 4 weeks had whole blood taurine concentrations reported to 
be 335 µmol/L (335 nmol/mL) and 490 µmol/L (590 nmol/mL) (Douglass et al. 
1991).  At the end of 6 weeks, our mean plasma taurine concentration for cats on 
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the 0.70% taurine diet was 132 nmol/mL and 229 nmol/mL for whole blood (Fig 
5.1).  
The low plasma and whole blood taurine concentrations are likely due to 
the diet selected for the study. The six week duration of each dietary block 
should have been adequate for taurine repletion to occur, because the reported 
half-life for taurine repletion for plasma is 3.5 weeks and 0.74 weeks for whole 
blood (Pacioretty et al. 2001). The diet, a canine weight loss maintenance 
commerical dry food, has a higher fiber content than most commercial cat foods.  
Soluble fiber such as pectin and guar gum has been shown to delplete hepatic 
taurine content (Baker 1991).  Fiber has also been shown to alter the bile acid 
metabolism (Eastwood 1992; Meyer et al. 1979; Story and Kritchevsky 1978).  In 
cats, secondary bile acids are formed almost exclusively through conjugation 
with taurine (Rabin et al. 1976).  Fibers that bind to bile acids, reduce the 
reabsoprtion and cause an increased loss of bile acids in the feces (Eastwood 
1992). Similar to when cats are given Cholestyramine©, an anion exchange resin 
that binds bile acids, the loss of bile acids causes plasma and whole blood 
taurine concentrations to become depleted (Morris et al. 1994). Throughout the 
40 week acclimation period to the canine diet and the study, it is likely that the 
high fiber content of the diet caused a chronic increased loss of taurine-
conjugated bile acids, this would help explain the low plasma and whole blood 
taurine levels observed.  The fiber content is also likely to help explain why the 
cats would be considered taurine deficient (defined as less than 40 nmol/mL for 
plasma and 200 nmol/mL for whole blood (National Research Council 2006)) 
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after 6 weeks on the control diet despite containing 0.25% taurine, well above the 
minimium recommended dietary taurine concentration for dry diets (National 
Research Council 2006). 
 In addition to altering the bile acid pool, it has also been suggested that 
fiber alters the gut microflora, causing an increase in bacterial cholylhydrolase 
(National Research Council 2006; Morris et al. 1994).  This increase of 
cholylhydrolase, causes increased cleavege of taurocholic acid in the illeum and 
increased oxidation of taurine (National Research Council 2006; Morris et al. 
1994).  The oxidation causes taurine to be unavailable for enterohepatic 
reuitilization (Morris et al. 1994) and therefore increases the loss of taurine by the 
body.  
Despite the taurine concentration in the plasma and whole blood being 
lower than expected, the circulating concentrations were clearly significanlty 
different when the cats were on the high taurine diet compaired to the control diet 
(Fig 5.1).  The fasting levels of of TT4, TT3, and FT3 varried significantly by 
week, but they were not influenced by dietary taurine (Table 5.4). While our 
central hypothesis was that excessive dietary taurine would determine alter the 
hypothalamic-pituitary-thyroid axis and lead to a rise in the production of 
circulating thyroid hormones T4, T3, FT4, and FT3, we had several underlying 
hypothesis about how taurine might alter the function of the thyroid axis which 
our study design did not adequately address.   
Taurine supplementation has been shown to increase the bile acid pool 
(Bellentani et al. 1987; Hickman et al. 1992).  Bile acid abundance has been 
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shown to affect thyroid hormone production (Ockenga et al. 2012).  Because the 
increase in the bile acid pool would cause an increase in the enterohepatic 
circuation of taurine-conjugated secondary bile acids, we hypothesized that 
circulating T4 and T3 would increase due to serum bile acids stimulating thyroid 
hormone production.  Unfortunately, we did not measure the bile acid pool and 
were unable to measure serum bile acids within our laboratory, so we do not 
know if the bile acid pool or circulating serum bile acids were altered.  Addtionally 
the selection of the high fiber weight loss diet was a confounding variable.  It is 
plausable that we did not see an increase in thyroid hormone due to the diet 
inhibiting the expansion of the bile acid pool and negatively impacting the 
reabsorption of bile acids into enterohepatic circulation.   
In additional to taurine altering bile acid metabolism, we hypothesized that 
excessive dietary taurine would result in a proliferation of thyroid cells and the 
formation of hyperfuncting thyroid nodules.  These hyperfunctioning thyroid 
nodules would yield an inappropriate rise in the production of the thyroid 
homones T4 and T3.  Our hypothesis was based upon the report by Jhiang et al. 
(1993) that the proliferation rate of thyroid cells from two human cell lines 
increased with increasing taurine in vitro (Jhiang et al. 1993).  While euthanasia 
would be required to grossely and histologically examine the thyroids for thyroid 
nodules, we elected to not euthanize the cats.  As an alternative to euthanasia, 
our laboratory conducted pilot work to determine if magnetic resonance imaging 
(MRI) coupled with mass resonance spectroscopy (MRS) could be used to non-
terminally examine the thyroid gland and measure the concentration of taurine in 
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the thyroid gland.  MRI/MRS has been successfully used to quantify metabolites, 
including taurine, in brain tissue (Tong et al. 2004).  In our pilot study of two cats, 
we determined that the microchips embended in the subcutaneous tissue within 
the neck region caused interference and the thyroids could not be visualized 
(Hooper and Backus 2015, unpublished data).  The thyroid glands could be 
imaged on cats who did not have a microchip, however the imaging quality was 
not adequate to detect small hyperfunctioning thyroid nodules.  Additionally, it 
was determined that the region of interest (ROI) of the MRS was too large and 
could not isolate the thyroid gland from the muscle.  With the high taurine content 
of the muscle, we were unable to measure the thyroid taurine content.  Future 
studies may be able to incorporate this technology, however the animals cannot 
be microchipped and a MRI of sufficient strength and MRS capabilities will need 
to be used. 
While it is unknown if the high dietary taurine caused formation of thyroid 
nodules in our cats, it is likely that the formation of thyroid nodules occurs with 
chronic exposure rather than an acute exposure of six week duration.  
Hyperthyroidism generally affects cats 7 years or older (Mooney 2012), therefore 
a more long-term study is most likely needed to understand the effects of high 
dietary taurine on the thyroid gland.  When designing a long-term study, it may 
be worthwhile to include a group which receives fluctiations in taurine 
concentrations as fluctuations in dietary iodine have been suggested as a risk 
factor for the development of hyperthyroidism (Edinboro et al. 2013), but to date 
no studies have evaluated this hypothesis.   
168 
A single study conducted by our laboratory reported that T4 and T3 were 
increased post prandially (Hooper et al. 2014).  The present study confirms that 
T4, T3, as well as FT4 increase signficantly 4 hours post-prandially (Fig 5.2).  It 
remains unclear if this elevation could contribute to the pathopsyiology of feline 
hyperthyroidism.  Future studies should evaluate when is the optimal time to 
collect blood for studying the effects of dietary nutrients on thyroid hormone 
production.  If high levels of taurine or other suspected dietary constitutents alter 
the maximal peak of circulating thyroid hormones it could be important to 
understand if the fluxations in thyroid hormones play a role in the 
etiopathophysiology of feline hyperthyroidism. 
The secondary aim of this study was to determine if excessive dietary 
taurine caused an increase in circulating serum IGF-1. While IGF-1 and insulin-
like growth factor binding protein-1 are elevated in human hyperthyroid patients 
(Miell et al. 1993), it is unknown whether IGF-1 levels are elevated during the 
development of hyperthyroidism or if IGF-1 levels are elevated in subclinical 
hyperthyroidism.  Some evidence exists that IGF-1 affects thyroid function based 
upon knockout mouse studies that showed TSH and IGF-1 are both required to 
regulate thyroid growth (Ock et al. 2013).  Additionally, intravenously 
administered taurine has been shown to increase growth hormone (Ikuyama et 
al. 1988).  If dietary taurine can cause an increase in growth hormone (GH), then 
an increase in GH will directly raise the circulating serum IGF-1 concentrations 
(Kalu et al. 1998).  We chose to measure IGF-1 rather than GH for several 
reasons.  IGF-1 has a fifteen-hour half-life wheras GH has a half-life of 
 169 
 
approximately 12 minutes (Bright et al. 1999).   GH is secreted in a pulsatile 
manner that is highly variable within and between individuals (Tannenbaum and 
Martin 1976) whereas IGF-1 is not secreted in the pulsatile manner (Brabant 
2003).  Additionally, there are no diagnostic labs or commerical assays available 
to measure feline GH.  A feline specific IGF-1 assay was developed and 
validated by Michigan State Diagnostic Center for Population and Animal Health 
in collaboration with other researchers and diagnostic laboratories (Reusch et al. 
2006).   
We did not observe a dietary taurine effect on IGF-1 (Table 5.5), however 
the mean IGF-1 concentrations when the cats were on the control and high 
taurine diet were considered elevated.  The reference for this assay is quite large 
and based upon 38 healthy cats, a relatively small sample size (Reusch et al. 
2006). IGF-1 is typically only measured in cats that are diabetic and/or are 
suspected to have acromegaly, an endocrine disorder characterized by 
excessive growth hormone secretion caused by a functional somatotrophic 
adenoma in the pars distalis of the anterior pituitary gland (Niessen et al. 2007).  
The acromegaly diagnosis is supported by a combination of clinical symptoms 
and circulating IGF-1 concentrations above 1,000 ng/mL (131 nmol/L). We 
suspect the values obtained were normal individual variation of IGF-1.  
Conclusion 
Our study documents that feline thyroid hormones are affected by feed 
consumption.  It has been hypothesized, though not tested, that fluxations in 
dietary iodine could contribute to the development of feline hyperthyroidism 
(Edinboro et al. 2013).  Understanding the effects of dietary constituents on post-
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prandial thyroid hormone concentrations should be pursued in future studies as it 
is unknown if post-prandial thyroid hormone elevations play a role in the 
development of feline hyperthyroidism.  While this study did not support 
excessive taurine as a risk factor for the development of feline hyperthyroidism, 
another study looking at chronic taurine administration and utilizing a feline diet 
without excessive fiber or a purrified diet would be of value to the veterinary 
community to better address this study’s hypothesis. 
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APPENDIX 
Taurine HPLC assay 
Serum/plasma/whole blood sample prep 
• Freeze-thaw three times whole blood samples to help lyse cells (whole 
blood only) 
• Equal volume of acetonitrile with standard and sample  (50 µL ACN and 
50 µL sample) 
o Acetonitrile containing 100 ng/mL trans-4-hydroxy-L-proline internal 
standard 
o Ensure 2 quality control samples are prepared to run before and 
after samples 
• Vortex thoroughly, centrifuge at 16g for 15 min 
• Take 50µL to use, and transfer to a labeled 13 x 100 mm glass tube 
o Spiked standards containing 100 ng/mL trans-4-hydroxy-L-proline 
internal standard and taurine should be included 
o Continue to Drying and Derivatization below 
Tissue homogenate sample prep 
• One whole thyroid gland 
o homogenize in 1 mL of distilled water 
• Approximately 50 grams of the frozen liver and kidney  
o homogenize in 1.5 mL of distilled water 
• Approximately 25 grams of quadriceps muscle  
o homogenize in 500 µL of distilled water 
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• Equal volume of acetonitrile with standard and homogenized sample  (50
µL ACN and 50 µL sample)
o Acetonitrile containing 100 ng/mL proline internal standard
o Ensure 2 quality control samples are prepared to run before and
after samples
• Vortex thoroughly, centrifuge at 16g for 15 min
• Take 50µL to use, and transfer to a labeled 13 x 100 mm glass tube
o Spiked standards containing 100 ng/mL trans-4-hydroxy-L-proline
internal standard and taurine should be included
o Continue to Drying and Derivatization below
Drying and Derivatization 
• After adding 50 µL of sample to tubes
• Evaporate to dryness at 35°C for 15 minutes
• After dry add 50 µL of 1:1:1 of methanol +water + TEA (50 µL of each in
mix)
o Increase amount as needed for number of samples
• Evaporate to dryness at 35°C for 15 minutes
• Derivatization, prepare after samples dry and immediately before use
o 200µL methanol + 50µL water + 50µL TEA + 20µL PITC
o Increase amount as needed for number of samples
• 50µL of derivatization  into each tube, leave 20 min at room temp
o Cover with parafilm or cap
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• After 20 min, evaporate to dryness at 35°C for 60 minutes (sometimes 
takes longer for samples based upon number of samples) 
• Redesolve samples in 200 µL of sample diluent 
o Sample diluent = 710 mg disodium hydrogen + 1 liter water-
acetonitrile (19+1) and adjust to pH 5.4 with phosphoric acid 
o 100 mL = 71 mg + 95 mL H2O + 5 mL acetonitrile 
• Transfer to 0.2 µm filter ependorfs 
• Centrifuge for 15 min at 15g 
• Transfer to HPLC vials 
• Centrifuge for 10 min at 3g 
• Inject 5 µL of sample into HPLC 
Solvent A 
• Sodium acetate HPLC 11.45 grams 
• ddH2O 900 mL 
• Acetonitrile 15 mL LC-MS grade 
• TEA 0.5 mL 
• adjust to pH 5.4 with glacial acetic acid 
Solvent B 
• 410g H2O 
• 475g acetonitrile 
o This is 1:1 water:acetonitrile 
• Filter solvents with Millipore 0.2µm filter, carefully pour to avoid air. 
HPLC Column Varian Miscrosorb 100-5C18, temperature should be 45°C 
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Gilkson HPLC  
• Turn on column heater and assure that it is set to 45°C 
o Allow column to heat for a minimum of 30 minutes prior to first 
sample run 
• Turn on pumps, injector, detector 
o Ensure waste contains are empty and/or open 
• Make sure Solvent A and B are on the system 
• Ensure that new solvents are primed through system 
o Open valve Prime  Run for pump A, then stop and change 
pumps to B to run, then  stop  close valve 
• Condition column 
o Condition  enter 3.5 minutes for the time   Flow  1.0 ml/min 
 %B should be at 0 automatically 
• Program 4 will be used for taurine 
o Make sure that you edit the number of loops you want to run 
▪ Fileeditenter # of loops 
• While column conditions for 15-20 minutes  
o Turn on computer  start Peak simple program  Open control file 
“Taurine”  ensure axis are 0 to 45 on x axis, and 120 on y axis 
o Make sure that you can see the entire run (0-45 minutes) 
▪ Overall enter “0” for start time and “45” for end time 
o Make sure to change post-run to today’s date and auto increment is 
on 
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▪ i.e. 2016_7_22_ 
o Run time will be 45 minutes 
o Zero detector 
• Injector file is also #4 
o Injection is 5 µL with a run time of 45 minutes 
• Make sure detector is not running, then press “run” for program 4 on 
pumps 
o Subsequently press run on the injector and choose the number of 
samples you have prepared  
o Ensure that sample injects and detector is running okay after 
injection 
Peak Simple Analysis of samples 
• Choose overall and view only in 10 and 25 min region 
• Right click on screen above peak of interest  choose add component 
• Add component for both taurine and proline peaks 
• See next page for example of where Taurine and proline peaks are 
o First chromatogram is a cat consuming a “high taurine” diet and the 
second chromatogram is a cat consuming a “low taurine”.  Both are 
plasma samples 
• After peaks have component above them choose “results” 
• Record the area on an Excel spread sheet to allow calculations 
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HPLC Appendix Figure 1 Example chromatograph 
A representative example of the plasma taurine peak from a rat on the (A) high taurine 
diet and (B) low taurine diet. 
Proline 
Proline 
Taurine 
Taurine A 
B 
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Microbiome Extraction Protocol 
 
As described in (Hart et al. 2015) 
Cell Lysis 
• Make cell lysis buffer 
o 500 mM NaCl, 50 mM Tris-HCl pH 8.0, 50 mM EDTA, and 4% 
sodium dodecyl sulfate (SDS) 
• Warm lysis buffer in 37°C water bath until SDS is completely suspended  
• Place 1-2 fecal pellets or entire cecal contents in 2.0 mL round-bottom 
tube with ball bearing 
• Add 800 µLof cell lysis buffer to tube 
• Homogenize at maximum speed for 3 minutes in TissueLyser 
• Incubate at 70°C for 20 minutes with brief vortexing every 5-10 minutes 
• Spin at room temperature for 5 minutes at 5000×g 
• Transfer entire supernatant to fresh 1.5 mL Eppendorf tube  
Precipitation of Nucleic Acids 
• Place isopropanol on ice (approximately 800 µL per sample to be 
extracted) 
• Add 200 µL of 10 mM ammonium acetate to lysate (supernatant that was 
transferred to fresh Eppendorf tube) and mix well 
• Incubate on ice for 5 minutes 
• Spin at room temperature for 5 minutes at 5,000×g  
• Transfer 750 µL of supernatant to new 1.5 mL Eppendorf tube  
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• Add 750 µL (or one volume) chilled isopropanol to each tube and vortex 
well 
• Incubate on ice for 30 minutes (30 minutes is minimum, up to 1.5 hours) 
• Spin at 4°C for 15 minutes at 16,000×g (temperature is critical) 
• Aspirate supernatant and discard 
• Add 150 µL of 70% EtOH to nucleic acid pellet; aspirate (avoiding the 
nucleic acid pellet) and discard EtOH (quick in and out rinse) 
• Resuspend pellet in 150 µL of Tris-EDTA (may help to place in 37°C water 
bath for 10-30 minutes with intermittent vortexing or pipetting to loosen 
DNA pellet) up to one hour 
Removal of RNA, protein, and purification 
• All of the following reagents, buffers, and columns are from the Qiagen 
DNeasy extraction kit (blood and tissue kit) 
• Add 15 µL of proteinase K and 200 µL of Buffer AL and mix well 
• Incubate at 70°C for 10 minutes 
• Add 200 µL of 100% EtOH and mix well 
• Transfer to DNeasy column and spin at 16,000×g for 1 minute 
• Discard flow-through and collection tube, add 500 µL of Buffer AW1 and 
spin at 16,000×g for 1 minute at room temp 
• Discard flow-through and collection tube, add 500 µL of Buffer AW2 and 
spin at 16,000×g for 3 minutes at room temp 
• Transfer column to clean 1.5 ml Eppendorf tube 
• Add 200 µL of EB buffer and incubate at room temp. for 2 minutes  
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• Spin at 16,000×g at room temp. for 1 minute to elute DNA; discard column 
• Store DNA at -80°C for long-term storage or refrigerate if analyzing within 
2-3 weeks 
• The extracted DNA is submitted through the MU Metagenomics Core 
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Thyroid hormone liver extraction protocol  
 
Adapted from (Morreale de Escobar et al. 1985) 
 
Day 1 
• Weigh out 1 gram liver 
• MeOH should be prepared with 1 mM 6-propyl-2-thiouracil (PTU) to 
prevent degradation of T4 to T3 
• Homogenize in 1 mL MeOH in silanized glass tube 
• Add ~2,000 counts per minute (CPM) T4 or T3 I125  
• Transfer homogenate to Teflon stoppered, salinized glass tube 
o Rinse tube used for homogenate in 1 mL aliquots to bring MeOH up 
to 4 mL total in the stoppered glass tube 
• To the liver-MeOH homogenate in the glass tube add chloroform 2x the 
volume of MeOH 
o So add 8 mL of chloroform to the 4 mL of MeOH 
• Cap tightly and shake for 30 seconds 
• Centrifuge at 2,000g for 15 minutes 
• Remove upper layer and place in stoppered, silanized glass tube 
o Repeat 
o Add chloroform 2x the volume of MeOH 
▪ (so add 8 mL of chloroform to the 4 mL of MeOH) 
o Cap tightly and shake for 30 seconds 
o Centrifuge at 2,000g for 15 minutes 
o Remove upper layer and place in stoppered, silanized glass tube 
 191 
 
o Discard MeOH:CHCl3 in appropriate waste container 
• To the upper layer that was removed add 0.05% CaCl2 and shake 
o 2mL of CaCl2 per 10mL extract 
o Allow to sit on ice for 30 minutes 
o Repeat by adding 0.05% CaCl2, shake and transfer to new 
silanized glass vial 
o Repeat with pure upper phase 1x to 2x 
▪ CHCl3:CH3OH:0.05% CaCl2 (3:49:48) 
• Determine percent recovery by counting the 0.05% CaCl2 and the pure 
upper phase (CHCl3:CH3OH:0.05% CaCl2) 
o Place in fridge overnight 
Day 2 
• Evaporate extract from previous day until ~0.5 mL of solution remains 
o While this is occurring construct resin columns and make reagents 
• Construct resin column 
o Pack glass wool in bottom of column 
o Add 1 mL of Bio-RAD AG 1 x 2, 200-400 mesh, acetate resin 
▪ First hydrate resin in 0.2 M acetic acid solution 
▪ Do not use chloride form or other brands 
• Make the following reagents 
o Acetate buffer at pH 3, 4, and 7 
▪ Use 0.2 M sodium acetate and 0.2 M acetic acid 
• 18 mL sodium acetate and 82 mL acetic acid for pH 4 
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• Use NaOH to obtain acetate buffer at pH 3 
o 100% EtOH with 0.1 mM PTU 
• Prep column by running 5 mL of acetic acid followed by 5 mL acetate 
buffer pH 7 
• Place day 1, concentrated (~1 mL) thyroid hormone extract directly on 
resin  
o 0.1-0.2 mL/min 
• Use syringe pump for 0.2 mL/min flow rate for all of the following wash 
steps 
o 2 mL acetate buffer pH 7 
o 2 mL EtOH-0.1mM PTU 
o 4 mL acetate buffer pH 7  
o 2 mL EtOH-0.1mM PTU 
o 2 mL acetate buffer pH 7  
o 2 mL acetate buffer pH 4 
o 2 mL acetate buffer pH 3  
o 2 mL 1% acetic acid 
o 2 mL 35% acetic acid 
• Collect the following wash step in a plastic tube 
o 3 mL of 70% acetic acid 
o Evaporate and cover tube with parafilm before placing in fridge 
▪ Can also put 25 µL of 0 ng/mL T4 human serum 
▪ Or 100 µL of 0 ng/mL T3 human serum 
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Day 3 
• Determine number of RIA coated antibody tubes required to run each 
standard twice (in duplicate) 
o Evaporate 3 mL of 70% acetic acid in a plastic tube for each of the 
standard tubes 
▪ After the acetic acid has fully evaporated pipet the standard 
according to the manufacturer’s recommendations into these 
tubes prior to pipetting the standards into the antibody 
coated RIA tubes 
• Follow  directions for assay procedure according to the manufacture’s 
recommendation 
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Validation of MP Biomedicals total thyroxine and triiodothyronine 
radioimmunoassay (RIA) kit 
 
This validation project was selected for funding by the University of Missouri 
College of Veterinary Medicine Phi Zeta Chapter. 
Background 
In the United States, it is currently estimated that over 10% of the adult 
feline population has clinical hyperthyroidism (Edinboro et al. 2004; Kass et al. 
1999; Martin et al. 2000; Peterson 2012).  With such a high prevalence, both the 
American Association of Feline Practitioners and the American Animal Hospital 
Association (AAHA) have recommended that total thyroxine (T4) testing be 
considered a baseline test which should be done yearly in all senior cats (Epstein 
et al. 2005; Pittari et al. 2009).  Total T4 is recommended as when 
hyperthyroidism develops, the thyroid hormone thyroxine (T4) becomes 
significantly elevated in 90% of hyperthyroid cats with clinical signs (e.g. weight 
loss with voracious appetite) (Peterson 2013).  In 70-75% of hyperthyroid cats, 
the thyroid hormone triiodothyronine (T3) will also become elevated (Peterson et 
al. 2001) and thyroid stimulating hormone (TSH) becomes low or undetectable 
(Wakeling et al. 2007).  With the large demand for measuring the thyroid 
hormones T4 and T3, there are four main diagnostic assay techniques, 
radioimmunoassays (RIA), homogenous enzyme immunoassays (EIA), and 
chemiluminescent enzyme immunoassays (CEIA), and enzyme-linked 
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immunosorbent assays (ELISA) that are marketed to diagnostic labs, veterinary 
clinics, and researchers. 
Since the development of RIAs in the 1960s, they have served as the gold 
standard for measuring total T4 and total T3.  RIAs are usually very sensitive and 
specific to the antigen of interest such as thyroid hormones (Goldsmith 1975).  
As depicted in the schematic diagram (figure 1), RIAs are a competitive binding 
assay.  The radioactive antigen (the “tracer”) competes with endogenous T4 and 
T3 in the serum samples for a limited number of antibody or receptor binding 
sites that are coated on the tube.  As the endogenous T4 and T3 (non-
radioactive antigen) increases in our samples there is a direct decrease in the 
tracer binding.  After an incubation period the tube is decanted and the amount of 
radioactivity emitting from the tube is counted (counts per minute, CPM).  The 
concentrations of the endogenous thyroid hormones are calculated based upon 
the generation of a standard curve from known sample concentrations (Feldman 
2004; Peterson 2013).  
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RIA Validation Appendix Figure 1 Schematic diagram of a radioimmuno 
assay 
 
The tracer is thyroxine labelled with radioactive iodine (I125). This diagram was 
created using images on https://openclipart.org under Creative Commons Zero 
1.0 Public Domain License. 
 
Since RIAs employ radioactive isotopes, there is interest in developing 
alternative assay techniques that do not rely on radioactive reagents and this is 
why the company manufacturing the validated canine and feline thyroid RIAs 
discontinued the production abruptly this fall.  Prior to the discontinuation of the 
validated RIAs, a chemiluminescent enzyme assay (CEIA) was validated for 
I125
T4 
Antibody coated tube 
Serum 
Incubate 
and 
decant 
Non-
bound 
 
I125
T4 
Antibody bound 
serum T4 and 
I125
T4 
Gamma radiation counter 
Lower tube radiation 
Equals  
Higher serum T4 
 197 
 
canine and feline T4 measurements.  This particular CEIA assay employs the 
same antibody as the RIA (Peterson 2013), but rather than a radioactive tracer, 
there is a chemiluminescent substrate used that emits light when it reacts with 
the bound label (Peterson 2013; Singh et al. 1997).  The concentration of T4 in 
the sample is directly proportional from the amount of light emitted (Peterson 
2013).  The major drawback for using this method, especially for smaller 
laboratories and researchers, is the cost to purchase the specific machine and 
maintain it (Singh et al. 1997). Due to this cost these CEIA assays are only 
economically viable for large commercial veterinary laboratories that receive a 
high volume of samples.  Also, to the primary investigator’s (PI) knowledge 
technique has not been validated for T3 measurements in felines. 
In addition to CEIA assays, there have been various attempts to validate a 
variety of ELISA kits for use with feline plasma and serum, however the 
published attempts have been contradictory.   One paper reported that when 
ELISA kits were compared to the validated RIAs, the results were similar and 
highly correlative (Kemppainen and Birchfield 2006).  Another paper reported 
substantial differences between the measured concentrations of T4.  This paper 
also determined that the ELISA results would have resulted in an inappropriate 
clinical decision for 25 of the 50 feline samples (Lurye et al. 2002). 
The last analysis method which is currently employed by several large 
commercial veterinary laboratories is the homogenous enzyme immunoassay 
(EIA).  This method uses recombinant fragments of E.coli Beta-galactosidase 
which become an active enzyme when the different fragments are combined.  
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When a patient’s serum is added to select E-coli fragments, the T4 becomes 
covalent bond to one type of recombinant fragments.  When all recombinant E-
coli fragments and the feline serum are exposed to a monoclonal antibody 
solution, the T4 can bind to the antibody which blocks the formation of the active 
enzyme.  The amount of active enzyme is directly proportional to the 
concentration of the T4 in the feline blood sample and is measured through 
hydrolysis of a component of the reaction substrate (Horney et al. 1999; Peterson 
2013).  This technique has been validated for canine and feline T4, but to the PIs 
knowledge this technique has not been validated for T3 in feline plasma. 
With the current lack of a commercially available validated assay for T3, and with 
the lack of a commercially available “gold standard” assay for T4, this project 
seeks to fill that void.  Our hypothesis is that commercially available human T4 
and T3 RIA kits can be used to measure feline T4 and T3.  While there is a 
difference in thyroid binding proteins between cats and human, the structures of 
T4 and T3 are identical between the two species (Fig 2) (Wang and Stapleton 
2010).   Therefore, we expect the kits to exhibit good cross-reactivity to feline T4 
and T3, because these RIA kits are designed to measure both bound and free 
thyroid hormones; the antibody is not designed to measure the proteins.   
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RIA Validation Appendix Figure 2 Chemical structure of the thyroid 
hormones T4 and T3 
 
Description of experiment 1:  The first study completed was a dilutional 
parallelism study.   
Animals: Three, purpose-bred, University-owned, adult (>1 yr), lean (<30% body 
fat), neutered male, domestic short-hair cats presently being studied by the PI.  
Three milliliters of blood was collected from the jugular vein of each cat and left 
at room temperature for 30 minutes to allow a clot to form.  The serum was 
extracted after centrifuging the blood at 3,000 x g for 10 minutes.   
Techniques: Commercially available human RIA T4 and T3 kits (MP 
Biomedicals LLC, Santa Ann, CA, USA) were used for this study.  The serum 
from the three cats was diluted with a standard solution.  The standard solution 
concentrations were 18 µg/dL for T4 and 700 ng/dL for T3 which were made 
utilizing HPLC grade T4 and T3 (Sigma Aldrich, St. Louis, MO, USA).    The 
dilutions and the five expected concentrations are shown in table 1.  
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RIA Validation Appendix Table 1 Serial dilution of feline serum samples 
expected concentrations 
 
Sample Percent 
serum 
Percent 
standard 
concentration 
Expected concentration T4/T3 
1 100% 0% Endogenous concentration (EC) 
2 75% 25% EC+4.5 µg/dL   /   EC+175 ng/dL 
3 50% 50% EC+ 9.0 µg/dL   /   EC+350 ng/dL 
4 25% 75% EC+13.5 µg/dL   /  EC+525 ng/dL 
5 0% 100% EC+18  µg/dL   /   EC+700 ng/dL 
 
 The five dilutions were chosen based upon the T4 assay range of 0-20 
µg/dl and the T3 assay range of 0-800 ng/dl as well as the Food and Drug 
Administration’s (FDA) Guidance for Industry Bioanalytical Method Validation.  
The FDA guidelines recommend a minimum of three concentrations representing 
the entire range of the standard curve (Food and Drug Administration 1998).  
After the samples were serially diluted, a standard curve was established and the 
feline samples run in duplicate following the kit directions.  After the completion of 
the assay procedure, the radioactive counts per minute (CPM) of the standard 
curve vials and the feline serum samples were measured using an automated 
gamma counter (Beckman Coulter, Brea, CA, USA).  The standard curve CPM 
data was logit transformed to generate a standard curve.  The values on the y-
axis were the logit and the values on the x-axis were calculated from the natural 
log of the known concentration (equation 1) (Grutzner et al. 2013).  
 
Equation 1:  Y = loge[(Bstandard/Bzero)/(1 − (Bstandard/Bzero)] 
 
Expected data:  Based upon previous values obtained from the validated RIA 
(Hooper et. al. 2014), we expected euthyroid cat serum to have values in the 
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bottom 25% of the standard curve.  With the addition of the standard, we 
expected the highest dilution (100% standard) to be near the top of the standard 
curve and the subsequent dilutions to span the entire standard curve.  We expect 
the accuracy and precision to be similar to the specific performance 
characteristics provided by the manufacturer for human sera.   
 
Actual data: 
RIA Validation Appendix Table 2 Serial dilution of pooled feline serum 
samples measured T4 concentrations 
Expected concentration T4 
Measured concentration 
nmol/L µg/dL 
Endogenous concentration (EC) 69.5 5.4 
EC+4.5 µg/dL 127.4 9.9 
EC+ 9.0 µg/dL 141.6 11.0 
EC+13.5 µg/dL 180.2 14.0 
EC+18  µg/dL 244.6 19.0 
 
RIA Validation Appendix Table 3 Serial dilution of pooled feline serum 
samples measured T3 concentrations 
Expected concentration T3 Measured concentration 
nmol/L ng/dL 
Endogenous concentration (EC) 1.2 77 
EC + 175 ng/dL 4.8 311 
EC + 350 ng/dL 7.9 516 
EC + 525 ng/dL 10.5 681 
EC + 700 ng/dL 14.0 909 
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Brief discussion 
Siemens Coat-a-Count© thyroxine and triiodothyronine radioimmunoassay 
kits were validated by Peterson et al. (1994) to measure T4 and T3 in feline 
serum.  In 2014, Siemens Healthcare discontinued producing 
radioimmunoassays and replaced the assays with veterinary specific non-
radioactive chemiluminescent immunoassays which utilized their IMMULITE© 
immunoassay systems.  These chemiluminescent analyzers are cost prohibitive 
for in-house laboratories as they are expensive to purchase and maintain (Higgs 
et al. 2014), hence the purpose of this study.  
The endogenous T4 concentration in the pooled serum was elevated 
compared to samples previously run on the Siemen’s validated RIA kits. Typically 
T4 over 60 nmol/L is considered diagnostic for feline hyperthyroidism (Peterson 
et al. 2001), therefore our cats would be considered hyperthyroid based upon the 
results.  Therefore, the following experiments were undertaken to determine if the 
kit performance could be improved by altering the incubation time and if the 
endogenous T4 was truly being measured. 
The endogenous T3 concentration was not elevated above the reference 
range; however, cat’s diagnosed with mild hyperthyroidism have been observed 
to have similar serum T3 concentrations (Peterson et al. 2001). 
 
Description of experiment 2:  The second study completed was to assess the 
performance of the assay at 2 and 3 hour incubation times. 
Techniques: Using the same commercially available human RIA T4 and T3 kits 
(MP Biomedicals LLC, Santa Ann, CA, USA) and feline serum as in experiment 
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1, the samples were measured in duplicate.  The kit directions were modified by 
incubating the samples for 2 or 3 hours rather than the 1 hour as suggested.  
After the completion of the assay procedure, the radioactive counts per minute 
(CPM) of the standard curve vials and the feline serum samples were measured 
using an automated gamma counter (Beckman Coulter, Brea, CA, USA).  The 
standard curve CPM data was logit transformed to generate a standard curve as 
in experiment 1.   
 
Results 
 
RIA Validation Appendix Table 4 Serial dilution of pooled feline serum 
samples measured T4 concentrations 
Expected concentration T4 Measured 
concentration 
2 hour incubation 
Measured 
concentration 3 
hour incubation 
  
nmol/L µg/dL nmol/L µg/dL 
Endogenous concentration (EC) 60.5 4.7 20.6 1.6 
EC+4.5 µg/dL 109.4 8.5 - - 
EC+ 9.0 µg/dL 168.6 13.1 - - 
EC+13.5 µg/dL 208.5 16.2 - - 
EC+18  µg/dL 260 20.2 - - 
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RIA Validation Appendix Table 5 Serial dilution of pooled feline serum 
samples measured T3 concentrations 
Expected concentration T4 
Measured 
concentration 
2 hour incubation 
Measured 
concentration 3 
hour incubation 
nmol/L ng/dL nmol/L ng/dL 
Endogenous concentration (EC) 0.80 52 0.86 56 
EC+ 175 ng/dL 4.19 273 4.27 278 
EC + 350 ng/dL 7.79 507 7.19 468 
EC + 525 ng/dL 11.51 749 10.18 663 
EC + 700 ng/dL 16.16 1052 15.19 989 
Brief Discussion 
Since T3 was minimally altered by incubation time, we pursued 
measuring T3 with the RIA kits using samples that were previously measured 
using the validated Siemen’s T3 RIA kit (Hooper et al. 2014). This was completed 
in experiment 3. 
The measured endogenous concentrations of T4 were altered based 
upon the incubation time.  It may be a compound within the serum caused 
interference with the binding of the T4 to the antibody coated tube or the 
compound itself could bind to the antibody (cross-reactivity).  Interference can 
lead to falsely elevated or falsely low analyte concentration depending on the site 
of the interference in the immunoassay reaction (Tate and Ward 2004).   
Description of experiment 3: The purpose of this third study was to measure 
the T3 concentrations in cat serum with a known quantity of T3. 
Techniques: Using the same commercially available human RIA T3 kit (MP 
Biomedicals LLC, Santa Ann, CA, USA) as in experiment 1, cat serum from a 
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previously reported study (Hooper et al. 2014) were measured in duplicates 
following the RIA kit directions.  After the completion of the assay procedure, the 
radioactive counts per minute (CPM) of the standard curve vials and the feline 
serum samples were measured using an automated gamma counter (Beckman 
Coulter, Brea, CA, USA).  The standard curve CPM data was logit transformed to 
generate a standard curve as in experiment 1.   
Expected data:  We did not expect any statistically significant differences 
between values measured with the different assays and we expect the data to be 
similarly distributed for both assay methods.  We believe the two methods will 
have a good correlation with an rs of 0.80 to 0.92. 
Actual data: 
RIA Validation Appendix Table 6 Comparison of T3 concentrations 
measured by RIA 
 
 
 
Brief discussion: Our results were inconsistent with the previously measured T3 
concentrations.  A diagnostic lab also looking for a replacement for the Siemens 
Coat-a-Count© kits completed a charcoal-separation step as described by Refsal 
Previously 
measured 
concentration 
Measured 
concentration 
nmol/L ng/dL nmol/L ng/dL 
0.67 43.5 1.04 68 
0.84 54.8 1.73 112.4 
0.81 53.0 2.23 145.1 
0.65 42.3 0.64 41.5 
0.56 36.4 1.57 102.1 
0.49 32.0 2.23 144.9 
0.57 36.9 0.63 40.7 
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et al. (1991), however the lab reported the MP Biomedicals kit performance did 
not improve.  The diagnostic lab decided to not further pursue the use of the MP 
Biomedical’s kit to measure feline T3.  We decided to conduct one additional 
experiment to determine if using a resin to purify our feline samples would be 
feasible. 
Experiment 4: The purpose of this study was to determine the feasibility of using 
a resin to extract T3 from the serum matrix. 
Techniques: Following day 2 and day 3 of the liver thyroid hormone extraction 
protocol (Appendix), T4 was extracted from cat serum samples.  The samples 
selected were from a previously reported study (Hooper et al. 2014), because T4 
was previously measured using the validated Siemen’s T4 RIA kits.  The T4 in 
the samples was measured in duplicate using the MP Biomedicals T4 RIA kit 
following the kit directions.   
Results 
RIA Validation Appendix Table 7 T3 concentration measured after resin 
purrification 
These samples were run in duplicate with the mean value reported. 
Previously 
measured TT3 
Concentration 
Measured 
concentration 
Measured 
concentration after 
resin extraction 
Recovery 
nmol/L ng/dL nmol/L ng/dL nmol/L ng/dL % 
0.84 54.8 1.73 112.4 0.56 36.2 64 
0.81 53.0 2.23 145.1 0.52 33.7 68 
0.65 42.3 0.63 41.5 0.45 29.6 55 
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Brief discussion  
The results obtained using the resin to extract the T3 from the serum matrix, 
appear that this antibody used in the MP Biomedicals kit detects T3 similar to the 
discontinued Siemen’s RIA kits.   However, it appears that the antibody is not as 
specific for T3 due to interference caused by cross-reactivity of an unknown 
compound in the serum matrix.  Because of the multi-day process and the limited 
number of samples that could be processed, it is more cost-efficient to submit 
samples to a diagnostic lab who use feline specific in-house validated RIA kits 
(e.g. Michigan State Diagnostic Center for Population and Animal Health) or non-
RIA based validated thyroid hormone assays (e.g. IDEXX). 
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